CAMK2D
Normalized values from positional scanning peptide array
Phospho-serine (pS) is a duplicate of phospho-tyrosine (pT) in PSPA
Position-wise Probabilities
Log-Odds: Probabilities / STY Background
Sites with acceptor types representing >8% and count ≥10 are included
S Sites Probabilities
T Sites Probabilities
Log-Odds: S Sites / S Background
Log-Odds: T Sites / T Background
Sites with acceptor types representing >8% and count ≥10 are included
Motif clusters with count ≥ 10 are shown
Download
| substrate_uniprot | site | source | substrate_genes | site_seq |
|---|---|---|---|---|
| A0A2R8Y4L2 | S22 | Sugiyama | HNRNPA1L3 HNRNPA1P48 | SKSEsPKEPEQLRKLFIGGLsFEtTDESLRSHFEQWGTLTD |
| A0A2R8Y4L2 | S95 | Sugiyama | HNRNPA1L3 HNRNPA1P48 | RPHKVDGRVVEPKRAVSREDsQRPDAHLTVKKIFVGGIKED |
| A0A2R8Y4L2 | T25 | Sugiyama | HNRNPA1L3 HNRNPA1P48 | EsPKEPEQLRKLFIGGLsFEtTDESLRSHFEQWGTLTDCVV |
| A4FU28 | S140 | Sugiyama | CTAGE9 | AAAEEARSLEATCEKLSRsNsELEDEILCLEKDLKEEKSKH |
| A5A3E0 | Y940 | Sugiyama | POTEF A26C1B | ALDFEQEMATVAsSSSLEKsyELPDGQVItIGNERFRCPEA |
| O00273 | S28 | Sugiyama | DFFA DFF1 DFF45 H13 | GVPESGEIRTLKPCLLRRNysREQHGVAAsCLEDLRSKACD |
| O00488 | S93 | Sugiyama | ZNF593 ZT86 | STNLKTHFRSKDHKKRLKQLsVEPysQEEAERAAGMGSYVP |
| O00488 | Y97 | Sugiyama | ZNF593 ZT86 | KTHFRSKDHKKRLKQLsVEPysQEEAERAAGMGSYVPPRRL |
| O14974 | S910 | Sugiyama | PPP1R12A MBS MYPT1 | yETssTsAGDRyDsLLGRsGsysYLEERKPYSSRLEKDDST |
| O14974 | S995 | Sugiyama | PPP1R12A MBS MYPT1 | ADRSLLEMEKRERRALERRIsEMEEELKMLPDLKADNQRLK |
| O15084 | S1011 | SIGNOR|EPSD|PSP | ANKRD28 KIAA0379 | PLssLTFNAINRYTNTsKtVsFEALPIMRNEPSSYCSFNNI |
| O15212 | T38 | Sugiyama | PFDN6 HKE2 PFD6 | QLQKDLSKSMSGRQKLEAQLtENNIVKEELALLDGsNVVFK |
| O43164 | S253 | Sugiyama | PJA2 KIAA0438 RNF131 | LDsVPLVKssAGDTEFVHQNsQEIQRSSQDEMVSTKQQNNT |
| O43399 | S161 | Sugiyama | TPD52L2 | sAALstVGsAIsRKLGDMRNsAtFKsFEDRVGtIKSKVVGD |
| O43399 | S166 | Sugiyama | TPD52L2 | tVGsAIsRKLGDMRNsAtFKsFEDRVGtIKSKVVGDRENGs |
| O43399 | T163 | Sugiyama | TPD52L2 | ALstVGsAIsRKLGDMRNsAtFKsFEDRVGtIKSKVVGDRE |
| O43423 | S100 | Sugiyama | ANP32CP PP32R1 | AEKCPNLTHLYLSGNKIKDLstIEPLKQLENLKSLDLFNCE |
| O43852 | S44 | Sugiyama | CALU | KKDRVHHEPQLsDKVHNDAQsFDyDHDAFLGAEEAKtFDQL |
| O43852 | T196 | Sugiyama | CALU | FtAFLHPEEyDyMKDIVVQEtMEDIDKNADGFIDLEEyIGD |
| O60220 | S94 | Sugiyama | TIMM8A DDP DDP1 TIM8A | SQFILNRLEQTQKSKPVFSEsLsD_________________ |
| O60763 | S805 | Sugiyama | USO1 VDP | EQVAELKQELATLKSQLNSQsVEITKLQTEKQELLQKTEAF |
| O60841 | S107 | Sugiyama | EIF5B IF2 KIAA0741 | NEEEFtsKDKKKKGQKGKKQsFDDNDsEELEDKDsKSKKTA |
| O60841 | S182 | Sugiyama | EIF5B IF2 KIAA0741 | DGsEEDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKK |
| O60841 | S186 | Sugiyama | EIF5B IF2 KIAA0741 | EDEDNsKKIKERsRINssGEsGDEsDEFLQsRKGQKKNQKN |
| O60927 | S74 | Sugiyama | PPP1R11 HCGV TCTE5 | GRRssKCCCIyEKPRAFGEsstEsDEEEEEGCGHtHCVRGH |
| O60927 | T75 | Sugiyama | PPP1R11 HCGV TCTE5 | RRssKCCCIyEKPRAFGEsstEsDEEEEEGCGHtHCVRGHR |
| O94992 | S268 | Sugiyama | HEXIM1 CLP1 EDG1 HIS1 MAQ1 | EDGGsDGMGGDGSEFLQRDFsEtyERyHTEsLQNMsKQELI |
| O94992 | T270 | Sugiyama | HEXIM1 CLP1 EDG1 HIS1 MAQ1 | GGsDGMGGDGSEFLQRDFsEtyERyHTEsLQNMsKQELIKE |
| O95155 | S105 | Sugiyama | UBE4B HDNB1 KIAA0684 UFD2 | LsssPsNsLEtQsQsLsRsQsMDIDGVSCEKsMsQVDVDsG |
| O95218 | S120 | Sugiyama | ZRANB2 ZIS ZNF265 | tGYGGGFNERENVEyIEREEsDGEyDEFGRKKKKYRGKAVG |
| O95218 | S188 | Sugiyama | ZRANB2 ZIS ZNF265 | KLDEDEDEDDADLsKyNLDAsEEEDsNKKKSNRRSRSKSRS |
| O95425 | S968 | Sugiyama | SVIL | GETESKRALTGRDSGMEKyGsFEEAEASYPILNRAREGDSH |
| O95626 | S104 | Sugiyama | ANP32D PP32R2 | AEKCPNLIHLNLSGNKIKDLstIEPLKKLENLESLDLFTCE |
| P00558 | S390 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | IIGGGDtAtCCAKWNtEDKVsHVstGGGAsLELLEGKVLPG |
| P00558 | T394 | Sugiyama | PGK1 PGKA MIG10 OK/SW-cl.110 | GDtAtCCAKWNtEDKVsHVstGGGAsLELLEGKVLPGVDAL |
| P04075 | S336 | Sugiyama | ALDOA ALDA | GKKENLKAAQEEYVKRALANsLACQGKytPsGQAGAAAsEs |
| P04075 | S36 | Sugiyama | ALDOA ALDA | LsDIAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENR |
| P04075 | S39 | Sugiyama | ALDOA ALDA | IAHRIVAPGKGILAADEstGsIAKRLQsIGtENtEENRRFy |
| P04406 | S210 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | GPsGKLWRDGRGALQNIIPAstGAAKAVGKVIPELNGKLtG |
| P04406 | S241 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDDIKKV |
| P04406 | S312 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | sstFDAGAGIALNDHFVKLIsWyDNEFGysNRVVDLMAHMA |
| P04406 | S321 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | IALNDHFVKLIsWyDNEFGysNRVVDLMAHMAsKE______ |
| P04406 | T211 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | PsGKLWRDGRGALQNIIPAstGAAKAVGKVIPELNGKLtGM |
| P04406 | T237 | Sugiyama | GAPDH GAPD CDABP0047 OK/SW-cl.12 | VGKVIPELNGKLtGMAFRVPtANVsVVDLtCRLEKPAKyDD |
| P04792 | S78 | Sugiyama | HSPB1 HSP27 HSP28 | LPPAAIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVs |
| P04792 | S82 | Sugiyama | HSPB1 HSP27 HSP28 | AIEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVN |
| P04792 | S83 | Sugiyama | HSPB1 HSP27 HSP28 | IEsPAVAAPAYsRALsRQLssGVsEIRHtADRWRVsLDVNH |
| P05362 | S43 | Sugiyama | ICAM1 | GPGNAQTSVSPSKVILPRGGsVLVTCstsCDQPKLLGIETP |
| P05386 | S101 | Sugiyama | RPLP1 RRP1 | APstAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD_______ |
| P05386 | S104 | Sugiyama | RPLP1 RRP1 | tAAAPAEEKKVEAKKEEsEEsDDDMGFGLFD__________ |
| P05387 | S102 | Sugiyama | RPLP2 D11S2243E RPP2 | PAAGsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD_______ |
| P05387 | S105 | Sugiyama | RPLP2 D11S2243E RPP2 | GsAPAAAEEKKDEKKEEsEEsDDDMGFGLFD__________ |
| P05387 | S29 | Sugiyama | RPLP2 D11S2243E RPP2 | LAALGGNssPsAKDIKKILDsVGIEADDDRLNKVIsELNGK |
| P05388 | S304 | Sugiyama | RPLP0 | AttAAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD_______ |
| P05783 | S93 | Sugiyama | KRT18 CYK18 PIG46 | GMGGIQNEKETMQsLNDRLAsyLDRVRSLETENRRLESKIR |
| P05787 | S330 | Sugiyama | KRT8 CYK8 | MNRNISRLQAEIEGLKGQRAsLEAAIADAEQRGELAIKDAN |
| P06733 | S37 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | NPtVEVDLFtsKGLFRAAVPsGAstGIyEALELRDNDKtRY |
| P06733 | S40 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | VEVDLFtsKGLFRAAVPsGAstGIyEALELRDNDKtRYMGK |
| P06733 | T205 | Sugiyama | ENO1 ENO1L1 MBPB1 MPB1 | GAEVyHNLKNVIKEKyGKDAtNVGDEGGFAPNILENKEGLE |
| P07195 | S44 | Sugiyama | LDHB | ITVVGVGQVGMACAISILGKsLADELALVDVLEDKLKGEMM |
| P07205 | S390 | Sugiyama | PGK2 PGKB | VIGGGDTATCCAKWNtEDKVsHVstGGGAsLELLEGKILPG |
| P07205 | T394 | Sugiyama | PGK2 PGKB | GDTATCCAKWNtEDKVsHVstGGGAsLELLEGKILPGVEAL |
| P07237 | S427 | Sugiyama | P4HB ERBA2L PDI PDIA1 PO4DB | WDKLGEtyKDHENIVIAKMDstANEVEAVKVHsFPtLKFFP |
| P07355 | S184 | Sugiyama | ANXA2 ANX2 ANX2L4 CAL1H LPC2D | sGDFRKLMVALAKGRRAEDGsVIDyELIDQDARDLyDAGVK |
| P07437 | S75 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | tGGKyVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVFGQs |
| P07437 | T72 | Sugiyama | TUBB TUBB5 OK/SW-cl.56 | NEAtGGKyVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVF |
| P07814 | S747 | Sugiyama | EPRS1 EPRS GLNS PARS QARS QPRS PIG32 | ETSAPFKERPtPsLNNNCttsEDsLVLyNRVAVQGDVVREL |
| P07900 | S468 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | GIHEDsQNRKKLsELLRyytsAsGDEMVsLKDYCTRMKENQ |
| P07900 | S52 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | LIINtFySNKEIFLRELIsNssDALDKIRyEsLtDPsKLDs |
| P07900 | T467 | Sugiyama | HSP90AA1 HSP90A HSPC1 HSPCA | LGIHEDsQNRKKLsELLRyytsAsGDEMVsLKDYCTRMKEN |
| P08238 | S45 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | MSLIINTFYSNKEIFLRELIsNAsDALDKIRyEsLtDPsKL |
| P08238 | S460 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | GIHEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQ |
| P08238 | S462 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | HEDstNRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKs |
| P08238 | S48 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | IINTFYSNKEIFLRELIsNAsDALDKIRyEsLtDPsKLDsG |
| P08238 | T297 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | IDQEELNKtKPIWtRNPDDItQEEyGEFyKsLtNDWEDHLA |
| P08238 | T467 | Sugiyama | HSP90AB1 HSP90B HSPC2 HSPC3 HSPCB | NRRRLsELLRyHtsQsGDEMtsLsEyVsRMKEtQKsIyyIt |
| P08670 | S83 | SIGNOR|iPTMNet | VIM | tRssAVRLRssVPGVRLLQDsVDFsLADAINTEFKNTRTNE |
| P09104 | S37 | Sugiyama | ENO2 | NPtVEVDLyTAKGLFRAAVPsGAstGIyEALELRDGDKQRY |
| P09104 | S40 | Sugiyama | ENO2 | VEVDLyTAKGLFRAAVPsGAstGIyEALELRDGDKQRYLGK |
| P09104 | T19 | Sugiyama | ENO2 | __MSIEKIWAREILDSRGNPtVEVDLyTAKGLFRAAVPsGA |
| P09104 | Y25 | Sugiyama | ENO2 | KIWAREILDSRGNPtVEVDLyTAKGLFRAAVPsGAstGIyE |
| P09382 | S63 | Sugiyama | LGALS1 | CLHFNPRFNAHGDANtIVCNsKDGGAWGTEQREAVFPFQPG |
| P09651 | S22 | Sugiyama | HNRNPA1 HNRPA1 | sKsEsPKEPEQLRKLFIGGLsFEtTDESLRSHFEQWGTLTD |
| P09651 | S95 | Sugiyama | HNRNPA1 HNRPA1 | RPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| P09651 | T25 | Sugiyama | HNRNPA1 HNRPA1 | EsPKEPEQLRKLFIGGLsFEtTDESLRSHFEQWGTLTDCVV |
| P0CG41 | S140 | Sugiyama | CTAGE8 | AAAEEARSLEATCEKLNRsNsELEDEILCLEKDLKEEKSKH |
| P10412 | S55 | Sugiyama | H1-4 H1F4 HIST1H1E | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P10412 | S86 | Sugiyama | H1-4 H1F4 HIST1H1E | LAAAGyDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFK |
| P10412 | S89 | Sugiyama | H1-4 H1F4 HIST1H1E | AGyDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNK |
| P10412 | T92 | Sugiyama | H1-4 H1F4 HIST1H1E | DVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNKKAA |
| P10809 | S488 | Sugiyama | HSPD1 HSP60 | IKRTLKIPAMtIAKNAGVEGsLIVEKIMQSSsEVGYDAMAG |
| P11717 | S1378 | Sugiyama | IGF2R MPRI | QYACPPFDLTECSFKDGAGNsFDLsSLSRYSDNWEAITGTG |
| P12268 | S416 | Sugiyama | IMPDH2 IMPD2 | APGEYFFSDGIRLKKyRGMGsLDAMDKHLssQNRyFsEADK |
| P13073 | S74 | Sugiyama | COX4I1 COX4 | HLSASQKALKEKEKASWssLsMDEKVELYRIKFKEsFAEMN |
| P13639 | T5 | Sugiyama | EEF2 EF2 | ________________MVNFtVDQIRAIMDKKANIRNMsVI |
| P13688 | T457 | SIGNOR|EPSD | CEACAM1 BGP BGP1 | VVALVALIAVALACFLHFGKtGRAsDQRDLtEHKPsVSNHT |
| P13861 | S99 | Sugiyama | PRKAR2A PKR2 PRKAR2 | EsEEDEDLEVPVPsRFNRRVsVCAEtyNPDEEEEDTDPRVI |
| P13929 | S37 | Sugiyama | ENO3 | NPtVEVDLHtAKGRFRAAVPsGAstGIyEALELRDGDKGRY |
| P13929 | S40 | Sugiyama | ENO3 | VEVDLHtAKGRFRAAVPsGAstGIyEALELRDGDKGRYLGK |
| P14625 | S106 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | MKLIINSLYKNKEIFLRELIsNAsDALDKIRLISLTDENAL |
| P14625 | S109 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | IINSLYKNKEIFLRELIsNAsDALDKIRLISLTDENALSGN |
| P14625 | S514 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | LGVIEDHsNRtRLAKLLRFQssHHPtDItsLDQyVERMKEK |
| P14625 | S515 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | GVIEDHsNRtRLAKLLRFQssHHPtDItsLDQyVERMKEKQ |
| P14625 | S523 | Sugiyama | HSP90B1 GRP94 HSPC4 TRA1 | RtRLAKLLRFQssHHPtDItsLDQyVERMKEKQDKIyFMAG |
| P14854 | S52 | Sugiyama | COX6B1 COX6B | QNyLDFHRCQKAMTAKGGDIsVCEWyQRVYQsLCPtsWVTD |
| P15311 | S535 | Sugiyama | EZR VIL2 | EKRITEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHN |
| P15311 | S536 | Sugiyama | EZR VIL2 | KRITEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHNE |
| P15311 | S539 | Sugiyama | EZR VIL2 | TEAEKNERVQRQLLtLssELsQARDENKRTHNDIIHNENMR |
| P15311 | T533 | Sugiyama | EZR VIL2 | NEEKRITEAEKNERVQRQLLtLssELsQARDENKRTHNDII |
| P15336 | S62 | Sugiyama | ATF2 CREB2 CREBP1 | LAVHKHKHEMtLKFGPARNDsVIVADQtPtPtRFLKNCEEV |
| P15531 | S120 | Sugiyama | NME1 NDPKA NM23 | KPGtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELV |
| P15531 | S122 | Sugiyama | NME1 NDPKA NM23 | GtIRGDFCIQVGRNIIHGsDsVEsAEKEIGLWFHPEELVDy |
| P16070 | S71 | Sugiyama | CD44 LHR MDU2 MDU3 MIC4 | DLCKAFNSTLPTMAQMEKALsIGFEtCRyGFIEGHVVIPRI |
| P16401 | S89 | Sugiyama | H1-5 H1F5 HIST1H1B | LAAGGYDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFK |
| P16401 | S92 | Sugiyama | H1-5 H1F5 HIST1H1B | GGYDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNK |
| P16401 | T95 | Sugiyama | H1-5 H1F5 HIST1H1B | DVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNKKAA |
| P16402 | S56 | Sugiyama | H1-3 H1F3 HIST1H1D | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P16402 | S87 | Sugiyama | H1-3 H1F3 HIST1H1D | LAAAGyDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFK |
| P16402 | S90 | Sugiyama | H1-3 H1F3 HIST1H1D | AGyDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNK |
| P16402 | T93 | Sugiyama | H1-3 H1F3 HIST1H1D | DVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNKKAA |
| P16403 | S55 | Sugiyama | H1-2 H1F2 HIST1H1C | AsGPPVsELItKAVAASKERsGVsLAALKKALAAAGyDVEK |
| P16403 | S86 | Sugiyama | H1-2 H1F2 HIST1H1C | LAAAGyDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFK |
| P16403 | S89 | Sugiyama | H1-2 H1F2 HIST1H1C | AGyDVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNK |
| P16403 | T92 | Sugiyama | H1-2 H1F2 HIST1H1C | DVEKNNSRIKLGLKsLVsKGtLVQtKGtGAsGsFKLNKKAA |
| P16949 | S46 | Sugiyama | STMN1 C1orf215 LAP18 OP18 | PRsKEsVPEFPLsPPKKKDLsLEEIQKKLEAAEERRKsHEA |
| P17096 | S102 | Sugiyama | HMGA1 HMGIY | KPRGRPKKLEKEEEEGIsQEssEEEQ_______________ |
| P17096 | S99 | Sugiyama | HMGA1 HMGIY | PGRKPRGRPKKLEKEEEEGIsQEssEEEQ____________ |
| P17544 | S44 | Sugiyama | ATF7 ATFA | LAVHKHKHEMTLKFGPARtDsVIIADQtPtPtRFLKNCEEV |
| P18615 | S115 | Sugiyama | NELFE RD RDBP | KLKDPEKGPVPTFQPFQRsIsADDDLQEsSRRPQRKsLyEs |
| P18615 | S131 | Sugiyama | NELFE RD RDBP | QRsIsADDDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGE |
| P18615 | S135 | Sugiyama | NELFE RD RDBP | sADDDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGEEAEG |
| P18615 | S165 | Sugiyama | NELFE RD RDBP | ELGPDGEEAEGPGAGDGPPRsFDWGyEERSGAHSsAsPPRs |
| P18615 | Y133 | Sugiyama | NELFE RD RDBP | sIsADDDLQEsSRRPQRKsLyEsFVsssDRLRELGPDGEEA |
| P18621 | S5 | Sugiyama | RPL17 | ________________MVRysLDPENPtKsCKSRGSNLRVH |
| P18621 | T79 | Sugiyama | RPL17 | PFRRYNGGVGRCAQAKQWGWtQGRWPKKSAEFLLHMLKNAE |
| P19338 | S458 | Sugiyama | NCL | TEADAEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKN |
| P19338 | S460 | Sugiyama | NCL | ADAEKTFEEKQGtEIDGRsIsLyytGEKGQNQDYRGGKNST |
| P19338 | S580 | Sugiyama | NCL | PRGsPNARSQPSKTLFVKGLsEDttEEtLKEsFDGsVRARI |
| P19338 | S619 | Sugiyama | NCL | RIVTDRETGssKGFGFVDFNsEEDAKAAKEAMEDGEIDGNK |
| P20042 | S67 | Sugiyama | EIF2S2 EIF2B | EPtEDKDLEADEEDTRKKDAsDDLDDLNFFNQKKKKKKTKK |
| P22090 | S204 | Sugiyama | RPS4Y1 RPS4Y PRO2646 | IGGANLGRVGVITNRERHPGsFDVVHVKDANGNSFATRLSN |
| P22626 | S189 | Sugiyama | HNRNPA2B1 HNRPA2B1 | IVLQKyHtINGHNAEVRKALsRQEMQEVQssRsGRGGNFGF |
| P22626 | S212 | Sugiyama | HNRNPA2B1 HNRPA2B1 | EMQEVQssRsGRGGNFGFGDsRGGGGNFGPGPGsNFRGGsD |
| P23528 | S41 | Sugiyama | CFL1 CFL | RKsstPEEVKKRKKAVLFCLsEDKKNIILEEGKEILVGDVG |
| P23528 | T63 | Sugiyama | CFL1 CFL | DKKNIILEEGKEILVGDVGQtVDDPyAtFVKMLPDKDCRyA |
| P23528 | T70 | Sugiyama | CFL1 CFL | EEGKEILVGDVGQtVDDPyAtFVKMLPDKDCRyALyDAtyE |
| P23588 | S122 | Sugiyama | EIF4B | NLPyDVTEESIKEFFRGLNIsAVRLPREPsNPERLKGFGyA |
| P23588 | S207 | Sugiyama | EIF4B | DRNRDsDKtDTDWRARPAtDsFDDyPPRRGDDsFGDKYRDR |
| P23588 | S597 | Sugiyama | EIF4B | KKPEENPASKFssASKyAALsVDGEDENEGEDyAE______ |
| P23921 | S780 | Sugiyama | RRM1 RR1 | KEKVSKEEEEKERNtAAMVCsLENRDECLMCGS________ |
| P24534 | S141 | Sugiyama | EEF1B2 EEF1B EF1B | ERLAQYESKKAKKPALVAKssILLDVKPWDDEtDMAKLEEC |
| P25054 | S1389 | Sugiyama | APC DP2.5 | PKsPPEHYVQETPLMFsRCTsVSsLDSFESRSIASSVQSEP |
| P25054 | S1861 | Sugiyama | APC DP2.5 | DsPHHytPIEGTPYCFsRNDsLssLDFDDDDVDLSREKAEL |
| P25054 | S2129 | Sugiyama | APC DP2.5 | NSIVSSLHQAAAAACLsRQAssDSDSILSLKsGIsLGsPFH |
| P25705 | S65 | Sugiyama | ATP5F1A ATP5A ATP5A1 ATP5AL2 ATPM | KtGtAEMssILEERILGADtsVDLEETGRVLsIGDGIARVH |
| P26038 | S527 | Sugiyama | MSN | ERTTEAEKNERVQKHLKALtsELANARDEsKKTANDMIHAE |
| P26038 | S576 | Sugiyama | MSN | YKtLRQIRQGNTKQRIDEFEsM___________________ |
| P26038 | T526 | Sugiyama | MSN | EERTTEAEKNERVQKHLKALtsELANARDEsKKTANDMIHA |
| P26373 | S181 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | YKKEKARVItEEEKNFKAFAsLRMARANARLFGIRAKRAKE |
| P26373 | S77 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PIVRCPTVRYHTKVRAGRGFsLEELRVAGIHKKVARTIGIs |
| P26373 | T148 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PRKPSAPKKGDssAEELKLAtQLtGPVMPVRNVYKKEKARV |
| P26373 | T151 | Sugiyama | RPL13 BBC1 OK/SW-cl.46 | PSAPKKGDssAEELKLAtQLtGPVMPVRNVYKKEKARVItE |
| P26678 | S16 | GPS6 | PLN PLB | _____MEKVQYLTRSAIRRAstIEMPQQARQKLQNLFINFC |
| P26678 | T17 | GPS6 | PLN PLB | ____MEKVQYLTRSAIRRAstIEMPQQARQKLQNLFINFCL |
| P27348 | S45 | Sugiyama | YWHAQ | CMKAVtEQGAELsNEERNLLsVAyKNVVGGRRSAWRVIsSI |
| P27797 | T34 | Sugiyama | CALR CRTC | LAVAEPAVYFKEQFLDGDGWtsRWIEsKHKSDFGKFVLssG |
| P29401 | S295 | Sugiyama | TKT | ysQIQsKKKILAtPPQEDAPsVDIANIRMPsLPsyKVGDKI |
| P29692 | S74 | Sugiyama | EEF1D EF1D | RENIQKsLAGssGPGAssGtsGDHGELVVRIAsLEVENQsL |
| P29692 | S86 | Sugiyama | EEF1D EF1D | GPGAssGtsGDHGELVVRIAsLEVENQsLRGVVQELQQAIs |
| P30043 | T190 | Sugiyama | BLVRB FLR SCAN | RGPSRVISKHDLGHFMLRCLttDEyDGHstyPsHQyQ____ |
| P30050 | S138 | Sugiyama | RPL12 | HRSLARELsGtIKEILGtAQsVGCNVDGRHPHDIIDDINsG |
| P30086 | T167 | Sugiyama | PEBP1 PBP PEBP | GKFKVAsFRKKyELRAPVAGtCyQAEWDDyVPKLyEQLsGK |
| P30086 | T51 | Sugiyama | PEBP1 PBP PEBP | GAAVDELGKVLtPtQVKNRPtsIsWDGLDsGKLytLVLtDP |
| P30101 | S474 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | yFsPANKKLNPKKyEGGRELsDFIsyLQREAtNPPVIQEEK |
| P30101 | S478 | Sugiyama | PDIA3 ERP57 ERP60 GRP58 | ANKKLNPKKyEGGRELsDFIsyLQREAtNPPVIQEEKPKKK |
| P30533 | S242 | Sugiyama | LRPAP1 A2MRAP | TELKEKLRsINQGLDRLRRVsHQGystEAEFEEPRVIDLWD |
| P30533 | S247 | Sugiyama | LRPAP1 A2MRAP | KLRsINQGLDRLRRVsHQGystEAEFEEPRVIDLWDLAQSA |
| P30533 | Y246 | Sugiyama | LRPAP1 A2MRAP | EKLRsINQGLDRLRRVsHQGystEAEFEEPRVIDLWDLAQS |
| P31327 | S564 | Sugiyama | CPS1 | TEDRQLFSDKLNEINEKIAPsFAVEsIEDALKAADTIGyPV |
| P31327 | S569 | Sugiyama | CPS1 | LFSDKLNEINEKIAPsFAVEsIEDALKAADTIGyPVMIRSA |
| P31943 | S23 | Sugiyama | HNRNPH1 HNRPH HNRPH1 | LGTEGGEGFVVKVRGLPWsCsADEVQRFFSDCKIQNGAQGI |
| P31946 | S47 | Sugiyama | YWHAB | AMKAVtEQGHELsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P31947 | S45 | Sugiyama | SFN HME1 | FMKGAVEKGEELsCEERNLLsVAyKNVVGGQRAAWRVLSsI |
| P31947 | S69 | Sugiyama | SFN HME1 | KNVVGGQRAAWRVLSsIEQKsNEEGsEEKGPEVREYREKVE |
| P32119 | T142 | Sugiyama | PRDX2 NKEFB TDPX1 | EGIAYRGLFIIDGKGVLRQItVNDLPVGRsVDEALRLVQAF |
| P35269 | T154 | Sugiyama | GTF2F1 RAP74 | AFEAFPVHNWYNFTPLARHRtLtAEEAEEEWERRNKVLNHF |
| P35637 | S340 | Sugiyama | FUS TLS | PMINLyTDRETGKLKGEAtVsFDDPPsAKAAIDWFDGKEFs |
| P35637 | T338 | Sugiyama | FUS TLS | GQPMINLyTDRETGKLKGEAtVsFDDPPsAKAAIDWFDGKE |
| P36578 | S87 | Sugiyama | RPL4 RPL1 | WGtGRAVARIPRVRGGGtHRsGQGAFGNMCRGGRMFAPTKT |
| P36578 | T84 | Sugiyama | RPL4 RPL1 | AEsWGtGRAVARIPRVRGGGtHRsGQGAFGNMCRGGRMFAP |
| P37108 | T45 | Sugiyama | SRP14 | sVyItLKKYDGRTKPIPKKGtVEGFEPADNKCLLRATDGKK |
| P37802 | S163 | Sugiyama | TAGLN2 KIAA0120 CDABP0035 | LFsGDPNWFPKKSKENPRNFsDNQLQEGKNVIGLQMGtNRG |
| P39019 | S59 | Sugiyama | RPS19 | LAKHKELAPyDENWFytRAAstARHLYLRGGAGVGsMTKIY |
| P39019 | Y48 | Sugiyama | RPS19 | LKVPEWVDtVKLAKHKELAPyDENWFytRAAstARHLYLRG |
| P39019 | Y54 | Sugiyama | RPS19 | VDtVKLAKHKELAPyDENWFytRAAstARHLYLRGGAGVGs |
| P39023 | S13 | Sugiyama | RPL3 OK/SW-cl.32 | ________MSHRKFSAPRHGsLGFLPRKRSSRHRGKVKSFP |
| P39023 | S265 | Sugiyama | RPL3 OK/SW-cl.32 | HRGLRKVACIGAWHPARVAFsVARAGQKGYHHRTEINKKIY |
| P39023 | S304 | Sugiyama | RPL3 OK/SW-cl.32 | IYKIGQGyLIKDGKLIKNNAstDyDLSDKSINPLGGFVHYG |
| P39687 | S104 | Sugiyama | ANP32A C15orf1 LANP MAPM PHAP1 | AEKCPNLTHLNLsGNKIKDLstIEPLKKLENLKsLDLFNCE |
| P39687 | S117 | Sugiyama | ANP32A C15orf1 LANP MAPM PHAP1 | GNKIKDLstIEPLKKLENLKsLDLFNCEVtNLNDyRENVFK |
| P39748 | S255 | Sugiyama | FEN1 RAD2 | CESIRGIGPKRAVDLIQKHKsIEEIVRRLDPNKYPVPENWL |
| P41236 | S121 | Sugiyama | PPP1R2 IPP2 | ARKLAAAEGLEPKyRIQEQEssGEEDsDLsPEEREKKRQFE |
| P42677 | S78 | Sugiyama | RPS27 MPS1 | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| P42677 | T74 | Sugiyama | RPS27 MPS1 | VLCVGCSTVLCQPTGGKARLtEGCsFRRKQH__________ |
| P43243 | S188 | Sugiyama | MATR3 KIAA0723 | EPPyRVPRDDWEEKRHFRRDsFDDRGPsLNPVLDyDHGsRs |
| P43487 | S60 | Sugiyama | RANBP1 | TLEEDEEELFKMRAKLFRFAsENDLPEWKERGTGDVKLLKH |
| P43490 | S472 | Sugiyama | NAMPT PBEF PBEF1 | EYGQDLLHTVFKNGKVTKsysFDEIRKNAQLNIELEAAHH_ |
| P46087 | S36 | Sugiyama | NOP2 NOL1 NSUN1 | RKARKQKGAEtELVRFLPAVsDENsKRLsSRARKRAAKRRL |
| P46776 | S68 | Sugiyama | RPL27A | yHPGyFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRV |
| P46776 | T72 | Sugiyama | RPL27A | yFGKVGMKHYHLKRNQsFCPtVNLDKLWtLVsEQtRVNAAK |
| P46777 | S172 | Sugiyama | RPL5 MSTP030 | RTTTGNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNA |
| P46777 | S176 | Sugiyama | RPL5 MSTP030 | GNKVFGALKGAVDGGLsIPHstKRFPGyDsEsKEFNAEVHR |
| P46777 | S224 | Sugiyama | RPL5 MSTP030 | VADyMRyLMEEDEDAyKKQFsQyIKNsVtPDMMEEMyKKAH |
| P46937 | S109 | Sugiyama | YAP1 YAP65 | RKLPDsFFKPPEPKsHsRQAstDAGtAGALtPQHVRAHssP |
| P47914 | S142 | Sugiyama | RPL29 | KAKAKAKAKDQTKAQAAAPAsVPAQAPKRtQAPtKAsE___ |
| P49327 | S1597 | Sugiyama | FASN FAS | MLATGKLsPDAIPGKWTSQDsLLGMEFSGRDASGKRVMGLV |
| P50454 | S139 | Sugiyama | SERPINH1 CBP1 CBP2 HSP47 SERPINH2 PIG14 | SNSTARNVTWKLGsRLyGPssVsFADDFVRssKQHYNCEHS |
| P50454 | S141 | Sugiyama | SERPINH1 CBP1 CBP2 HSP47 SERPINH2 PIG14 | STARNVTWKLGsRLyGPssVsFADDFVRssKQHYNCEHSKI |
| P50454 | Y135 | Sugiyama | SERPINH1 CBP1 CBP2 HSP47 SERPINH2 PIG14 | LRSLSNSTARNVTWKLGsRLyGPssVsFADDFVRssKQHYN |
| P51116 | S601 | Sugiyama | FXR2 FMR1L2 | RPQRRNRSRRRRNRGNRtDGsIsGDRQPVtVADyIsRAEsQ |
| P51787 | S484 | SIGNOR|PSP | KCNQ1 KCNA8 KCNA9 KVLQT1 | sVRKsPtLLEVSMPHFMRtNsFAEDLDLEGETLLTPITHIS |
| P51787 | T482 | PSP | KCNQ1 KCNA8 KCNA9 KVLQT1 | DSsVRKsPtLLEVSMPHFMRtNsFAEDLDLEGETLLTPITH |
| P51858 | S83 | Sugiyama | HDGF HMG1L2 | LFPyEEsKEKFGKPNKRKGFsEGLWEIENNPtVKASGYQSs |
| P52272 | S528 | Sugiyama | HNRNPM HNRPM NAGR1 | IERMGsGVERMGPAIERMGLsMERMVPAGMGAGLERMGPVM |
| P52272 | S618 | Sugiyama | HNRNPM HNRPM NAGR1 | PALGAGIERMGLAMGGGGGAsFDRAIEMERGNFGGsFAGsF |
| P52298 | S13 | Sugiyama | NCBP2 CBP20 PIG55 | ________MSGGLLKALRsDsyVELSQYRDQHFRGDNEEQE |
| P52907 | S106 | Sugiyama | CAPZA1 | RFLDPRNKISFKFDHLRKEAsDPQPEEADGGLKsWREsCDs |
| P52948 | S683 | Sugiyama | NUP98 ADAR2 | IAKPIPQtPEsAGNKHsNsNsVDDtIVALNMRAALRNGLEG |
| P53396 | S455 | Sugiyama | ACLY | ANFLLNAsGststPAPsRtAsFsEsRADEVAPAKKAKPAMP |
| P53999 | S104 | Sugiyama | SUB1 PC4 RPO2TC1 | DIREYWMDPEGEMKPGRKGIsLNPEQWsQLKEQIsDIDDAV |
| P53999 | S111 | Sugiyama | SUB1 PC4 RPO2TC1 | DPEGEMKPGRKGIsLNPEQWsQLKEQIsDIDDAVRKL____ |
| P53999 | S118 | Sugiyama | SUB1 PC4 RPO2TC1 | PGRKGIsLNPEQWsQLKEQIsDIDDAVRKL___________ |
| P53999 | S12 | Sugiyama | SUB1 PC4 RPO2TC1 | _________MPKSKELVsssssGsDsDsEVDKKLKRKKQVA |
| P54105 | Y214 | Sugiyama | CLNS1A CLCI ICLN | QsVssQYNMAGVRtEDsIRDyEDGMEVDttPtVAGQFEDAD |
| P55081 | S133 | Sugiyama | MFAP1 | VGEsDsEVEGDAWRMEREDssEEEEEEIDDEEIERRRGMMR |
| P55327 | S176 | SIGNOR|PSP | TPD52 | SVGSVITKKLEDVKNSPTFKsFEEKVENLKSKVGGTKPAGG |
| P56524 | S210 | SIGNOR|EPSD|PSP | HDAC4 KIAA0288 | NLNHCIsSDPRYWYGKtQHssLDQssPPQsGVstsYNHPVL |
| P60174 | S198 | Sugiyama | TPI1 TPI | TPQQAQEVHEKLRGWLKsNVsDAVAQstRIIyGGsVtGAtC |
| P60174 | S212 | Sugiyama | TPI1 TPI | WLKsNVsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLV |
| P60174 | S97 | Sugiyama | TPI1 TPI | GEIsPGMIKDCGAtWVVLGHsERRHVFGEsDELIGQKVAHA |
| P60174 | T217 | Sugiyama | TPI1 TPI | VsDAVAQstRIIyGGsVtGAtCKELASQPDVDGFLVGGAsL |
| P60709 | S199 | Sugiyama | ACTB | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P60709 | S52 | Sugiyama | ACTB | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P60709 | T201 | Sugiyama | ACTB | AGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyVAL |
| P60709 | T203 | Sugiyama | ACTB | RDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyVALDF |
| P60709 | Y240 | Sugiyama | ACTB | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P61247 | S236 | Sugiyama | RPS3A FTE1 MFTL | KMLKKPKFELGKLMELHGEGsssGKAtGDEtGAKVERADGy |
| P61254 | T8 | Sugiyama | RPL26 | _____________MKFNPFVtsDRsKNRKRHFNAPsHIRRK |
| P61353 | S86 | Sugiyama | RPL27 | SKIKSFVKVyNyNHLMPtRysVDIPLDKtVVNKDVFRDPAL |
| P61978 | S401 | Sugiyama | HNRNPK HNRPK | GDLGGPIIttQVtIPKDLAGsIIGKGGQRIKQIRHEsGAsI |
| P61978 | S417 | Sugiyama | HNRNPK HNRPK | DLAGsIIGKGGQRIKQIRHEsGAsIKIDEPLEGsEDRIITI |
| P61978 | S420 | Sugiyama | HNRNPK HNRPK | GsIIGKGGQRIKQIRHEsGAsIKIDEPLEGsEDRIITItGt |
| P61978 | S75 | Sugiyama | HNRNPK HNRPK | GAVIGKGGKNIKALRtDyNAsVsVPDssGPERILsISADIE |
| P61981 | S38 | Sugiyama | YWHAG | ERyDDMAAAMKNVtELNEPLsNEERNLLsVAyKNVVGARRS |
| P61981 | S46 | Sugiyama | YWHAG | AMKNVtELNEPLsNEERNLLsVAyKNVVGARRSsWRVIsSI |
| P61981 | T31 | Sugiyama | YWHAG | ARLAEQAERyDDMAAAMKNVtELNEPLsNEERNLLsVAyKN |
| P62072 | S48 | Sugiyama | TIMM10 TIM10 | ACHRKCVPPHYKEAELSKGEsVCLDRCVSKYLDIHERMGKK |
| P62249 | S9 | Sugiyama | RPS16 | ____________MPsKGPLQsVQVFGRKKTATAVAHCKRGN |
| P62258 | S46 | Sugiyama | YWHAE | SMKKVAGMDVELTVEERNLLsVAyKNVIGARRASWRIIssI |
| P62258 | T229 | Sugiyama | YWHAE | LsEEsyKDstLIMQLLRDNLtLWtsDMQGDGEEQNKEALQD |
| P62266 | S45 | Sugiyama | RPS23 | KQYKKAHLGtALKANPFGGAsHAKGIVLEKVGVEAKQPNSA |
| P62269 | S96 | Sugiyama | RPS18 D6S218E | QYKIPDWFLNRQKDVKDGKysQVLANGLDNKLREDLERLKK |
| P62277 | S12 | Sugiyama | RPS13 | _________MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDD |
| P62277 | S14 | Sugiyama | RPS13 | _______MGRMHAPGKGLsQsALPyRRsVPtWLKLTsDDVK |
| P62280 | T15 | Sugiyama | RPS11 | ______MADIQTERAyQKQPtIFQNKKRVLLGEtGKEKLPR |
| P62424 | T84 | Sugiyama | RPL7A SURF-3 SURF3 | QRQRAILyKRLKVPPAINQFtQALDRQTAtQLLKLAHKYRP |
| P62701 | S204 | Sugiyama | RPS4X CCG2 RPS4 SCAR | tGGANLGRIGVITNRERHPGsFDVVHVKDANGNSFATRLsN |
| P62736 | S54 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P62736 | Y242 | Sugiyama | ACTA2 ACTSA ACTVS GIG46 | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P62857 | S23 | Sugiyama | RPS28 | TSRVQPIKLARVTKVLGRtGsQGQCtQVRVEFMDDtsRsII |
| P62857 | T28 | Sugiyama | RPS28 | PIKLARVTKVLGRtGsQGQCtQVRVEFMDDtsRsIIRNVKG |
| P62899 | S15 | Sugiyama | RPL31 | ______MAPAKKGGEKKKGRsAINEVVtREytINIHKRIHG |
| P62899 | T107 | Sugiyama | RPL31 | RLSRKRNEDEDsPNKLytLVtyVPVttFKNLQtVNVDEN__ |
| P62899 | T119 | Sugiyama | RPL31 | PNKLytLVtyVPVttFKNLQtVNVDEN______________ |
| P62899 | T26 | Sugiyama | RPL31 | KGGEKKKGRsAINEVVtREytINIHKRIHGVGFKKRAPRAL |
| P62906 | S64 | Sugiyama | RPL10A NEDD6 | QKDKRFsGTVRLKSTPRPKFsVCVLGDQQHCDEAKAVDIPH |
| P62917 | S130 | Sugiyama | RPL8 | GTIVCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKL |
| P62917 | T135 | Sugiyama | RPL8 | CLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSGSK |
| P62917 | Y133 | Sugiyama | RPL8 | VCCLEEKPGDRGKLARAsGNyAtVIsHNPEtKKtRVKLPSG |
| P62937 | T157 | Sugiyama | PPIA CYPA | NIVEAMERFGsRNGKTSKKItIADCGQLE____________ |
| P62942 | T22 | Sugiyama | FKBP1A FKBP1 FKBP12 | GVQVEtIsPGDGRtFPKRGQtCVVHytGMLEDGKKFDSSRD |
| P62942 | T7 | Sugiyama | FKBP1A FKBP1 FKBP12 | ______________MGVQVEtIsPGDGRtFPKRGQtCVVHy |
| P62979 | S123 | Sugiyama | RPS27A UBA80 UBCEP1 | LKYYKVDENGKIsRLRRECPsDECGAGVFMAsHFDRHyCGK |
| P62979 | S134 | Sugiyama | RPS27A UBA80 UBCEP1 | IsRLRRECPsDECGAGVFMAsHFDRHyCGKCCLtyCFNKPE |
| P63104 | S28 | Sugiyama | YWHAZ | QKAKLAEQAERyDDMAACMKsVtEQGAELsNEERNLLsVAy |
| P63104 | S45 | Sugiyama | YWHAZ | CMKsVtEQGAELsNEERNLLsVAyKNVVGARRssWRVVssI |
| P63167 | S21 | Sugiyama | DYNLL1 DLC1 DNCL1 DNCLC1 HDLC1 | MCDRKAVIKNADMsEEMQQDsVECAtQALEKYNIEKDIAAH |
| P63220 | S31 | Sugiyama | RPS21 | LYVPRKCSASNRIIGAKDHAsIQMNVAEVDKVTGRFNGQFK |
| P63220 | S65 | Sugiyama | RPS21 | RFNGQFKtyAICGAIRRMGEsDDsILRLAKADGIVSKNF__ |
| P63261 | S199 | Sugiyama | ACTG1 ACTG | DLAGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyV |
| P63261 | S52 | Sugiyama | ACTG1 ACTG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKYPIE |
| P63261 | T201 | Sugiyama | ACTG1 ACTG | AGRDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyVAL |
| P63261 | T203 | Sugiyama | ACTG1 ACTG | RDLTDyLMKILtERGysFtttAEREIVRDIKEKLCyVALDF |
| P63261 | Y240 | Sugiyama | ACTG1 ACTG | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| P63267 | S53 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P63267 | Y241 | Sugiyama | ACTG2 ACTA3 ACTL3 ACTSG | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P67809 | S102 | Sugiyama | YBX1 NSEP1 YB1 | EDVFVHQtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKGAEA |
| P67809 | S136 | Sugiyama | YBX1 NSEP1 YB1 | GEKGAEAANVtGPGGVPVQGsKYAADRNHYRRYPRRRGPPR |
| P67809 | S209 | Sugiyama | YBX1 NSEP1 YB1 | RRRRFPPyyMRRPYGRRPQysNPPVQGEVMEGADNQGAGEQ |
| P67809 | T108 | Sugiyama | YBX1 NSEP1 YB1 | QtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKGAEAANVtGP |
| P67809 | T80 | Sugiyama | YBX1 NSEP1 YB1 | LGTVKWFNVRNGyGFINRNDtKEDVFVHQtAIKKNNPRKyL |
| P67809 | Y99 | Sugiyama | YBX1 NSEP1 YB1 | DtKEDVFVHQtAIKKNNPRKyLRsVGDGEtVEFDVVEGEKG |
| P68032 | S54 | Sugiyama | ACTC1 ACTC | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68032 | Y242 | Sugiyama | ACTC1 ACTC | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68133 | S54 | Sugiyama | ACTA1 ACTA | PsIVGRPRHQGVMVGMGQKDsyVGDEAQsKRGILTLKyPIE |
| P68133 | Y242 | Sugiyama | ACTA1 ACTA | ALDFENEMAtAAssssLEKsyELPDGQVItIGNERFRCPET |
| P68363 | S439 | Sugiyama | TUBA1B | SEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy________ |
| P68363 | Y432 | Sugiyama | TUBA1B | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| P83731 | S38 | Sugiyama | RPL24 | GRRYARTDGKVFQFLNAKCEsAFLSKRNPRQINWtVLyRRK |
| P83731 | S7 | Sugiyama | RPL24 | ______________MKVELCsFsGyKIYPGHGRRYARTDGK |
| P83731 | S86 | Sugiyama | RPL24 | EIQKKRTRRAVKFQRAItGAsLADIMAKRNQKPEVRKAQRE |
| P83731 | T83 | Sugiyama | RPL24 | QsEEIQKKRTRRAVKFQRAItGAsLADIMAKRNQKPEVRKA |
| P84098 | S12 | Sugiyama | RPL19 | _________MSMLRLQKRLAssVLRCGKKKVWLDPNEtNEI |
| P84098 | S13 | Sugiyama | RPL19 | ________MSMLRLQKRLAssVLRCGKKKVWLDPNEtNEIA |
| P84098 | S37 | Sugiyama | RPL19 | CGKKKVWLDPNEtNEIANANsRQQIRKLIKDGLIIRKPVtV |
| P84098 | T29 | Sugiyama | RPL19 | RLAssVLRCGKKKVWLDPNEtNEIANANsRQQIRKLIKDGL |
| P98175 | S733 | Sugiyama | RBM10 DXS8237E GPATC9 GPATCH9 KIAA0122 | LPKLAsDDRPsPPRGLVAAysGEsDsEEEQERGGPEREEKL |
| Q00688 | T11 | Sugiyama | FKBP3 FKBP25 | __________MAAAVPQRAWtVEQLRSEQLPKKDIIKFLQE |
| Q00839 | S59 | Sugiyama | HNRNPU C1orf199 HNRPU SAFA U21.1 | QAALDDEEAGGRPAMEPGNGsLDLGGDsAGRSGAGLEQEAA |
| Q01650 | S35 | Sugiyama | SLC7A5 CD98LC LAT1 MPE16 | AAEEKEEAREKMLAAKsADGsAPAGEGEGVtLQRNITLLNG |
| Q02539 | S89 | Sugiyama | H1-1 H1F1 HIST1H1A | LAAAGyDVEKNNSRIKLGIKsLVsKGtLVQtKGtGAsGsFK |
| Q02539 | S92 | Sugiyama | H1-1 H1F1 HIST1H1A | AGyDVEKNNSRIKLGIKsLVsKGtLVQtKGtGAsGsFKLNK |
| Q02539 | T95 | Sugiyama | H1-1 H1F1 HIST1H1A | DVEKNNSRIKLGIKsLVsKGtLVQtKGtGAsGsFKLNKKAS |
| Q02543 | S123 | Sugiyama | RPL18A | AGAVtQCyRDMGARHRARAHsIQIMKVEEIAASKCRRPAVK |
| Q02878 | T118 | Sugiyama | RPL6 TXREB1 | GDKNGGTRVVKLRKMPRyyPtEDVPRKLLSHGKKPFSQHVR |
| Q02878 | Y116 | Sugiyama | RPL6 TXREB1 | VGGDKNGGTRVVKLRKMPRyyPtEDVPRKLLSHGKKPFSQH |
| Q04917 | S46 | Sugiyama | YWHAH YWHA1 | AMKAVtELNEPLsNEDRNLLsVAyKNVVGARRSsWRVIsSI |
| Q05682 | S58 | Sugiyama | CALD1 CAD CDM | ARERRRRARQERLRQKQEEEsLGQVTDQVEVNAQNsVPDEE |
| Q06830 | S152 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | IIDDKGILRQItVNDLPVGRsVDEtLRLVQAFQFtDKHGEV |
| Q06830 | T143 | Sugiyama | PRDX1 PAGA PAGB TDPX2 | EGIsFRGLFIIDDKGILRQItVNDLPVGRsVDEtLRLVQAF |
| Q07020 | S140 | Sugiyama | RPL18 | ILtFDQLALDsPKGCGtVLLsGPRKGREVYRHFGKAPGtPH |
| Q07020 | T136 | Sugiyama | RPL18 | AGGKILtFDQLALDsPKGCGtVLLsGPRKGREVYRHFGKAP |
| Q07020 | T85 | Sugiyama | RPL18 | RMIRKMKLPGRENKtAVVVGtItDDVRVQEVPKLKVCALRV |
| Q07157 | S1051 | Sugiyama | TJP1 ZO1 | PDKEPNLTyEPQLPYVEKQAsRDLEQPtyRyEsssytDQFs |
| Q07666 | S20 | Sugiyama | KHDRBS1 SAM68 | _MQRRDDPAARMsRssGRsGsMDPsGAHPsVRQtPsRQPPL |
| Q08289 | T554 | SIGNOR | CACNB2 CACNLB2 MYSB | sSAPHHNHRSGTSRGLSRQEtFDSETQESRDSAYVEPKEDY |
| Q08AD1 | S1313 | Sugiyama | CAMSAP2 CAMSAP1L1 KIAA1078 | sLNtGDNEsVHsGKRtPRsEsVEGFLsPsRCGsRNGEKDWE |
| Q12830 | S1310 | Sugiyama | BPTF FAC1 FALZ | DRVLDDVsIRsPEtKCPKQNsIENDIEEKVSDLASRGQEPS |
| Q13428 | S88 | Sugiyama | TCOF1 | DAALQAKKTRVsDPIstsEssEEEEEAEAETAKAtPRLAst |
| Q13435 | S307 | Sugiyama | SF3B2 SAP145 | MNsQQEEEEMETDARssLGQsAsEtEEDtVsVsKKEKNRKR |
| Q13439 | S41 | Sugiyama | GOLGA4 | APAQAssNsstPtRMRsRtssFtEQLDEGtPNRESGDTQSF |
| Q13442 | S19 | Sugiyama | PDAP1 HASPP28 | __MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREEEE |
| Q13442 | S63 | Sugiyama | PDAP1 HASPP28 | GGDGAAGDPKKEKKsLDsDEsEDEEDDyQQKRKGVEGLIDI |
| Q13442 | T18 | Sugiyama | PDAP1 HASPP28 | ___MPKGGRKGGHKGRARQytsPEEIDAQLQAEKQKAREEE |
| Q13509 | S75 | Sugiyama | TUBB3 TUBB4 | SSHKYVPRAILVDLEPGtMDsVRSGAFGHLFRPDNFIFGQS |
| Q13509 | T72 | Sugiyama | TUBB3 TUBB4 | NEASSHKYVPRAILVDLEPGtMDsVRSGAFGHLFRPDNFIF |
| Q13554 | S26 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | TCTRFTDEYQLYEDIGKGAFsVVRRCVKLCTGHEYAAKIIN |
| Q13554 | S280 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | RITAHEALKHPWVCQRstVAsMMHRQEtVECLKKFNARRKL |
| Q13554 | T240 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | HKLYQQIKAGAyDFPsPEWDtVTPEAKNLINQMLTINPAKR |
| Q13554 | T277 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | PAKRITAHEALKHPWVCQRstVAsMMHRQEtVECLKKFNAR |
| Q13554 | T306 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | EtVECLKKFNARRKLKGAILttMLAtRNFSVGRQTtAPAtM |
| Q13554 | T307 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | tVECLKKFNARRKLKGAILttMLAtRNFSVGRQTtAPAtMS |
| Q13554 | T311 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | LKKFNARRKLKGAILttMLAtRNFSVGRQTtAPAtMSTAAS |
| Q13554 | Y231 | Sugiyama | CAMK2B CAM2 CAMK2 CAMKB | YPPFWDEDQHKLYQQIKAGAyDFPsPEWDtVTPEAKNLINQ |
| Q13555 | S26 | Sugiyama | CAMK2G CAMK CAMK-II CAMKG | TCTRFTDDYQLFEELGKGAFsVVRRCVKKTstQEYAAKIIN |
| Q13555 | S280 | Sugiyama | CAMK2G CAMK CAMK-II CAMKG | RITADQALKHPWVCQRstVAsMMHRQEtVECLRKFNARRKL |
| Q13555 | T240 | Sugiyama | CAMK2G CAMK CAMK-II CAMKG | HKLYQQIKAGAyDFPsPEWDtVTPEAKNLINQMLTINPAKR |
| Q13555 | T277 | Sugiyama | CAMK2G CAMK CAMK-II CAMKG | PAKRITADQALKHPWVCQRstVAsMMHRQEtVECLRKFNAR |
| Q13555 | Y231 | Sugiyama | CAMK2G CAMK CAMK-II CAMKG | YPPFWDEDQHKLYQQIKAGAyDFPsPEWDtVTPEAKNLINQ |
| Q13557 | S26 | Sugiyama | CAMK2D CAMKD | TCTRFTDEyQLFEELGKGAFsVVRRCMKIPTGQEYAAKIIN |
| Q13557 | S264 | Sugiyama | CAMK2D CAMKD | EAKDLINKMLTINPAKRItAsEALKHPWICQRstVAsMMHR |
| Q13557 | S276 | Sugiyama | CAMK2D CAMKD | NPAKRItAsEALKHPWICQRstVAsMMHRQEtVDCLKKFNA |
| Q13557 | S280 | Sugiyama | CAMK2D CAMKD | RItAsEALKHPWICQRstVAsMMHRQEtVDCLKKFNARRKL |
| Q13557 | S315 | iPTMNet|Sugiyama | CAMK2D CAMKD | NARRKLKGAILttMLAtRNFsAAKsLLKKPDGVKEstEssN |
| Q13557 | S319 | iPTMNet | CAMK2D CAMKD | KLKGAILttMLAtRNFsAAKsLLKKPDGVKEstEssNttIE |
| Q13557 | S330 | Sugiyama | CAMK2D CAMKD | AtRNFsAAKsLLKKPDGVKEstEssNttIEDEDVKARKQEI |
| Q13557 | S333 | iPTMNet|Sugiyama | CAMK2D CAMKD | NFsAAKsLLKKPDGVKEstEssNttIEDEDVKARKQEIIKV |
| Q13557 | S334 | iPTMNet|Sugiyama | CAMK2D CAMKD | FsAAKsLLKKPDGVKEstEssNttIEDEDVKARKQEIIKVT |
| Q13557 | T240 | Sugiyama | CAMK2D CAMKD | HRLYQQIKAGAyDFPsPEWDtVTPEAKDLINKMLTINPAKR |
| Q13557 | T262 | Sugiyama | CAMK2D CAMKD | TPEAKDLINKMLTINPAKRItAsEALKHPWICQRstVAsMM |
| Q13557 | T277 | Sugiyama | CAMK2D CAMKD | PAKRItAsEALKHPWICQRstVAsMMHRQEtVDCLKKFNAR |
| Q13557 | T287 | GPS6|EPSD|PSP | CAMK2D CAMKD | LKHPWICQRstVAsMMHRQEtVDCLKKFNARRKLKGAILtt |
| Q13557 | T306 | Sugiyama | CAMK2D CAMKD | EtVDCLKKFNARRKLKGAILttMLAtRNFsAAKsLLKKPDG |
| Q13557 | T307 | GPS6|Sugiyama | CAMK2D CAMKD | tVDCLKKFNARRKLKGAILttMLAtRNFsAAKsLLKKPDGV |
| Q13557 | T311 | Sugiyama | CAMK2D CAMKD | LKKFNARRKLKGAILttMLAtRNFsAAKsLLKKPDGVKEst |
| Q13557 | T331 | iPTMNet|Sugiyama | CAMK2D CAMKD | tRNFsAAKsLLKKPDGVKEstEssNttIEDEDVKARKQEII |
| Q13557 | T337 | iPTMNet|Sugiyama | CAMK2D CAMKD | AKsLLKKPDGVKEstEssNttIEDEDVKARKQEIIKVTEQL |
| Q13557 | Y231 | Sugiyama | CAMK2D CAMKD | YPPFWDEDQHRLYQQIKAGAyDFPsPEWDtVTPEAKDLINK |
| Q13573 | T261 | Sugiyama | SNW1 SKIIP SKIP | EQQEWKIPPCISNWKNAKGytIPLDKRLAADGRGLQTVHIN |
| Q13885 | S75 | Sugiyama | TUBB2A TUBB2 | AGNKYVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVFGQs |
| Q13885 | T72 | Sugiyama | TUBB2A TUBB2 | NEAAGNKYVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVF |
| Q14151 | S613 | Sugiyama | SAFB2 KIAA0138 | ERSSKSQDRKSESKEKRDILsFDKIKEQRERERQRQREREI |
| Q14152 | S1188 | Sugiyama | EIF3A EIF3S10 KIAA0139 | PWRPLVKPGGWREKEKAREEsWGPPRESRPsEEREWDREKE |
| Q14152 | S584 | Sugiyama | EIF3A EIF3S10 KIAA0139 | EHQRILARRQtIEERKERLEsLNIQREKEELEQREAELQKV |
| Q14157 | T239 | Sugiyama | UBAP2L KIAA0144 NICE4 | GNTWNNTGHFEPDDGTSAWRtAtEEWGtEDWNEDLsEtKIF |
| Q14157 | T241 | Sugiyama | UBAP2L KIAA0144 NICE4 | TWNNTGHFEPDDGTSAWRtAtEEWGtEDWNEDLsEtKIFtA |
| Q14157 | T246 | Sugiyama | UBAP2L KIAA0144 NICE4 | GHFEPDDGTSAWRtAtEEWGtEDWNEDLsEtKIFtAsNVss |
| Q14192 | S238 | Sugiyama | FHL2 DRAL SLIM3 | AKKCAGCTNPISGLGGtKyIsFEERQWHNDCFNCKKCsLsL |
| Q14247 | S282 | Sugiyama | CTTN EMS1 | QKDyKTGFGGKFGVQsERQDsAAVGFDyKEKLAKHEsQQDy |
| Q14247 | S322 | Sugiyama | CTTN EMS1 | ySKGFGGKyGVQKDRMDKNAstFEDVtQVssAyQKTVPVEA |
| Q14524 | S1934 | SIGNOR | SCN5A | RHLLQRsLKHAsFLFRQQAGsGLsEEDAPEREGLIAYVMSE |
| Q14524 | S1985 | SIGNOR | SCN5A | SSSISSTSFPPSYDSVTRATsDNLQVRGSDYSHsEDLADFP |
| Q14524 | S516 | SIGNOR|EPSD|PSP | SCN5A | KsDsEDGPRAMNHLsLTRGLsRTSMKPRssRGsIFTFRRRD |
| Q14524 | S571 | SIGNOR | SCN5A | AGESESHHTSLLVPWPLRRtsAQGQPsPGTSAPGHALHGKK |
| Q14524 | T594 | SIGNOR|EPSD|PSP | SCN5A | GQPsPGTSAPGHALHGKKNStVDCNGVVSLLGAGDPEATSP |
| Q14568 | S52 | Sugiyama | HSP90AA2P HSP90AA2 HSPC2 HSPCAL3 | LIINTFYSNKEIFLRELIsNssDALDKIWYESLTDPSKLDS |
| Q14571 | S150 | SIGNOR | ITPR2 | KYLTVNKRLPALLEKNAMRVsLDAAGNEGSWFYIHPFWKLR |
| Q14654 | T224 | SIGNOR|EPSD|PSP | KCNJ11 | DLRKSMIISATIHMQVVRKTtSPEGEVVPLHQVDIPMENGV |
| Q14676 | T449 | Sugiyama | MDC1 KIAA0170 NFBD1 | RDAEEDMPQRVVLLQRsQtttERDsDtDVEEEELPVENREA |
| Q14677 | S164 | Sugiyama | CLINT1 ENTH EPN4 EPNR KIAA0171 | RLREERKKAKKNKDKyVGVssDsVGGFRysERYDPEPKSKW |
| Q14677 | S166 | Sugiyama | CLINT1 ENTH EPN4 EPNR KIAA0171 | REERKKAKKNKDKyVGVssDsVGGFRysERYDPEPKSKWDE |
| Q14847 | S146 | Sugiyama | LASP1 MLN50 | FEKSRMGPsGGEGMEPERRDsQDGssyRRPLEQQQPHHIPt |
| Q14847 | S99 | Sugiyama | LASP1 MLN50 | ELQsQVRYKEEFEKNKGKGFsVVADtPELQRIKKTQDQIsN |
| Q15084 | S169 | Sugiyama | PDIA6 ERP5 P5 TXNDC7 | GKQGRSDsSSKKDVIELtDDsFDKNVLDSEDVWMVEFYAPW |
| Q15121 | S116 | Sugiyama | PEA15 | DtKLtRIPsAKKYKDIIRQPsEEEIIKLAPPPKKA______ |
| Q15139 | S247 | Sugiyama | PRKD1 PKD PKD1 PRKCM | PDEPLLQKsPsEsFIGREKRsNsQsyIGRPIHLDKILMSKV |
| Q15139 | S249 | Sugiyama | PRKD1 PKD PKD1 PRKCM | EPLLQKsPsEsFIGREKRsNsQsyIGRPIHLDKILMSKVKV |
| Q15139 | S251 | Sugiyama | PRKD1 PKD PKD1 PRKCM | LLQKsPsEsFIGREKRsNsQsyIGRPIHLDKILMSKVKVPH |
| Q15185 | S113 | Sugiyama | PTGES3 P23 TEBP | RAKLNWLsVDFNNWKDWEDDsDEDMsNFDRFSEMMNNMGGD |
| Q15185 | S82 | Sugiyama | PTGES3 P23 TEBP | NDsKHKRtDRsILCCLRKGEsGQsWPRLTKERAKLNWLsVD |
| Q15293 | S69 | Sugiyama | RCN1 RCN | PPEDNQsFQYDHEAFLGKEDsKtFDQLtPDEsKERLGKIVD |
| Q16204 | S323 | Sugiyama | CCDC6 D10S170 TST1 | RLQRKLQREMERREALCRQLsEsEssLEMDDERYFNEMsAQ |
| Q16204 | S328 | Sugiyama | CCDC6 D10S170 TST1 | LQREMERREALCRQLsEsEssLEMDDERYFNEMsAQGLRPR |
| Q16625 | S471 | EPSD|PSP | OCLN | DEINKELSRLDKELDDYREEsEEyMAAADEYNRLKQVKGsA |
| Q16626 | S163 | Sugiyama | MEA1 MEA | RTMAGVSLPAPGVPAWAREIsDAQWEDVVQKALQARQAsPA |
| Q32P51 | S22 | Sugiyama | HNRNPA1L2 HNRNPA1L | SKSASPKEPEQLRKLFIGGLsFEtTDESLRSHFEQWGTLTD |
| Q32P51 | S95 | Sugiyama | HNRNPA1L2 HNRNPA1L | TPHKVDGRVVEPKRAVsREDsQRPGAHLtVKKIFVGGIKED |
| Q32P51 | T25 | Sugiyama | HNRNPA1L2 HNRNPA1L | ASPKEPEQLRKLFIGGLsFEtTDESLRSHFEQWGTLTDCVV |
| Q3ZCM7 | S75 | Sugiyama | TUBB8 | SGGRYVPRAVLVDLEPGtMDsVRSGPFGQVFRPDNFIFGQC |
| Q3ZCM7 | T72 | Sugiyama | TUBB8 | NEASGGRYVPRAVLVDLEPGtMDsVRSGPFGQVFRPDNFIF |
| Q562R1 | Y241 | Sugiyama | ACTBL2 | ALDFEQEMVRAAAssSPERsyELPDGQVItIGNERFRCPEA |
| Q5SW79 | S881 | Sugiyama | CEP170 FAM68A KAB KIAA0470 | sstPssLALtsAsRIRERsEsLDPDssMDTtLILKDTEAVM |
| Q5VT52 | S1177 | Sugiyama | RPRD2 KIAA0460 HSPC099 | GGLTGFKTAPYKERAPQFQEsVGsFRsNsFNstFEHHLPPs |
| Q6GYQ0 | T798 | Sugiyama | RALGAPA1 GARNL1 KIAA0884 TULIP1 | tGNEVFGALNEEQPLPRssstsDILEPFTVERAKVNKEDMS |
| Q6P996 | S724 | Sugiyama | PDXDC1 KIAA0251 | QKPFKRsLRGsDALsEtssVsHIEDLEKVERLssGPEQItL |
| Q6S8J3 | Y940 | Sugiyama | POTEE A26C1A POTE2 | ALDFEQEMAtAAssssLEKsyELPDGQVItIGNERFRCPEA |
| Q71U36 | S439 | Sugiyama | TUBA1A TUBA3 | SEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy________ |
| Q71U36 | Y432 | Sugiyama | TUBA1A TUBA3 | GMEEGEFSEAREDMAALEKDyEEVGVDsVEGEGEEEGEEy_ |
| Q71UM5 | S78 | Sugiyama | RPS27L | GCSTVLCQPTGGKARLtEGCsFRRKQH______________ |
| Q71UM5 | T74 | Sugiyama | RPS27L | VLCVGCSTVLCQPTGGKARLtEGCsFRRKQH__________ |
| Q7LBC6 | S816 | Sugiyama | KDM3B C5orf7 JHDM2B JMJD1B KIAA1082 | RFsLDERSLACRQDsDSSTNsDLSDLSDSEEQLQAKTGLKG |
| Q7Z417 | S652 | Sugiyama | NUFIP2 KIAA1321 PIG1 | NtLLGsAKEQRYQRGLERNDsWGsFDLRAAIVYHTKEMEsI |
| Q7Z4V5 | S369 | Sugiyama | HDGFL2 HDGF2 HDGFRP2 HRP2 UNQ785/PRO1604 | EKERRRERADRGEAERGsGGssGDELREDDEPVKKRGRKGR |
| Q7Z7L8 | S425 | Sugiyama | C11orf96 AG2 | RstQsLSLQREQLSSCKLRNsLDssDsDsAL__________ |
| Q86UF2 | S140 | Sugiyama | CTAGE6 CTAGE6P | AAAEEARSLEATCEKLNRsNsELEDEILCLEKDLKEEKSKH |
| Q86V81 | S239 | Sugiyama | ALYREF ALY BEF THOC4 | tRGGARGRGRGAGRNSKQQLsAEELDAQLDAyNARMDts__ |
| Q86V81 | S8 | Sugiyama | ALYREF ALY BEF THOC4 | _____________MADKMDMsLDDIIKLNRSQRGGRGGGRG |
| Q86V81 | T148 | Sugiyama | ALYREF ALY BEF THOC4 | EFGtLKKAAVHYDRsGRsLGtADVHFERKADALKAMKQYNG |
| Q86VQ1 | S223 | Sugiyama | GLCCI1 | QTPsCWAEEGAEKRSHQRsAsWGsADQLKEQIAKLRQQLQR |
| Q86W56 | S133 | Sugiyama | PARG | VQKDNFyQHNVEKLENVsQLsLDKsPtEKSTQYLNQHQTAA |
| Q8IX94 | S140 | Sugiyama | CTAGE4 | AAAEEARSLEATCEKLNRsNsELEDEILCLEKDLKEEKSKH |
| Q8N3V7 | S263 | Sugiyama | SYNPO KIAA1029 | HsMEGYSEEASLLRHLEKVAsEEEEVPLVVYLKENAALLTA |
| Q8N6H7 | S368 | Sugiyama | ARFGAP2 ZNF289 Nbla10535 | VGTFASGPPKYKDNPFsLGEsFGsRWDTDAAWGMDRVEEKE |
| Q8N6H7 | S432 | Sugiyama | ARFGAP2 ZNF289 Nbla10535 | RssGLEssEARQKFAGAKAIssDMFFGREVDAEyEARSRLQ |
| Q8N8S7 | S125 | Sugiyama | ENAH MENA | MHALEVLNSQETGPTLPRQNsQLPAQVQNGPSQEELEIQRR |
| Q8NE71 | S140 | Sugiyama | ABCF1 ABC50 | PRGGKKTKGGNVFAALIQDQsEEEEEEEKHPPKPAKPEKNR |
| Q8NFH8 | S631 | Sugiyama | REPS2 POB1 | AIQTAIRKNKEANAVLARLNsELQQQLKEVHQERIALENQL |
| Q8NHW5 | S304 | Sugiyama | RPLP0P6 | DTTAAPAAAAAPAKVEAKEEsEEsDEDMGFGLFD_______ |
| Q8TAM6 | S280 | Sugiyama | ERMN KIAA1189 | TISYRKIRKGNTKQRIDEFEsMMHL________________ |
| Q8TEQ6 | S757 | Sugiyama | GEMIN5 | PKAKPKKKKKPTLRtPVKLEsIDGNEEEsMKENsGPVENGV |
| Q8WVC0 | T477 | Sugiyama | LEO1 RDL | FDVYKAPLQGDHNHLFIRQGtGLQGQAVFKTKLTFRPHstD |
| Q8WWI1 | S1510 | Sugiyama | LMO7 FBX20 FBXO20 KIAA0858 | RsAsVNKEPVSLPGIMRRGEsLDNLDsPRSNSWRQPPWLNQ |
| Q8WWI1 | S706 | Sugiyama | LMO7 FBX20 FBXO20 KIAA0858 | RLMVERLFQKIYGENGsKsMsDVsAEDVQNLRQLRYEEMQK |
| Q8WWI1 | T932 | Sugiyama | LMO7 FBX20 FBXO20 KIAA0858 | VtPRPFGsQtRGISsLPRsYtMDDAWKYNGDVEDIKRtPNN |
| Q8WX93 | S479 | Sugiyama | PALLD KIAA0992 CGI-151 | VLECRVRGAPPLQVQWFRQGsEIQDsPDFRILQKKPRSTAE |
| Q8WZ42 | S11878 | EPSD|PSP | TTN | KVRKLLPERKPEPKEEVVLKsVLRKRPEEEEPKVEPKKLEK |
| Q8WZ42 | S12022 | EPSD|PSP | TTN | GVPKKTPSPIEAERRKLRPGsGGEKPPDEAPFTYQLKAVPL |
| Q8WZ42 | T11922 | PSP | TTN | PAVPEPPPPKPVEEVEVPTVtKRERKIPEPtKVPEIKPAIP |
| Q8WZ42 | T11932 | PSP | TTN | PVEEVEVPTVtKRERKIPEPtKVPEIKPAIPLPAPEPKPKP |
| Q8WZ42 | T11969 | PSP | TTN | KPKPEAEVKTIKPPPVEPEPtPIAAPVTVPVVGKKAEAKAP |
| Q92625 | S663 | Sugiyama | ANKS1A ANKS1 KIAA0229 ODIN | sRsEsLsNCsIGKKRLEKsPsFAsEWDEIEKIMssIGEGID |
| Q92688 | S117 | Sugiyama | ANP32B APRIL PHAPI2 | GNKLKDIstLEPLKKLECLKsLDLFNCEVtNLNDyREsVFK |
| Q92736 | S2808 | EPSD | RYR2 | RIERTREGDSMALYNRTRRIsQTSQVsVDAAHGYSPRAIDM |
| Q92736 | S2814 | EPSD | RYR2 | EGDSMALYNRTRRIsQTSQVsVDAAHGYSPRAIDMSNVTLS |
| Q92769 | S424 | Sugiyama | HDAC2 | KRIsIRAsDKRIACDEEFsDsEDEGEGGRRNVADHKKGAKK |
| Q92804 | S289 | Sugiyama | TAF15 RBP56 TAF2N | PMINLYTDKDTGKPKGEAtVsFDDPPsAKAAIDWFDGKEFH |
| Q92804 | T287 | Sugiyama | TAF15 RBP56 TAF2N | GKPMINLYTDKDTGKPKGEAtVsFDDPPsAKAAIDWFDGKE |
| Q93045 | S80 | Sugiyama | STMN2 SCG10 SCGN10 | PPsPISEAPRTLAsPKKKDLsLEEIQKKLEAAEERRKsQEA |
| Q96D71 | S767 | Sugiyama | REPS1 | AIQAsIRRNKETNTVLARLNsELQQQLKDVLEERISLEVQL |
| Q96E11 | S239 | Sugiyama | MRRF | LKKSKDTVsEDtIRLIEKQIsQMADDtVAELDRHLAVKTKE |
| Q96MH2 | S194 | Sugiyama | HEXIM2 L3 | EAGDSDGRGRAHGEFQRKDFsEtYERFHTESLQGRSKQELV |
| Q96MH2 | T196 | Sugiyama | HEXIM2 L3 | GDSDGRGRAHGEFQRKDFsEtYERFHTESLQGRSKQELVRD |
| Q96S59 | S714 | Sugiyama | RANBP9 RANBPM | QPPLALAMGQATQCLGLMARsGIGSCAFAtVEDYLH_____ |
| Q96S59 | T723 | Sugiyama | RANBP9 RANBPM | QATQCLGLMARsGIGSCAFAtVEDYLH______________ |
| Q96ST3 | S158 | Sugiyama | SIN3A | GSQPQVYNDFLDIMKEFKSQsIDtPGVISRVSQLFKGHPDL |
| Q99613 | S39 | Sugiyama | EIF3C EIF3S8 | GEELVTKPVGGNyGKQPLLLsEDEEDTKRVVRSAKDKRFEE |
| Q99613 | S865 | Sugiyama | EIF3C EIF3S8 | HRTEPTAQQNLALQLAEKLGsLVENNERVFDHKQGtyGGyF |
| Q99618 | S94 | Sugiyama | CDCA3 C8 GRCC8 TOME1 | ARtPMKTSsGDPPsPLVKQLsEVFETEDSKSNLPPEPVLPP |
| Q99755 | S486 | Sugiyama | PIP5K1A | GssFSRRAGssGNsCItyQPsVsGEHKAQVTTKAEVEPGVH |
| Q9BTE6 | S174 | Sugiyama | AARSD1 | IEQSVNEKIRDRLPVNVRELsLDDPEVEQVsGRGLPDDHAG |
| Q9BVA1 | S75 | Sugiyama | TUBB2B | tGNKYVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVFGQs |
| Q9BVA1 | T72 | Sugiyama | TUBB2B | NEAtGNKYVPRAILVDLEPGtMDsVRsGPFGQIFRPDNFVF |
| Q9BY44 | S526 | Sugiyama | EIF2A CDA02 MSTP004 MSTP089 | sPDLAPtPAPQstPRNtVsQsIsGDPEIDKKIKNLKKKLKA |
| Q9BYX7 | Y240 | Sugiyama | POTEKP ACTBL3 FKSG30 | ALDSEQEMAMAASSSSVEKsyELPDGQVItIGNERFRCPEA |
| Q9BZI7 | S166 | Sugiyama | UPF3B RENT3B UPF3X | KRDTKVGtIDDDPEyRKFLEsyAtDNEKMTstPEtLLEEIE |
| Q9C0C2 | S1620 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | ADsDAHLFQDSTEPRAsRVPssDEEVVEEPQsRRTRMsLGT |
| Q9C0C2 | S435 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | DAHLRPtsLVQRRFsEGVLQsPsQDQEKLGGsLAALPQGQG |
| Q9C0C2 | S437 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | HLRPtsLVQRRFsEGVLQsPsQDQEKLGGsLAALPQGQGsQ |
| Q9C0C2 | S836 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | GVLTAQDRVVGKPAQLGtQRsQEADVQDWEFRKRDsQGtys |
| Q9C0C2 | S899 | Sugiyama | TNKS1BP1 KIAA1741 TAB182 | RDVsLGDWEFGKRDsLGAyAsQDANEQGQDLGKRDHHGRys |
| Q9H1E3 | S113 | Sugiyama | NUCKS1 NUCKS JC7 | RQAASKAASKQREMLMEDVGsEEEQEEEDEAPFQEKDsGsD |
| Q9H444 | T85 | Sugiyama | CHMP4B C20orf178 SHAX1 | ALQALKRKKRYEKQLAQIDGtLstIEFQREALENANtNtEV |
| Q9H444 | T88 | Sugiyama | CHMP4B C20orf178 SHAX1 | ALKRKKRYEKQLAQIDGtLstIEFQREALENANtNtEVLKN |
| Q9H6S3 | S693 | Sugiyama | EPS8L2 EPS8R2 PP13181 | EGVRVySQLTMQKAFLEKQQsGSELEELMNKFHSMNQRRGE |
| Q9HCN8 | T70 | Sugiyama | SDF2L1 UNQ1941/PRO4424 | RVRLHSHDIKYGSGSGQQSVtGVEAsDDANSyWRIRGGSEG |
| Q9NP61 | S366 | Sugiyama | ARFGAP3 ARFGAP1 | DDsyFTSSSSYFDEPVELRsssFssWDDssDSyWKKETSKD |
| Q9NP61 | S367 | Sugiyama | ARFGAP3 ARFGAP1 | DsyFTSSSSYFDEPVELRsssFssWDDssDSyWKKETSKDT |
| Q9NR30 | S706 | Sugiyama | DDX21 | PTASVTEIQEKWHDSRRWQLsVATEQPELEGPREGYGGFRG |
| Q9NUU7 | T467 | Sugiyama | DDX19A DDX19L | SMNILNRIQEHFNKKIERLDtDDLDEIEKIAN_________ |
| Q9UHA3 | S68 | Sugiyama | RSL24D1 C15orf15 RPL24L My024 | KVRWTKAFRKAAGKELtVDNsFEFEKRRNEPIKYQRELWNK |
| Q9UHA3 | T64 | Sugiyama | RSL24D1 C15orf15 RPL24L My024 | RNPRKVRWTKAFRKAAGKELtVDNsFEFEKRRNEPIKYQRE |
| Q9UII2 | S63 | Sugiyama | ATP5IF1 ATPI ATPIF1 | AGGAFGKREQAEEERyFRAQsREQLAALKKHHEEEIVHHKK |
| Q9UKY7 | S106 | Sugiyama | CDV3 H41 | KELEQKEVDysGLRVQAMQIssEKEEDDNEKRQDPGDNWEE |
| Q9ULD2 | S1203 | Sugiyama | MTUS1 ATBP ATIP GK1 KIAA1288 MTSG1 | QENEELKARMDKHMAISRQLstEQAVLQESLEKESKVNKRL |
| Q9ULD2 | T1204 | Sugiyama | MTUS1 ATBP ATIP GK1 KIAA1288 MTSG1 | ENEELKARMDKHMAISRQLstEQAVLQESLEKESKVNKRLs |
| Q9UMR2 | T468 | Sugiyama | DDX19B DBP5 DDX19 TDBP | SMNILNRIQEHFNKKIERLDtDDLDEIEKIAN_________ |
| Q9UNX3 | T8 | Sugiyama | RPL26L1 RPL26P1 | _____________MKFNPFVtsDRsKNRKRHFNAPSHVRRK |
| Q9UNZ2 | S176 | Sugiyama | NSFL1C UBXN2C | RLGAAPEEEsAyVAGEKRQHssQDVHVVLKLWKsGFsLDNG |
| Q9UNZ2 | S192 | Sugiyama | NSFL1C UBXN2C | KRQHssQDVHVVLKLWKsGFsLDNGELRSyQDPsNAQFLEs |
| Q9UPQ0 | S201 | Sugiyama | LIMCH1 KIAA1102 | DCWDsERsDsLsPPRHGRDDsFDsLDsFGsRsRQtPsPDVV |
| Q9UPR0 | T584 | Sugiyama | PLCL2 KIAA1092 PLCE2 | KILIKAKKLsSNCSGVEGDVtDEDEGAEMSQRMGKENMEQP |
| Q9UQ35 | S854 | Sugiyama | SRRM2 KIAA0324 SRL300 SRM300 HSPC075 | sHSsssPHPKVKsGtPPRQGsItsPQANEQsVtPQRRsCFE |
| Q9UQD0 | S561 | SIGNOR | SCN8A MED | sIMNQSLLSIPGSPFLSRHNsKSSIFSFRGPGRFRDPGSEN |
| Q9UQD0 | S641 | SIGNOR | SCN8A MED | SQGSRSSRIFPSLRRSVKRNstVDCNGVVSLIGGPGSHIGG |
| Q9UQD0 | T642 | SIGNOR | SCN8A MED | QGSRSSRIFPSLRRSVKRNstVDCNGVVSLIGGPGSHIGGR |
| Q9UQM7 | S25 | Sugiyama | CAMK2A CAMKA KIAA0968 | TCTRFTEEYQLFEELGKGAFsVVRRCVKVLAGQEYAAKIIN |
| Q9UQM7 | T239 | Sugiyama | CAMK2A CAMKA KIAA0968 | HRLYQQIKAGAyDFPsPEWDtVTPEAKDLINKMLtINPsKR |
| Q9UQM7 | T305 | Sugiyama | CAMK2A CAMKA KIAA0968 | EtVDCLKKFNARRKLKGAILttMLAtRNFsGGKSGGNKKSD |
| Q9UQM7 | T306 | Sugiyama | CAMK2A CAMKA KIAA0968 | tVDCLKKFNARRKLKGAILttMLAtRNFsGGKSGGNKKSDG |
| Q9UQM7 | T310 | Sugiyama | CAMK2A CAMKA KIAA0968 | LKKFNARRKLKGAILttMLAtRNFsGGKSGGNKKSDGVKEs |
| Q9UQM7 | Y230 | Sugiyama | CAMK2A CAMKA KIAA0968 | YPPFWDEDQHRLYQQIKAGAyDFPsPEWDtVTPEAKDLINK |
| Q9Y237 | S72 | Sugiyama | PIN4 | MEAMEKLKSGMRFNEVAAQysEDKARQGGDLGWMTRGSMVG |
| Q9Y285 | S352 | Sugiyama | FARSA FARS FARSL FARSLA | SARALYRLAQKKPFTPVKYFsIDRVFRNETLDATHLAEFHQ |
| Q9Y2B0 | S115 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | QIDPstHRKNYVRVVGRNGEssELDLQGIRIDsDISGtLKF |
| Q9Y2B0 | S116 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | IDPstHRKNYVRVVGRNGEssELDLQGIRIDsDISGtLKFA |
| Q9Y2B0 | S63 | Sugiyama | CNPY2 MSAP TMEM4 ZSIG9 UNQ1943/PRO4426 | AQVDPKKTIQMGsFRINPDGsQsVVEVPyARsEAHLtELLE |
| Q9Y2T7 | S137 | Sugiyama | YBX2 CSDA3 MSY2 | EDVFVHQtAIKRNNPRKFLRsVGDGEtVEFDVVEGEKGAEA |
| Q9Y2T7 | T115 | Sugiyama | YBX2 CSDA3 MSY2 | LGTVKWFNVRNGyGFINRNDtKEDVFVHQtAIKRNNPRKFL |
| Q9Y2T7 | T143 | Sugiyama | YBX2 CSDA3 MSY2 | QtAIKRNNPRKFLRsVGDGEtVEFDVVEGEKGAEATNVTGP |
| Q9Y383 | S347 | Sugiyama | LUC7L2 CGI-59 CGI-74 | SRERSKRRSSKERFRDQDLAsCDRDRssRDRSPRDRDRKDK |
| Q9Y3T9 | S673 | Sugiyama | NOC2L NIR | MADRKDEDRKQFKDLFDLNssEEDDtEGFsERGILRPLStR |
| Q9Y3U8 | S91 | Sugiyama | RPL36 | KFIKKRVGTHIRAKRKREELsNVLAAMRKAAAKKD______ |
| Q9Y4L1 | S742 | Sugiyama | HYOU1 GRP170 HSPH4 ORP150 | KLQDLTLRDLEKQEREKAANsLEAFIFEtQDKLyQPEyQEV |
| Q9Y4L1 | T750 | Sugiyama | HYOU1 GRP170 HSPH4 ORP150 | DLEKQEREKAANsLEAFIFEtQDKLyQPEyQEVsTEEQREE |
| Q9Y5A9 | S394 | Sugiyama | YTHDF2 HGRG8 | SQAGSGStPSEPHPVLEKLRsINNYNPKDFDWNLKHGRVFI |
| Q9Y5B9 | S650 | Sugiyama | SUPT16H FACT140 FACTP140 | KRYKTREAEEKEKEGIVKQDsLVINLNRsNPKLKDLYIRPN |
| Q9Y5L4 | S57 | Sugiyama | TIMM13 TIM13B TIMM13A TIMM13B | ELLQRMTDKCFRKCIGKPGGsLDNSEQKCIAMCMDRyMDAW |
| Q9Y5S9 | S56 | Sugiyama | RBM8A RBM8 HSPC114 MDS014 | KGRGFGsEEGsRARMREDyDsVEQDGDEPGPQRSVEGWILF |
| Q9Y608 | S18 | Sugiyama | LRRFIP2 | ___MGTPASGRKRTPVKDRFsAEDEALsNIAREAEARLAAK |
Site Promiscuity
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 0.000004 | 5.391 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 0.000032 | 4.501 | 1 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 0.000105 | 3.980 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 0.000129 | 3.891 | 1 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 0.000103 | 3.988 | 1 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 0.000120 | 3.920 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 0.000141 | 3.852 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 0.000206 | 3.686 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 0.000217 | 3.664 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 0.000211 | 3.676 | 1 | 0 |
| Calmodulin induced events | R-HSA-111933 | 0.000217 | 3.663 | 1 | 0 |
| CaM pathway | R-HSA-111997 | 0.000217 | 3.663 | 1 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 0.000237 | 3.625 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 0.000267 | 3.574 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 0.000282 | 3.549 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 0.000391 | 3.408 | 1 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 0.000513 | 3.290 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 0.000515 | 3.288 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 0.000510 | 3.292 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 0.000524 | 3.281 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 0.000647 | 3.189 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 0.000651 | 3.186 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 0.000729 | 3.137 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 0.000826 | 3.083 | 0 | 0 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 0.000902 | 3.045 | 1 | 1 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 0.000902 | 3.045 | 1 | 1 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 0.000902 | 3.045 | 1 | 1 |
| HSF1-dependent transactivation | R-HSA-3371571 | 0.000919 | 3.036 | 1 | 1 |
| Signaling by RAS mutants | R-HSA-6802949 | 0.000902 | 3.045 | 1 | 0 |
| PLC beta mediated events | R-HSA-112043 | 0.000915 | 3.038 | 1 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 0.001017 | 2.993 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 0.001117 | 2.952 | 1 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 0.001773 | 2.751 | 1 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 0.002121 | 2.673 | 1 | 1 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 0.002275 | 2.643 | 1 | 1 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 0.002263 | 2.645 | 0 | 0 |
| G-protein mediated events | R-HSA-112040 | 0.002381 | 2.623 | 1 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 0.002400 | 2.620 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 0.002626 | 2.581 | 0 | 0 |
| Cell Cycle | R-HSA-1640170 | 0.002722 | 2.565 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 0.003050 | 2.516 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 0.003405 | 2.468 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 0.003405 | 2.468 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 0.003414 | 2.467 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 0.003815 | 2.418 | 1 | 1 |
| Cellular response to heat stress | R-HSA-3371556 | 0.003734 | 2.428 | 1 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 0.003803 | 2.420 | 1 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 0.003882 | 2.411 | 1 | 1 |
| Membrane Trafficking | R-HSA-199991 | 0.003925 | 2.406 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 0.004167 | 2.380 | 1 | 0 |
| Signal Transduction | R-HSA-162582 | 0.004217 | 2.375 | 1 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 0.004524 | 2.344 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 0.005184 | 2.285 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 0.005108 | 2.292 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 0.005076 | 2.295 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 0.005364 | 2.270 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 0.005708 | 2.244 | 1 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 0.005708 | 2.244 | 1 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 0.005795 | 2.237 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 0.006003 | 2.222 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 0.006481 | 2.188 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 0.006899 | 2.161 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 0.007531 | 2.123 | 1 | 1 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 0.008140 | 2.089 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 0.009103 | 2.041 | 1 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 0.009603 | 2.018 | 1 | 1 |
| Attenuation phase | R-HSA-3371568 | 0.009551 | 2.020 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 0.009789 | 2.009 | 0 | 0 |
| ChREBP activates metabolic gene expression | R-HSA-163765 | 0.010561 | 1.976 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 0.010561 | 1.976 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 0.011228 | 1.950 | 0 | 0 |
| PKA activation | R-HSA-163615 | 0.011228 | 1.950 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 0.011199 | 1.951 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 0.011496 | 1.939 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 0.011896 | 1.925 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 0.011835 | 1.927 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 0.012129 | 1.916 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 0.012614 | 1.899 | 0 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 0.013247 | 1.878 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 0.013759 | 1.861 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 0.014276 | 1.845 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 0.014286 | 1.845 | 0 | 0 |
| RSK activation | R-HSA-444257 | 0.015056 | 1.822 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of myeloid cells | R-HSA-8939246 | 0.015056 | 1.822 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 0.015635 | 1.806 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 0.016828 | 1.774 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 0.016418 | 1.785 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 0.017467 | 1.758 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 0.017771 | 1.750 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 0.018656 | 1.729 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 0.018656 | 1.729 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 0.019035 | 1.720 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 0.019758 | 1.704 | 1 | 1 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 0.021069 | 1.676 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 0.020983 | 1.678 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 0.021069 | 1.676 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 0.021374 | 1.670 | 1 | 1 |
| Cell Cycle Checkpoints | R-HSA-69620 | 0.020745 | 1.683 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 0.021096 | 1.676 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 0.021560 | 1.666 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 0.021566 | 1.666 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 0.023019 | 1.638 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 0.023315 | 1.632 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 0.024798 | 1.606 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 0.024643 | 1.608 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 0.024643 | 1.608 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 0.024833 | 1.605 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 0.028133 | 1.551 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 0.028133 | 1.551 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 0.028133 | 1.551 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 0.028133 | 1.551 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 0.028133 | 1.551 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 0.028133 | 1.551 | 0 | 0 |
| Negative regulation of TCF-dependent signaling by DVL-interacting proteins | R-HSA-5368598 | 0.027863 | 1.555 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 0.030567 | 1.515 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 0.031956 | 1.495 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 0.031378 | 1.503 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 0.030103 | 1.521 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 0.030103 | 1.521 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 0.030691 | 1.513 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 0.028334 | 1.548 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 0.032115 | 1.493 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 0.030559 | 1.515 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in metabolism | R-HSA-9854907 | 0.027863 | 1.555 | 0 | 0 |
| CREB phosphorylation | R-HSA-199920 | 0.030567 | 1.515 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 0.029394 | 1.532 | 1 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 0.030691 | 1.513 | 0 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 0.025937 | 1.586 | 1 | 1 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 0.026150 | 1.583 | 1 | 1 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 0.032303 | 1.491 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 0.033032 | 1.481 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 0.036431 | 1.439 | 1 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 0.036944 | 1.432 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 0.037279 | 1.429 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 0.038687 | 1.412 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 0.038089 | 1.419 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 0.041137 | 1.386 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 0.041308 | 1.384 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 0.041308 | 1.384 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 0.038687 | 1.412 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 0.040385 | 1.394 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 0.040385 | 1.394 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 0.038256 | 1.417 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 0.042218 | 1.375 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 0.043866 | 1.358 | 0 | 0 |
| Inhibition of TSC complex formation by PKB | R-HSA-165181 | 0.043866 | 1.358 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 0.043866 | 1.358 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 0.047111 | 1.327 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 0.047111 | 1.327 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 0.046283 | 1.335 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 0.046283 | 1.335 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 0.046283 | 1.335 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 0.046283 | 1.335 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 0.046283 | 1.335 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 0.046283 | 1.335 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 0.046891 | 1.329 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 0.047066 | 1.327 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 0.046891 | 1.329 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 0.046891 | 1.329 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 0.042431 | 1.372 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 0.047426 | 1.324 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 0.047980 | 1.319 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 0.048268 | 1.316 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 0.049753 | 1.303 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 0.050154 | 1.300 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 0.051213 | 1.291 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 0.052179 | 1.283 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 0.056043 | 1.251 | 0 | 0 |
| Regulation of FOXO transcriptional activity by acetylation | R-HSA-9617629 | 0.058779 | 1.231 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 0.057623 | 1.239 | 0 | 0 |
| The CRY:PER:kinase complex represses transactivation by the BMAL:CLOCK (ARNTL:CLOCK) complex | R-HSA-9931521 | 0.057623 | 1.239 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 0.057467 | 1.241 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 0.053910 | 1.268 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 0.059289 | 1.227 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 0.059289 | 1.227 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 0.057356 | 1.241 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 0.054577 | 1.263 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 0.056043 | 1.251 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 0.056043 | 1.251 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 0.056043 | 1.251 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 0.054421 | 1.264 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 0.061159 | 1.214 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 0.062053 | 1.207 | 0 | 0 |
| RUNX2 regulates chondrocyte maturation | R-HSA-8941284 | 0.063507 | 1.197 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 0.063507 | 1.197 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 0.063507 | 1.197 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 0.063507 | 1.197 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 0.063507 | 1.197 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 0.064121 | 1.193 | 0 | 0 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 0.064171 | 1.193 | 1 | 1 |
| MTOR signalling | R-HSA-165159 | 0.064246 | 1.192 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 0.064246 | 1.192 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 0.064270 | 1.192 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 0.066220 | 1.179 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 0.066220 | 1.179 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 0.066446 | 1.178 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 0.072006 | 1.143 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 0.071947 | 1.143 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 0.077095 | 1.113 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 0.072006 | 1.143 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 0.067742 | 1.169 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 0.075533 | 1.122 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 0.076296 | 1.117 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 0.072006 | 1.143 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 0.073807 | 1.132 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 0.077724 | 1.109 | 1 | 1 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 0.078392 | 1.106 | 0 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 0.078985 | 1.102 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 0.080867 | 1.092 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 0.080867 | 1.092 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 0.080867 | 1.092 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 0.080867 | 1.092 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 0.095284 | 1.021 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 0.095284 | 1.021 | 0 | 0 |
| Regulation of cortical dendrite branching | R-HSA-8985801 | 0.095284 | 1.021 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 0.095284 | 1.021 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 0.095284 | 1.021 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 0.095284 | 1.021 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 0.095284 | 1.021 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 0.095284 | 1.021 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 0.095284 | 1.021 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 0.095284 | 1.021 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 0.095284 | 1.021 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 0.095284 | 1.021 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 0.095284 | 1.021 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 0.095284 | 1.021 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 0.086491 | 1.063 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 0.086491 | 1.063 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 0.088093 | 1.055 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 0.099225 | 1.003 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 0.089089 | 1.050 | 0 | 0 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 0.100600 | 0.997 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 0.100087 | 1.000 | 0 | 0 |
| M Phase | R-HSA-68886 | 0.094920 | 1.023 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 0.086462 | 1.063 | 1 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 0.088474 | 1.053 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 0.097872 | 1.009 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 0.095503 | 1.020 | 1 | 0 |
| DARPP-32 events | R-HSA-180024 | 0.088093 | 1.055 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 0.087601 | 1.057 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 0.099225 | 1.003 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 0.100896 | 0.996 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 0.101351 | 0.994 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 0.102669 | 0.989 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 0.102669 | 0.989 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 0.102710 | 0.988 | 0 | 0 |
| Drug resistance of KIT mutants | R-HSA-9669937 | 0.121178 | 0.917 | 0 | 0 |
| KIT mutants bind TKIs | R-HSA-9669921 | 0.121178 | 0.917 | 0 | 0 |
| Sorafenib-resistant KIT mutants | R-HSA-9669936 | 0.121178 | 0.917 | 0 | 0 |
| Imatinib-resistant KIT mutants | R-HSA-9669917 | 0.121178 | 0.917 | 0 | 0 |
| Sunitinib-resistant KIT mutants | R-HSA-9669934 | 0.121178 | 0.917 | 0 | 0 |
| Masitinib-resistant KIT mutants | R-HSA-9669924 | 0.121178 | 0.917 | 0 | 0 |
| APC truncation mutants are not K63 polyubiquitinated | R-HSA-5467333 | 0.121178 | 0.917 | 0 | 0 |
| Regorafenib-resistant KIT mutants | R-HSA-9669929 | 0.121178 | 0.917 | 0 | 0 |
| Dasatinib-resistant KIT mutants | R-HSA-9669914 | 0.121178 | 0.917 | 0 | 0 |
| Nilotinib-resistant KIT mutants | R-HSA-9669926 | 0.121178 | 0.917 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 0.227677 | 0.643 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 0.227677 | 0.643 | 0 | 0 |
| Impaired BRCA2 translocation to the nucleus | R-HSA-9709275 | 0.227677 | 0.643 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH6 | R-HSA-5632968 | 0.227677 | 0.643 | 0 | 0 |
| Impaired BRCA2 binding to SEM1 (DSS1) | R-HSA-9763198 | 0.227677 | 0.643 | 0 | 0 |
| STAT6-mediated induction of chemokines | R-HSA-3249367 | 0.137197 | 0.863 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 0.137197 | 0.863 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 0.112438 | 0.949 | 0 | 0 |
| Regulation of HMOX1 expression and activity | R-HSA-9707587 | 0.182240 | 0.739 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 0.182240 | 0.739 | 0 | 0 |
| RUNX2 regulates genes involved in differentiation of myeloid cells | R-HSA-8941333 | 0.182240 | 0.739 | 0 | 0 |
| RUNX3 regulates BCL2L11 (BIM) transcription | R-HSA-8952158 | 0.182240 | 0.739 | 0 | 0 |
| GRB7 events in ERBB2 signaling | R-HSA-1306955 | 0.182240 | 0.739 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 0.182240 | 0.739 | 0 | 0 |
| FGFR4 mutant receptor activation | R-HSA-1839128 | 0.321277 | 0.493 | 0 | 0 |
| PI and PC transport between ER and Golgi membranes | R-HSA-1483196 | 0.321277 | 0.493 | 0 | 0 |
| ARL13B-mediated ciliary trafficking of INPP5E | R-HSA-5624958 | 0.321277 | 0.493 | 0 | 0 |
| Signaling by extracellular domain mutants of KIT | R-HSA-9680187 | 0.321277 | 0.493 | 0 | 0 |
| Signaling by juxtamembrane domain KIT mutants | R-HSA-9669935 | 0.321277 | 0.493 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 0.321277 | 0.493 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 0.321277 | 0.493 | 0 | 0 |
| Defective PGM1 causes PGM1-CDG | R-HSA-5609974 | 0.321277 | 0.493 | 0 | 0 |
| TALDO1 deficiency: failed conversion of SH7P, GA3P to Fru(6)P, E4P | R-HSA-6791055 | 0.321277 | 0.493 | 0 | 0 |
| TALDO1 deficiency: failed conversion of Fru(6)P, E4P to SH7P, GA3P | R-HSA-6791462 | 0.321277 | 0.493 | 0 | 0 |
| Defective HK1 causes hexokinase deficiency (HK deficiency) | R-HSA-5619056 | 0.321277 | 0.493 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 0.321277 | 0.493 | 0 | 0 |
| Defective SLC20A2 causes idiopathic basal ganglia calcification 1 (IBGC1) | R-HSA-5619111 | 0.321277 | 0.493 | 0 | 0 |
| Signaling by kinase domain mutants of KIT | R-HSA-9669933 | 0.321277 | 0.493 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 0.140926 | 0.851 | 0 | 0 |
| Activation of AKT2 | R-HSA-165158 | 0.229040 | 0.640 | 0 | 0 |
| IRS activation | R-HSA-74713 | 0.229040 | 0.640 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 0.229040 | 0.640 | 0 | 0 |
| G2 Phase | R-HSA-68911 | 0.229040 | 0.640 | 0 | 0 |
| NOSIP mediated eNOS trafficking | R-HSA-203754 | 0.229040 | 0.640 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 0.229040 | 0.640 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 0.171516 | 0.766 | 0 | 0 |
| Phosphorylation of CLOCK, acetylation of BMAL1 (ARNTL) at target gene promoters | R-HSA-9931512 | 0.131697 | 0.880 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 0.155021 | 0.810 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 0.155021 | 0.810 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 0.155021 | 0.810 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 0.155021 | 0.810 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 0.155021 | 0.810 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 0.203768 | 0.691 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 0.203768 | 0.691 | 0 | 0 |
| RUNX3 regulates CDKN1A transcription | R-HSA-8941855 | 0.276510 | 0.558 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 0.276510 | 0.558 | 0 | 0 |
| GLI proteins bind promoters of Hh responsive genes to promote transcription | R-HSA-5635851 | 0.276510 | 0.558 | 0 | 0 |
| SLIT2:ROBO1 increases RHOA activity | R-HSA-8985586 | 0.276510 | 0.558 | 0 | 0 |
| Signaling by MAPK mutants | R-HSA-9652817 | 0.276510 | 0.558 | 0 | 0 |
| RUNX3 regulates RUNX1-mediated transcription | R-HSA-8951911 | 0.403537 | 0.394 | 0 | 0 |
| Potassium transport channels | R-HSA-1296067 | 0.403537 | 0.394 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 0.403537 | 0.394 | 0 | 0 |
| Glycogen storage disease type XV (GYG1) | R-HSA-3814836 | 0.403537 | 0.394 | 0 | 0 |
| Defective visual phototransduction due to STRA6 loss of function | R-HSA-9918449 | 0.403537 | 0.394 | 0 | 0 |
| Mitotic Metaphase/Anaphase Transition | R-HSA-68881 | 0.403537 | 0.394 | 0 | 0 |
| Glycogen storage disease type 0 (muscle GYS1) | R-HSA-3828062 | 0.403537 | 0.394 | 0 | 0 |
| HHAT G278V doesn't palmitoylate Hh-Np | R-HSA-5658034 | 0.403537 | 0.394 | 0 | 0 |
| TWIK related potassium channel (TREK) | R-HSA-1299503 | 0.403537 | 0.394 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 0.138838 | 0.857 | 0 | 0 |
| Defective binding of RB1 mutants to E2F1,(E2F2, E2F3) | R-HSA-9661069 | 0.179751 | 0.745 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 0.237260 | 0.625 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 0.237260 | 0.625 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 0.110914 | 0.955 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 0.205684 | 0.687 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 0.205684 | 0.687 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 0.205684 | 0.687 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 0.323801 | 0.490 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 0.179744 | 0.745 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 0.111110 | 0.954 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 0.111110 | 0.954 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 0.158024 | 0.801 | 0 | 0 |
| Presynaptic depolarization and calcium channel opening | R-HSA-112308 | 0.271596 | 0.566 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 0.139574 | 0.855 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 0.139574 | 0.855 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 0.139574 | 0.855 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 0.232612 | 0.633 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 0.232612 | 0.633 | 0 | 0 |
| HSF1 activation | R-HSA-3371511 | 0.110019 | 0.959 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 0.201702 | 0.695 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 0.155123 | 0.809 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 0.155123 | 0.809 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 0.137073 | 0.863 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 0.195500 | 0.709 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 0.224501 | 0.649 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 0.260329 | 0.584 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 0.306412 | 0.514 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 0.306412 | 0.514 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 0.370260 | 0.431 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 0.370260 | 0.431 | 0 | 0 |
| TRIF-mediated programmed cell death | R-HSA-2562578 | 0.370260 | 0.431 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 0.370260 | 0.431 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 0.370260 | 0.431 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 0.370260 | 0.431 | 0 | 0 |
| PLC-gamma1 signalling | R-HSA-167021 | 0.475832 | 0.323 | 0 | 0 |
| Activated NTRK3 signals through PLCG1 | R-HSA-9034793 | 0.475832 | 0.323 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 0.475832 | 0.323 | 0 | 0 |
| The IPAF inflammasome | R-HSA-844623 | 0.475832 | 0.323 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of other transcription factors | R-HSA-8866906 | 0.475832 | 0.323 | 0 | 0 |
| Loss of Function of KMT2D in Kabuki Syndrome | R-HSA-9944971 | 0.475832 | 0.323 | 0 | 0 |
| Defective GCLC causes HAGGSD | R-HSA-5578999 | 0.475832 | 0.323 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 0.475832 | 0.323 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 0.475832 | 0.323 | 0 | 0 |
| Loss of Function of KMT2D in MLL4 Complex Formation in Kabuki Syndrome | R-HSA-9944997 | 0.475832 | 0.323 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 0.165795 | 0.780 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 0.165795 | 0.780 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 0.165795 | 0.780 | 0 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 0.188440 | 0.725 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 0.248018 | 0.606 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 0.206104 | 0.686 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 0.117493 | 0.930 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 0.341378 | 0.467 | 0 | 0 |
| RUNX3 regulates p14-ARF | R-HSA-8951936 | 0.341378 | 0.467 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 0.341378 | 0.467 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 0.341378 | 0.467 | 0 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 0.188263 | 0.725 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 0.159718 | 0.797 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 0.317330 | 0.498 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 0.415394 | 0.382 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 0.415394 | 0.382 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 0.415394 | 0.382 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 0.415394 | 0.382 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 0.415394 | 0.382 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 0.171927 | 0.765 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 0.164358 | 0.784 | 0 | 0 |
| Metabolism of non-coding RNA | R-HSA-194441 | 0.164358 | 0.784 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 0.376205 | 0.425 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 0.247834 | 0.606 | 0 | 0 |
| FOXO-mediated transcription of cell death genes | R-HSA-9614657 | 0.346238 | 0.461 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 0.346238 | 0.461 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 0.300554 | 0.522 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 0.300554 | 0.522 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 0.265651 | 0.576 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 0.265651 | 0.576 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 0.265651 | 0.576 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 0.250811 | 0.601 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 0.267444 | 0.573 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 0.322828 | 0.491 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 0.346746 | 0.460 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 0.410636 | 0.387 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 0.410636 | 0.387 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 0.410636 | 0.387 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 0.410636 | 0.387 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 0.458842 | 0.338 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 0.458842 | 0.338 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 0.458842 | 0.338 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 0.458842 | 0.338 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 0.458842 | 0.338 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 0.458842 | 0.338 | 0 | 0 |
| MTF1 activates gene expression | R-HSA-5660489 | 0.539368 | 0.268 | 0 | 0 |
| HCN channels | R-HSA-1296061 | 0.539368 | 0.268 | 0 | 0 |
| Activated NTRK2 signals through PLCG1 | R-HSA-9026527 | 0.539368 | 0.268 | 0 | 0 |
| NFE2L2 regulating ER-stress associated genes | R-HSA-9818035 | 0.539368 | 0.268 | 0 | 0 |
| betaKlotho-mediated ligand binding | R-HSA-1307965 | 0.539368 | 0.268 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 0.539368 | 0.268 | 0 | 0 |
| Phosphorylation of proteins involved in G1/S transition by active Cyclin E:Cdk2 complexes | R-HSA-69200 | 0.539368 | 0.268 | 0 | 0 |
| Signaling by MAP2K mutants | R-HSA-9652169 | 0.539368 | 0.268 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 0.322413 | 0.492 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 0.253917 | 0.595 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 0.371989 | 0.429 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 0.253791 | 0.596 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 0.282278 | 0.549 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 0.444455 | 0.352 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 0.444455 | 0.352 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 0.444455 | 0.352 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 0.280842 | 0.552 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 0.314244 | 0.503 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 0.314244 | 0.503 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 0.500350 | 0.301 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 0.500350 | 0.301 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 0.500350 | 0.301 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 0.500350 | 0.301 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 0.500350 | 0.301 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 0.477479 | 0.321 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 0.390574 | 0.408 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 0.447309 | 0.349 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 0.447309 | 0.349 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 0.447309 | 0.349 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 0.157989 | 0.801 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 0.401056 | 0.397 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 0.410185 | 0.387 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 0.446508 | 0.350 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 0.446508 | 0.350 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 0.471965 | 0.326 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 0.488445 | 0.311 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 0.488445 | 0.311 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG activate genes related to proliferation | R-HSA-2892247 | 0.509555 | 0.293 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 0.509555 | 0.293 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 0.509555 | 0.293 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 0.509555 | 0.293 | 0 | 0 |
| Phase 2 - plateau phase | R-HSA-5576893 | 0.509555 | 0.293 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 0.509555 | 0.293 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 0.539750 | 0.268 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 0.539750 | 0.268 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 0.539750 | 0.268 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 0.539750 | 0.268 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 0.539750 | 0.268 | 0 | 0 |
| Activation of AMPA receptors | R-HSA-399710 | 0.595206 | 0.225 | 0 | 0 |
| SMAC (DIABLO) binds to IAPs | R-HSA-111463 | 0.595206 | 0.225 | 0 | 0 |
| SMAC(DIABLO)-mediated dissociation of IAP:caspase complexes | R-HSA-111464 | 0.595206 | 0.225 | 0 | 0 |
| NFE2L2 regulating inflammation associated genes | R-HSA-9818026 | 0.595206 | 0.225 | 0 | 0 |
| Defective F9 activation | R-HSA-9673221 | 0.595206 | 0.225 | 0 | 0 |
| Enhanced binding of GP1BA variant to VWF multimer:collagen | R-HSA-9845620 | 0.595206 | 0.225 | 0 | 0 |
| Defective binding of VWF variant to GPIb:IX:V | R-HSA-9846298 | 0.595206 | 0.225 | 0 | 0 |
| FLT3 signaling by CBL mutants | R-HSA-9706377 | 0.595206 | 0.225 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 0.410538 | 0.387 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 0.410538 | 0.387 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 0.480482 | 0.318 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 0.540564 | 0.267 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 0.540564 | 0.267 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 0.453317 | 0.344 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 0.541911 | 0.266 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 0.576943 | 0.239 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 0.576943 | 0.239 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 0.527301 | 0.278 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 0.527301 | 0.278 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 0.570410 | 0.244 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 0.569441 | 0.245 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 0.588506 | 0.230 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 0.599024 | 0.223 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 0.599024 | 0.223 | 0 | 0 |
| RUNX3 regulates NOTCH signaling | R-HSA-8941856 | 0.611885 | 0.213 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 0.611885 | 0.213 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 0.611885 | 0.213 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 0.611885 | 0.213 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 0.611885 | 0.213 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 0.611885 | 0.213 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 0.611885 | 0.213 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 0.611885 | 0.213 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 0.644278 | 0.191 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 0.644278 | 0.191 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 0.644278 | 0.191 | 0 | 0 |
| Activation of caspases through apoptosome-mediated cleavage | R-HSA-111459 | 0.644278 | 0.191 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 0.644278 | 0.191 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 0.644278 | 0.191 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 0.644278 | 0.191 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 0.644278 | 0.191 | 0 | 0 |
| PTK6 Regulates Cell Cycle | R-HSA-8849470 | 0.644278 | 0.191 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 0.644278 | 0.191 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 0.616312 | 0.210 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 0.616312 | 0.210 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 0.626357 | 0.203 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 0.626357 | 0.203 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 0.638574 | 0.195 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 0.639366 | 0.194 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 0.108583 | 0.964 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 0.592359 | 0.227 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 0.480482 | 0.318 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 0.432586 | 0.364 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 0.432586 | 0.364 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 0.115539 | 0.937 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 0.118720 | 0.925 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 0.317330 | 0.498 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 0.317330 | 0.498 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 0.265651 | 0.576 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 0.266141 | 0.575 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 0.218666 | 0.660 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 0.170440 | 0.768 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 0.401056 | 0.397 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 0.181112 | 0.742 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 0.272125 | 0.565 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 0.311544 | 0.506 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 0.384328 | 0.415 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 0.498191 | 0.303 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 0.260329 | 0.584 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 0.203768 | 0.691 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 0.601187 | 0.221 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 0.188263 | 0.725 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 0.487368 | 0.312 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 0.215380 | 0.667 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 0.631406 | 0.200 | 0 | 0 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 0.283827 | 0.547 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 0.543482 | 0.265 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 0.551759 | 0.258 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 0.173800 | 0.760 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 0.444455 | 0.352 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 0.390574 | 0.408 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 0.509555 | 0.293 | 0 | 0 |
| Synthesis of PIPs at the late endosome membrane | R-HSA-1660517 | 0.540564 | 0.267 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 0.376205 | 0.425 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 0.201702 | 0.695 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 0.469093 | 0.329 | 0 | 0 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 0.110019 | 0.959 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 0.215380 | 0.667 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 0.317330 | 0.498 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 0.500350 | 0.301 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 0.474286 | 0.324 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 0.107395 | 0.969 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 0.523955 | 0.281 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 0.452159 | 0.345 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 0.599024 | 0.223 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 0.276510 | 0.558 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 0.276510 | 0.558 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 0.123733 | 0.908 | 0 | 0 |
| Activation of PUMA and translocation to mitochondria | R-HSA-139915 | 0.370260 | 0.431 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 0.317330 | 0.498 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 0.458842 | 0.338 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 0.500350 | 0.301 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 0.477479 | 0.321 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 0.488445 | 0.311 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 0.540564 | 0.267 | 0 | 0 |
| Terminal pathway of complement | R-HSA-166665 | 0.644278 | 0.191 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 0.181112 | 0.742 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 0.346238 | 0.461 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 0.151104 | 0.821 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 0.165795 | 0.780 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 0.188263 | 0.725 | 1 | 1 |
| Hedgehog 'off' state | R-HSA-5610787 | 0.364172 | 0.439 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 0.458293 | 0.339 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 0.201702 | 0.695 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 0.541604 | 0.266 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 0.586778 | 0.232 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 0.143268 | 0.844 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 0.201674 | 0.695 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 0.117381 | 0.930 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 0.458314 | 0.339 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 0.112438 | 0.949 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 0.179744 | 0.745 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 0.296697 | 0.528 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 0.321611 | 0.493 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 0.458842 | 0.338 | 0 | 0 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 0.216999 | 0.664 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 0.322413 | 0.492 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 0.319500 | 0.496 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 0.520118 | 0.284 | 0 | 0 |
| NF-kB is activated and signals survival | R-HSA-209560 | 0.576943 | 0.239 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 0.599024 | 0.223 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 0.611885 | 0.213 | 0 | 0 |
| Role of second messengers in netrin-1 signaling | R-HSA-418890 | 0.611885 | 0.213 | 0 | 0 |
| Signaling by MST1 | R-HSA-8852405 | 0.644278 | 0.191 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 0.639366 | 0.194 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 0.556505 | 0.255 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 0.243159 | 0.614 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 0.566293 | 0.247 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 0.160513 | 0.794 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 0.299590 | 0.523 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 0.522375 | 0.282 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 0.570410 | 0.244 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 0.625099 | 0.204 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 0.146508 | 0.834 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 0.181112 | 0.742 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 0.616312 | 0.210 | 0 | 0 |
| S Phase | R-HSA-69242 | 0.480776 | 0.318 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 0.390639 | 0.408 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 0.219834 | 0.658 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 0.133731 | 0.874 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 0.230424 | 0.637 | 0 | 0 |
| p75NTR signals via NF-kB | R-HSA-193639 | 0.444455 | 0.352 | 0 | 0 |
| Synthesis of PIPs at the early endosome membrane | R-HSA-1660516 | 0.567543 | 0.246 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 0.610325 | 0.214 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 0.622063 | 0.206 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 0.188263 | 0.725 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 0.341520 | 0.467 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 0.583437 | 0.234 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 0.610325 | 0.214 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 0.255102 | 0.593 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 0.108606 | 0.964 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 0.151104 | 0.821 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 0.151104 | 0.821 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 0.415394 | 0.382 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 0.243159 | 0.614 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 0.322828 | 0.491 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 0.410636 | 0.387 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 0.238284 | 0.623 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 0.432586 | 0.364 | 0 | 0 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 0.500350 | 0.301 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 0.471965 | 0.326 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 0.509555 | 0.293 | 0 | 0 |
| Resolution of AP sites via the single-nucleotide replacement pathway | R-HSA-110381 | 0.595206 | 0.225 | 0 | 0 |
| IRF3 mediated activation of type 1 IFN | R-HSA-1606341 | 0.595206 | 0.225 | 0 | 0 |
| Inhibition of replication initiation of damaged DNA by RB1/E2F1 | R-HSA-113501 | 0.576943 | 0.239 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 0.527301 | 0.278 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 0.567543 | 0.246 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 0.565892 | 0.247 | 0 | 0 |
| p75NTR recruits signalling complexes | R-HSA-209543 | 0.611885 | 0.213 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 0.243239 | 0.614 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 0.551759 | 0.258 | 0 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 0.170069 | 0.769 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 0.565984 | 0.247 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 0.155505 | 0.808 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 0.129919 | 0.886 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 0.413306 | 0.384 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 0.471965 | 0.326 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 0.553306 | 0.257 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 0.639366 | 0.194 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 0.231421 | 0.636 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 0.253989 | 0.595 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 0.641399 | 0.193 | 1 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 0.636427 | 0.196 | 1 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 0.131697 | 0.880 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 0.260329 | 0.584 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 0.371989 | 0.429 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 0.471965 | 0.326 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 0.567543 | 0.246 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 0.632035 | 0.199 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 0.455000 | 0.342 | 0 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 0.350164 | 0.456 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 0.142793 | 0.845 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 0.397230 | 0.401 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 0.610081 | 0.215 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 0.586178 | 0.232 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 0.372006 | 0.429 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 0.405103 | 0.392 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 0.211083 | 0.676 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 0.581956 | 0.235 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 0.112438 | 0.949 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 0.158024 | 0.801 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 0.166645 | 0.778 | 0 | 0 |
| SARS-CoV-1-mediated effects on programmed cell death | R-HSA-9692913 | 0.539368 | 0.268 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 0.126650 | 0.897 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 0.397230 | 0.401 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 0.329094 | 0.483 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 0.539750 | 0.268 | 0 | 0 |
| Activation of C3 and C5 | R-HSA-174577 | 0.595206 | 0.225 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 0.588506 | 0.230 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 0.291761 | 0.535 | 0 | 0 |
| Macroautophagy | R-HSA-1632852 | 0.390926 | 0.408 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 0.195500 | 0.709 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 0.195500 | 0.709 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 0.188440 | 0.725 | 0 | 0 |
| Glycogen synthesis | R-HSA-3322077 | 0.626357 | 0.203 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 0.375205 | 0.426 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 0.211083 | 0.676 | 1 | 1 |
| RAF-independent MAPK1/3 activation | R-HSA-112409 | 0.488445 | 0.311 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 0.520118 | 0.284 | 0 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 0.173375 | 0.761 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 0.592359 | 0.227 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 0.274872 | 0.561 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 0.112438 | 0.949 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 0.229040 | 0.640 | 0 | 0 |
| Regulation of NFE2L2 gene expression | R-HSA-9818749 | 0.323801 | 0.490 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 0.502971 | 0.298 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 0.225807 | 0.646 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 0.159873 | 0.796 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 0.268254 | 0.571 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 0.583957 | 0.234 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 0.390639 | 0.408 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 0.155697 | 0.808 | 0 | 0 |
| Regulation of innate immune responses to cytosolic DNA | R-HSA-3134975 | 0.509555 | 0.293 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 0.532056 | 0.274 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 0.444455 | 0.352 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 0.175554 | 0.756 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 0.257008 | 0.590 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 0.158024 | 0.801 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 0.611935 | 0.213 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 0.270448 | 0.568 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 0.401056 | 0.397 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 0.110914 | 0.955 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 0.435154 | 0.361 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 0.418110 | 0.379 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 0.123733 | 0.908 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 0.351364 | 0.454 | 1 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 0.172516 | 0.763 | 1 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 0.267444 | 0.573 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 0.425848 | 0.371 | 0 | 0 |
| FLT3 signaling through SRC family kinases | R-HSA-9706374 | 0.182240 | 0.739 | 0 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 0.321277 | 0.493 | 0 | 0 |
| Defective Mismatch Repair Associated With MSH2 | R-HSA-5632928 | 0.321277 | 0.493 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 0.120112 | 0.920 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 0.276510 | 0.558 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 0.403537 | 0.394 | 0 | 0 |
| Aberrant regulation of mitotic G1/S transition in cancer due to RB1 defects | R-HSA-9659787 | 0.179751 | 0.745 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 0.179744 | 0.745 | 0 | 0 |
| Activation of BIM and translocation to mitochondria | R-HSA-111446 | 0.475832 | 0.323 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 0.475832 | 0.323 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 0.248018 | 0.606 | 0 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 0.179894 | 0.745 | 0 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 0.213470 | 0.671 | 0 | 0 |
| Negative regulation of activity of TFAP2 (AP-2) family transcription factors | R-HSA-8866904 | 0.415394 | 0.382 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 0.415394 | 0.382 | 0 | 0 |
| Membrane binding and targetting of GAG proteins | R-HSA-174490 | 0.376205 | 0.425 | 0 | 0 |
| Activation of the TFAP2 (AP-2) family of transcription factors | R-HSA-8866907 | 0.458842 | 0.338 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of cell cycle factors | R-HSA-8866911 | 0.539368 | 0.268 | 0 | 0 |
| Transmission across Electrical Synapses | R-HSA-112307 | 0.539368 | 0.268 | 0 | 0 |
| Electric Transmission Across Gap Junctions | R-HSA-112303 | 0.539368 | 0.268 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 0.339995 | 0.469 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 0.378304 | 0.422 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 0.477479 | 0.321 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 0.333223 | 0.477 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 0.436085 | 0.360 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 0.539750 | 0.268 | 0 | 0 |
| FGFRL1 modulation of FGFR1 signaling | R-HSA-5658623 | 0.539750 | 0.268 | 0 | 0 |
| Suppression of autophagy | R-HSA-9636569 | 0.595206 | 0.225 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 0.390461 | 0.408 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 0.576943 | 0.239 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 0.576943 | 0.239 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 0.576943 | 0.239 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 0.533041 | 0.273 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 0.566984 | 0.246 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 0.584160 | 0.233 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 0.644278 | 0.191 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 0.644278 | 0.191 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 0.644278 | 0.191 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 0.644278 | 0.191 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 0.644278 | 0.191 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 0.603146 | 0.220 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 0.626357 | 0.203 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 0.211083 | 0.676 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 0.551759 | 0.258 | 0 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 0.431877 | 0.365 | 1 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 0.177785 | 0.750 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 0.290940 | 0.536 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 0.625195 | 0.204 | 1 | 0 |
| Mismatch Repair | R-HSA-5358508 | 0.570410 | 0.244 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 0.128409 | 0.891 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 0.170069 | 0.769 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 0.170069 | 0.769 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 0.603146 | 0.220 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 0.603146 | 0.220 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 0.360262 | 0.443 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 0.121260 | 0.916 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 0.621792 | 0.206 | 0 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 0.116702 | 0.933 | 0 | 0 |
| Chromatin organization | R-HSA-4839726 | 0.125459 | 0.901 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 0.550139 | 0.260 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 0.426692 | 0.370 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 0.442566 | 0.354 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 0.271596 | 0.566 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 0.271596 | 0.566 | 0 | 0 |
| Kinesins | R-HSA-983189 | 0.268367 | 0.571 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 0.432586 | 0.364 | 0 | 0 |
| Signal attenuation | R-HSA-74749 | 0.500350 | 0.301 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 0.471965 | 0.326 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 0.413316 | 0.384 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 0.523369 | 0.281 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 0.226098 | 0.646 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 0.322828 | 0.491 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 0.578282 | 0.238 | 0 | 0 |
| Negative regulation of FLT3 | R-HSA-9706369 | 0.477479 | 0.321 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 0.610585 | 0.214 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 0.480482 | 0.318 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in interleukin signaling | R-HSA-8939247 | 0.229040 | 0.640 | 0 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 0.232612 | 0.633 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 0.151104 | 0.821 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 0.272125 | 0.565 | 0 | 0 |
| Synthesis And Processing Of GAG, GAGPOL Polyproteins | R-HSA-174495 | 0.410636 | 0.387 | 0 | 0 |
| Activation of NOXA and translocation to mitochondria | R-HSA-111448 | 0.539368 | 0.268 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 0.444455 | 0.352 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 0.477479 | 0.321 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 0.595206 | 0.225 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 0.451729 | 0.345 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 0.576943 | 0.239 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 0.567543 | 0.246 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 0.567543 | 0.246 | 0 | 0 |
| Defects of platelet adhesion to exposed collagen | R-HSA-9823587 | 0.644278 | 0.191 | 0 | 0 |
| Release of Hh-Np from the secreting cell | R-HSA-5362798 | 0.644278 | 0.191 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 0.422368 | 0.374 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 0.566293 | 0.247 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 0.526451 | 0.279 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 0.517944 | 0.286 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 0.390574 | 0.408 | 0 | 0 |
| Interleukin-6 family signaling | R-HSA-6783589 | 0.346746 | 0.460 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 0.345322 | 0.462 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 0.151104 | 0.821 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 0.599024 | 0.223 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 0.562258 | 0.250 | 1 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 0.283428 | 0.548 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 0.576943 | 0.239 | 0 | 0 |
| TP53 Regulates Transcription of Caspase Activators and Caspases | R-HSA-6803207 | 0.260329 | 0.584 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 0.375186 | 0.426 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 0.583553 | 0.234 | 1 | 1 |
| Interleukin-6 signaling | R-HSA-1059683 | 0.376205 | 0.425 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 0.515521 | 0.288 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 0.583957 | 0.234 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 0.160866 | 0.794 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 0.546817 | 0.262 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 0.625219 | 0.204 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 0.321277 | 0.493 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 0.276510 | 0.558 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 0.205684 | 0.687 | 0 | 0 |
| Synthesis of PI | R-HSA-1483226 | 0.271596 | 0.566 | 0 | 0 |
| Diseases of Mismatch Repair (MMR) | R-HSA-5423599 | 0.475832 | 0.323 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 0.243159 | 0.614 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 0.458842 | 0.338 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 0.539368 | 0.268 | 0 | 0 |
| TLR3-mediated TICAM1-dependent programmed cell death | R-HSA-9013957 | 0.539368 | 0.268 | 0 | 0 |
| Other semaphorin interactions | R-HSA-416700 | 0.444455 | 0.352 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 0.444455 | 0.352 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 0.500350 | 0.301 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 0.477479 | 0.321 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 0.595206 | 0.225 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 0.541911 | 0.266 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 0.592359 | 0.227 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 0.599024 | 0.223 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 0.644278 | 0.191 | 0 | 0 |
| Intestinal hexose absorption | R-HSA-8981373 | 0.644278 | 0.191 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 0.303828 | 0.517 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 0.267444 | 0.573 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 0.246317 | 0.609 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 0.193036 | 0.714 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 0.496259 | 0.304 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 0.593195 | 0.227 | 1 | 0 |
| L1CAM interactions | R-HSA-373760 | 0.126262 | 0.899 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 0.379394 | 0.421 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 0.165795 | 0.780 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 0.500350 | 0.301 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 0.550139 | 0.260 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 0.639366 | 0.194 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 0.436085 | 0.360 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 0.175233 | 0.756 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 0.372552 | 0.429 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 0.515521 | 0.288 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 0.142164 | 0.847 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 0.390639 | 0.408 | 0 | 0 |
| Sodium-coupled phosphate cotransporters | R-HSA-427652 | 0.276510 | 0.558 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 0.370260 | 0.431 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 0.370260 | 0.431 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 0.272125 | 0.565 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 0.415394 | 0.382 | 0 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 0.265651 | 0.576 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 0.283827 | 0.547 | 0 | 0 |
| Dopamine receptors | R-HSA-390651 | 0.539368 | 0.268 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 0.539368 | 0.268 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 0.267199 | 0.573 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 0.483201 | 0.316 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 0.592359 | 0.227 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 0.644278 | 0.191 | 0 | 0 |
| Acetylcholine inhibits contraction of outer hair cells | R-HSA-9667769 | 0.644278 | 0.191 | 0 | 0 |
| CLEC7A/inflammasome pathway | R-HSA-5660668 | 0.644278 | 0.191 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 0.435719 | 0.361 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 0.523955 | 0.281 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 0.346238 | 0.461 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 0.432586 | 0.364 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 0.253576 | 0.596 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 0.567543 | 0.246 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 0.458842 | 0.338 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 0.317330 | 0.498 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 0.415394 | 0.382 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 0.458842 | 0.338 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 0.444455 | 0.352 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 0.595206 | 0.225 | 0 | 0 |
| DEx/H-box helicases activate type I IFN and inflammatory cytokines production | R-HSA-3134963 | 0.595206 | 0.225 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 0.644278 | 0.191 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 0.460767 | 0.337 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 0.511849 | 0.291 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 0.435880 | 0.361 | 0 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 0.247834 | 0.606 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 0.540564 | 0.267 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 0.460767 | 0.337 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 0.611885 | 0.213 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 0.458842 | 0.338 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 0.410636 | 0.387 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 0.432586 | 0.364 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 0.500350 | 0.301 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 0.488445 | 0.311 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 0.644575 | 0.191 | 0 | 0 |
| Adenylate cyclase activating pathway | R-HSA-170660 | 0.644575 | 0.191 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 0.644575 | 0.191 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 0.644575 | 0.191 | 0 | 0 |
| Processing of SMDT1 | R-HSA-8949664 | 0.644575 | 0.191 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 0.644575 | 0.191 | 0 | 0 |
| IL-6-type cytokine receptor ligand interactions | R-HSA-6788467 | 0.644575 | 0.191 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 0.644575 | 0.191 | 0 | 0 |
| rRNA modification in the mitochondrion | R-HSA-6793080 | 0.644575 | 0.191 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression linked to lipogenesis | R-HSA-9029558 | 0.644575 | 0.191 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 0.646681 | 0.189 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 0.648202 | 0.188 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 0.649208 | 0.188 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 0.649995 | 0.187 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 0.649995 | 0.187 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 0.649995 | 0.187 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 0.650603 | 0.187 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 0.651191 | 0.186 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 0.652378 | 0.186 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 0.652378 | 0.186 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 0.652378 | 0.186 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 0.652428 | 0.185 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 0.655461 | 0.183 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 0.661495 | 0.179 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 0.666370 | 0.176 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 0.670679 | 0.173 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 0.670679 | 0.173 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 0.672108 | 0.173 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 0.675046 | 0.171 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 0.675046 | 0.171 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 0.675046 | 0.171 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 0.675046 | 0.171 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 0.675046 | 0.171 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 0.675046 | 0.171 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 0.676136 | 0.170 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 0.677076 | 0.169 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 0.677076 | 0.169 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 0.678748 | 0.168 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 0.679589 | 0.168 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 0.679589 | 0.168 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 0.681491 | 0.167 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 0.682682 | 0.166 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 0.682682 | 0.166 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 0.682682 | 0.166 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 0.682682 | 0.166 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 0.683770 | 0.165 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 0.685344 | 0.164 | 0 | 0 |
| Small interfering RNA (siRNA) biogenesis | R-HSA-426486 | 0.687403 | 0.163 | 0 | 0 |
| STAT5 Activation | R-HSA-9645135 | 0.687403 | 0.163 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 0.687403 | 0.163 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 0.687403 | 0.163 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 0.687403 | 0.163 | 0 | 0 |
| Defective CYP11A1 causes AICSR | R-HSA-5579026 | 0.687403 | 0.163 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 0.687403 | 0.163 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 0.687403 | 0.163 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 0.687403 | 0.163 | 0 | 0 |
| Agmatine biosynthesis | R-HSA-351143 | 0.687403 | 0.163 | 0 | 0 |
| Leukotriene receptors | R-HSA-391906 | 0.687403 | 0.163 | 0 | 0 |
| Lipid particle organization | R-HSA-8964572 | 0.687403 | 0.163 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 0.687403 | 0.163 | 0 | 0 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 0.690295 | 0.161 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 0.690295 | 0.161 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 0.695152 | 0.158 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 0.696282 | 0.157 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 0.698594 | 0.156 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 0.700449 | 0.155 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 0.700449 | 0.155 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 0.700449 | 0.155 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 0.703355 | 0.153 | 0 | 0 |
| Adenylate cyclase inhibitory pathway | R-HSA-170670 | 0.703355 | 0.153 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 0.703355 | 0.153 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 0.703355 | 0.153 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 0.703355 | 0.153 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR4 | R-HSA-5654228 | 0.703355 | 0.153 | 0 | 0 |
| Telomere C-strand synthesis initiation | R-HSA-174430 | 0.703355 | 0.153 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 0.703355 | 0.153 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 0.703355 | 0.153 | 0 | 0 |
| Lysosphingolipid and LPA receptors | R-HSA-419408 | 0.703355 | 0.153 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 0.703355 | 0.153 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 0.704062 | 0.152 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 0.706450 | 0.151 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 0.707450 | 0.150 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 0.707450 | 0.150 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 0.710627 | 0.148 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 0.712856 | 0.147 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 0.714427 | 0.146 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 0.718006 | 0.144 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 0.718627 | 0.143 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 0.720913 | 0.142 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 0.722511 | 0.141 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 0.722511 | 0.141 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 0.722511 | 0.141 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 0.722511 | 0.141 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 0.724719 | 0.140 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 0.724719 | 0.140 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 0.724719 | 0.140 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 0.724719 | 0.140 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 0.725303 | 0.139 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 0.725303 | 0.139 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 0.725303 | 0.139 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 0.725303 | 0.139 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 0.725303 | 0.139 | 0 | 0 |
| SLBP independent Processing of Histone Pre-mRNAs | R-HSA-111367 | 0.725303 | 0.139 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 0.725303 | 0.139 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 0.725303 | 0.139 | 0 | 0 |
| PTK6 Expression | R-HSA-8849473 | 0.725303 | 0.139 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 0.725303 | 0.139 | 0 | 0 |
| Activated NTRK2 signals through CDK5 | R-HSA-9032845 | 0.725303 | 0.139 | 0 | 0 |
| Electron transport from NADPH to Ferredoxin | R-HSA-2395516 | 0.725303 | 0.139 | 0 | 0 |
| Microbial modulation of RIPK1-mediated regulated necrosis | R-HSA-9686347 | 0.725303 | 0.139 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 0.725303 | 0.139 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 0.725303 | 0.139 | 0 | 0 |
| Ca2+ activated K+ channels | R-HSA-1296052 | 0.725303 | 0.139 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 0.725303 | 0.139 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 0.725303 | 0.139 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 0.725303 | 0.139 | 0 | 0 |
| Phase 3 - rapid repolarisation | R-HSA-5576890 | 0.725303 | 0.139 | 0 | 0 |
| Glycoprotein hormones | R-HSA-209822 | 0.725303 | 0.139 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 0.725303 | 0.139 | 0 | 0 |
| CHL1 interactions | R-HSA-447041 | 0.725303 | 0.139 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 0.725303 | 0.139 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 0.725303 | 0.139 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 0.729579 | 0.137 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 0.729579 | 0.137 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 0.729579 | 0.137 | 0 | 0 |
| Killing mechanisms | R-HSA-9664420 | 0.729579 | 0.137 | 0 | 0 |
| WNT5:FZD7-mediated leishmania damping | R-HSA-9673324 | 0.729579 | 0.137 | 0 | 0 |
| Differentiation of naive CD+ T cells to T helper 1 cells (Th1 cells) | R-HSA-9942503 | 0.729579 | 0.137 | 0 | 0 |
| Differentiation of T cells | R-HSA-9945266 | 0.729579 | 0.137 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 0.729579 | 0.137 | 0 | 0 |
| Induction of Cell-Cell Fusion | R-HSA-9733458 | 0.729579 | 0.137 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 0.730403 | 0.136 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 0.730415 | 0.136 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 0.736583 | 0.133 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 0.737402 | 0.132 | 1 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 0.737956 | 0.132 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 0.738184 | 0.132 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 0.740550 | 0.130 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 0.740550 | 0.130 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 0.740550 | 0.130 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 0.740550 | 0.130 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 0.740550 | 0.130 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 0.743284 | 0.129 | 0 | 0 |
| TNFs bind their physiological receptors | R-HSA-5669034 | 0.743284 | 0.129 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 0.743284 | 0.129 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 0.743670 | 0.129 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 0.747465 | 0.126 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 0.752884 | 0.123 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 0.753807 | 0.123 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 0.753807 | 0.123 | 0 | 0 |
| Synthesis of PG | R-HSA-1483148 | 0.753807 | 0.123 | 0 | 0 |
| Chromosome Maintenance | R-HSA-73886 | 0.753867 | 0.123 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 0.757027 | 0.121 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 0.757027 | 0.121 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 0.757027 | 0.121 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 0.757027 | 0.121 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 0.757027 | 0.121 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 0.757027 | 0.121 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 0.758609 | 0.120 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 0.758609 | 0.120 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 0.758609 | 0.120 | 0 | 0 |
| SLBP Dependent Processing of Replication-Dependent Histone Pre-mRNAs | R-HSA-77588 | 0.758609 | 0.120 | 0 | 0 |
| Myoclonic epilepsy of Lafora | R-HSA-3785653 | 0.758609 | 0.120 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 0.758609 | 0.120 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 0.758609 | 0.120 | 0 | 0 |
| Nef mediated downregulation of MHC class I complex cell surface expression | R-HSA-164940 | 0.758609 | 0.120 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 0.758609 | 0.120 | 0 | 0 |
| Sodium/Proton exchangers | R-HSA-425986 | 0.758609 | 0.120 | 0 | 0 |
| Interleukin-9 signaling | R-HSA-8985947 | 0.758609 | 0.120 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 0.758609 | 0.120 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 0.758609 | 0.120 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 0.758609 | 0.120 | 0 | 0 |
| Activated NTRK2 signals through FYN | R-HSA-9032500 | 0.758609 | 0.120 | 0 | 0 |
| Alpha-defensins | R-HSA-1462054 | 0.758609 | 0.120 | 0 | 0 |
| Intestinal absorption | R-HSA-8963676 | 0.758609 | 0.120 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 0.763455 | 0.117 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 0.767750 | 0.115 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 0.772030 | 0.112 | 0 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 0.772453 | 0.112 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 0.772722 | 0.112 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 0.773353 | 0.112 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 0.774446 | 0.111 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 0.774446 | 0.111 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 0.776137 | 0.110 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 0.776137 | 0.110 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 0.776137 | 0.110 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 0.776137 | 0.110 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 0.778283 | 0.109 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 0.781088 | 0.107 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 0.781088 | 0.107 | 0 | 0 |
| Synthesis of PIPs at the Golgi membrane | R-HSA-1660514 | 0.781088 | 0.107 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 0.782389 | 0.107 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 0.784540 | 0.105 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 0.785301 | 0.105 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 0.785301 | 0.105 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 0.786149 | 0.104 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 0.786149 | 0.104 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 0.786402 | 0.104 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 0.786402 | 0.104 | 0 | 0 |
| Estrogen-stimulated signaling through PRKCZ | R-HSA-9634635 | 0.787879 | 0.104 | 0 | 0 |
| MAPK1 (ERK2) activation | R-HSA-112411 | 0.787879 | 0.104 | 0 | 0 |
| APEX1-Independent Resolution of AP Sites via the Single Nucleotide Replacement Pathway | R-HSA-5649702 | 0.787879 | 0.104 | 0 | 0 |
| MASTL Facilitates Mitotic Progression | R-HSA-2465910 | 0.787879 | 0.104 | 0 | 0 |
| Regulation of commissural axon pathfinding by SLIT and ROBO | R-HSA-428542 | 0.787879 | 0.104 | 0 | 0 |
| Interleukin-21 signaling | R-HSA-9020958 | 0.787879 | 0.104 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 0.787879 | 0.104 | 0 | 0 |
| Degradation of GABA | R-HSA-916853 | 0.787879 | 0.104 | 0 | 0 |
| AMPK inhibits chREBP transcriptional activation activity | R-HSA-163680 | 0.787879 | 0.104 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 0.787879 | 0.104 | 0 | 0 |
| Interleukin-1 processing | R-HSA-448706 | 0.787879 | 0.104 | 0 | 0 |
| Caspase activation via Dependence Receptors in the absence of ligand | R-HSA-418889 | 0.787879 | 0.104 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 0.791857 | 0.101 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 0.794955 | 0.100 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 0.796674 | 0.099 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 0.796674 | 0.099 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 0.796674 | 0.099 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 0.796674 | 0.099 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9679504 | 0.796674 | 0.099 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 0.797595 | 0.098 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 0.797595 | 0.098 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 0.797977 | 0.098 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 0.798198 | 0.098 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 0.798198 | 0.098 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 0.798198 | 0.098 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 0.798289 | 0.098 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 0.798289 | 0.098 | 0 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 0.799704 | 0.097 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 0.800018 | 0.097 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 0.800018 | 0.097 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 0.801500 | 0.096 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 0.801614 | 0.096 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 0.804750 | 0.094 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 0.804750 | 0.094 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 0.809003 | 0.092 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 0.809015 | 0.092 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 0.809015 | 0.092 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 0.809847 | 0.092 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 0.810066 | 0.091 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 0.810066 | 0.091 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 0.810278 | 0.091 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 0.811785 | 0.091 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 0.811785 | 0.091 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 0.812940 | 0.090 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 0.812940 | 0.090 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 0.813038 | 0.090 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 0.813601 | 0.090 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 0.813601 | 0.090 | 0 | 0 |
| DNA replication initiation | R-HSA-68952 | 0.813601 | 0.090 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 0.813601 | 0.090 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 0.813601 | 0.090 | 0 | 0 |
| Metabolism of serotonin | R-HSA-380612 | 0.813601 | 0.090 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 0.813601 | 0.090 | 0 | 0 |
| Defective RIPK1-mediated regulated necrosis | R-HSA-9693928 | 0.813601 | 0.090 | 0 | 0 |
| Pexophagy | R-HSA-9664873 | 0.813601 | 0.090 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 0.813601 | 0.090 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 0.813601 | 0.090 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 0.813601 | 0.090 | 0 | 0 |
| Defective factor IX causes hemophilia B | R-HSA-9668250 | 0.813601 | 0.090 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 0.813601 | 0.090 | 0 | 0 |
| Sperm Motility And Taxes | R-HSA-1300642 | 0.813601 | 0.090 | 0 | 0 |
| Peptide hormone biosynthesis | R-HSA-209952 | 0.813601 | 0.090 | 0 | 0 |
| Regulation of the apoptosome activity | R-HSA-9627069 | 0.813601 | 0.090 | 0 | 0 |
| Formation of apoptosome | R-HSA-111458 | 0.813601 | 0.090 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 0.814174 | 0.089 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 0.814174 | 0.089 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 0.815523 | 0.089 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 0.815523 | 0.089 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 0.815523 | 0.089 | 0 | 0 |
| Specification of the neural plate border | R-HSA-9834899 | 0.815523 | 0.089 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 0.815523 | 0.089 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 0.815523 | 0.089 | 0 | 0 |
| Strand-asynchronous mitochondrial DNA replication | R-HSA-9913635 | 0.815523 | 0.089 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 0.818614 | 0.087 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 0.818614 | 0.087 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 0.818614 | 0.087 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 0.819279 | 0.087 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 0.819279 | 0.087 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 0.819815 | 0.086 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 0.820523 | 0.086 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 0.821582 | 0.085 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 0.821582 | 0.085 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 0.825185 | 0.083 | 0 | 0 |
| Signaling by CSF3 (G-CSF) | R-HSA-9674555 | 0.829064 | 0.081 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 0.829064 | 0.081 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 0.829064 | 0.081 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 0.829064 | 0.081 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 0.831657 | 0.080 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 0.831657 | 0.080 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 0.831657 | 0.080 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 0.832112 | 0.080 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 0.832536 | 0.080 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 0.832792 | 0.079 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 0.832792 | 0.079 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 0.832792 | 0.079 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 0.832792 | 0.079 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 0.832792 | 0.079 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 0.835102 | 0.078 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 0.835102 | 0.078 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 0.836206 | 0.078 | 0 | 0 |
| Synthesis of PIPs at the ER membrane | R-HSA-1483248 | 0.836206 | 0.078 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 0.836206 | 0.078 | 0 | 0 |
| RHOBTB3 ATPase cycle | R-HSA-9706019 | 0.836206 | 0.078 | 0 | 0 |
| Cholesterol biosynthesis via desmosterol | R-HSA-6807047 | 0.836206 | 0.078 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 0.836206 | 0.078 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 0.836206 | 0.078 | 0 | 0 |
| SARS-CoV-2 modulates autophagy | R-HSA-9754560 | 0.836206 | 0.078 | 0 | 0 |
| Inorganic anion exchange by SLC26 transporters | R-HSA-427601 | 0.836206 | 0.078 | 0 | 0 |
| Transport of RCbl within the body | R-HSA-9758890 | 0.836206 | 0.078 | 0 | 0 |
| Interleukin-2 signaling | R-HSA-9020558 | 0.836206 | 0.078 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 0.836206 | 0.078 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 0.836772 | 0.077 | 0 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 0.838631 | 0.076 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 0.841802 | 0.075 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 0.842917 | 0.074 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 0.842917 | 0.074 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 0.842917 | 0.074 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 0.846717 | 0.072 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 0.847199 | 0.072 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 0.847722 | 0.072 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 0.848588 | 0.071 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 0.848588 | 0.071 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 0.848588 | 0.071 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 0.848672 | 0.071 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 0.849918 | 0.071 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 0.850663 | 0.070 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 0.852821 | 0.069 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 0.854136 | 0.068 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 0.855787 | 0.068 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 0.855787 | 0.068 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 0.855787 | 0.068 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 0.855787 | 0.068 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 0.855787 | 0.068 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 0.856070 | 0.067 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 0.856070 | 0.067 | 0 | 0 |
| Regulation of gene expression by Hypoxia-inducible Factor | R-HSA-1234158 | 0.856070 | 0.067 | 0 | 0 |
| NR1H2 & NR1H3 regulate gene expression to control bile acid homeostasis | R-HSA-9623433 | 0.856070 | 0.067 | 0 | 0 |
| Viral RNP Complexes in the Host Cell Nucleus | R-HSA-168330 | 0.856070 | 0.067 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 0.856070 | 0.067 | 0 | 0 |
| Cytochrome c-mediated apoptotic response | R-HSA-111461 | 0.856070 | 0.067 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 0.858057 | 0.066 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 0.858489 | 0.066 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 0.862183 | 0.064 | 0 | 0 |
| Inactivation of CSF3 (G-CSF) signaling | R-HSA-9705462 | 0.863012 | 0.064 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 0.863012 | 0.064 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 0.863012 | 0.064 | 0 | 0 |
| Glutathione synthesis and recycling | R-HSA-174403 | 0.863012 | 0.064 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 0.863012 | 0.064 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 0.863012 | 0.064 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 0.864359 | 0.063 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 0.864767 | 0.063 | 0 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 0.866163 | 0.062 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 0.867724 | 0.062 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 0.867724 | 0.062 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 0.867798 | 0.062 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 0.873527 | 0.059 | 0 | 0 |
| Activated NTRK2 signals through FRS2 and FRS3 | R-HSA-9028731 | 0.873527 | 0.059 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 0.873527 | 0.059 | 0 | 0 |
| SHC-related events triggered by IGF1R | R-HSA-2428933 | 0.873527 | 0.059 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 0.873527 | 0.059 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 0.873527 | 0.059 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 0.873527 | 0.059 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 0.873527 | 0.059 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 0.873527 | 0.059 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 0.873527 | 0.059 | 0 | 0 |
| Serotonin clearance from the synaptic cleft | R-HSA-380615 | 0.873527 | 0.059 | 0 | 0 |
| Synthesis of GDP-mannose | R-HSA-446205 | 0.873527 | 0.059 | 0 | 0 |
| Estrogen biosynthesis | R-HSA-193144 | 0.873527 | 0.059 | 0 | 0 |
| Interleukin-15 signaling | R-HSA-8983432 | 0.873527 | 0.059 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 0.873527 | 0.059 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 0.876006 | 0.057 | 0 | 0 |
| FRS-mediated FGFR4 signaling | R-HSA-5654712 | 0.876167 | 0.057 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 0.876167 | 0.057 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 0.876167 | 0.057 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 0.876167 | 0.057 | 0 | 0 |
| Ethanol oxidation | R-HSA-71384 | 0.876167 | 0.057 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 0.876167 | 0.057 | 0 | 0 |
| Cellular hexose transport | R-HSA-189200 | 0.876167 | 0.057 | 0 | 0 |
| Translation of Replicase and Assembly of the Replication Transcription Complex | R-HSA-9694676 | 0.876167 | 0.057 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 0.876230 | 0.057 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 0.876968 | 0.057 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 0.876968 | 0.057 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 0.878780 | 0.056 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 0.882572 | 0.054 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 0.885592 | 0.053 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 0.885592 | 0.053 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 0.885635 | 0.053 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 0.886497 | 0.052 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 0.886497 | 0.052 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 0.886755 | 0.052 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 0.887348 | 0.052 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 0.887783 | 0.052 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 0.888146 | 0.052 | 0 | 0 |
| Interleukin-20 family signaling | R-HSA-8854691 | 0.888146 | 0.052 | 0 | 0 |
| FGFR4 ligand binding and activation | R-HSA-190322 | 0.888867 | 0.051 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 0.888867 | 0.051 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 0.888867 | 0.051 | 0 | 0 |
| Reversible hydration of carbon dioxide | R-HSA-1475029 | 0.888867 | 0.051 | 0 | 0 |
| Platelet Adhesion to exposed collagen | R-HSA-75892 | 0.888867 | 0.051 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 0.888867 | 0.051 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 0.889007 | 0.051 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 0.889007 | 0.051 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 0.889007 | 0.051 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 0.892012 | 0.050 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 0.893691 | 0.049 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 0.894411 | 0.048 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 0.897100 | 0.047 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 0.897459 | 0.047 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 0.898255 | 0.047 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 0.898454 | 0.047 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 0.898454 | 0.047 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 0.898454 | 0.047 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 0.898454 | 0.047 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 0.898454 | 0.047 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 0.898454 | 0.047 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 0.899042 | 0.046 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 0.899042 | 0.046 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 0.899042 | 0.046 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 0.899337 | 0.046 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 0.899851 | 0.046 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR3 | R-HSA-5654227 | 0.902347 | 0.045 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 0.902347 | 0.045 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 0.902347 | 0.045 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 0.902347 | 0.045 | 0 | 0 |
| TP53 Regulates Transcription of Death Receptors and Ligands | R-HSA-6803211 | 0.902347 | 0.045 | 0 | 0 |
| Formation of the active cofactor, UDP-glucuronate | R-HSA-173599 | 0.902347 | 0.045 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 0.902347 | 0.045 | 0 | 0 |
| Glycerophospholipid catabolism | R-HSA-6814848 | 0.902347 | 0.045 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 0.902347 | 0.045 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 0.902347 | 0.045 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 0.902347 | 0.045 | 0 | 0 |
| G1 Phase | R-HSA-69236 | 0.902589 | 0.045 | 0 | 0 |
| Cyclin D associated events in G1 | R-HSA-69231 | 0.902589 | 0.045 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 0.902589 | 0.045 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 0.903040 | 0.044 | 0 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 0.905922 | 0.043 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 0.905922 | 0.043 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 0.906606 | 0.043 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 0.906606 | 0.043 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 0.906606 | 0.043 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 0.907170 | 0.042 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 0.907170 | 0.042 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 0.907170 | 0.042 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 0.907170 | 0.042 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 0.907170 | 0.042 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 0.907170 | 0.042 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 0.908413 | 0.042 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 0.908503 | 0.042 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 0.908688 | 0.042 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 0.908942 | 0.041 | 0 | 0 |
| Formation of the nephric duct | R-HSA-9830364 | 0.908942 | 0.041 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 0.909736 | 0.041 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 0.909736 | 0.041 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 0.910201 | 0.041 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 0.910201 | 0.041 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 0.910201 | 0.041 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 0.910201 | 0.041 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 0.913763 | 0.039 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 0.914193 | 0.039 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 0.914193 | 0.039 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 0.914193 | 0.039 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 0.914193 | 0.039 | 0 | 0 |
| Protein lipoylation | R-HSA-9857492 | 0.914193 | 0.039 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 0.914193 | 0.039 | 0 | 0 |
| FASTK family proteins regulate processing and stability of mitochondrial RNAs | R-HSA-9837092 | 0.914193 | 0.039 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 0.914193 | 0.039 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 0.914193 | 0.039 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 0.914193 | 0.039 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 0.914193 | 0.039 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 0.915081 | 0.039 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 0.915203 | 0.038 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 0.915203 | 0.038 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 0.916072 | 0.038 | 1 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 0.916701 | 0.038 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 0.917280 | 0.037 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 0.917926 | 0.037 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 0.917926 | 0.037 | 0 | 0 |
| Synthesis of IP2, IP, and Ins in the cytosol | R-HSA-1855183 | 0.917926 | 0.037 | 0 | 0 |
| Caspase activation via extrinsic apoptotic signalling pathway | R-HSA-5357769 | 0.917926 | 0.037 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 0.920616 | 0.036 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 0.921077 | 0.036 | 0 | 0 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 0.922289 | 0.035 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 0.922597 | 0.035 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 0.922597 | 0.035 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 0.923855 | 0.034 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 0.924602 | 0.034 | 0 | 0 |
| Serotonin and melatonin biosynthesis | R-HSA-209931 | 0.924602 | 0.034 | 0 | 0 |
| Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells | R-HSA-210744 | 0.924602 | 0.034 | 0 | 0 |
| Fructose catabolism | R-HSA-70350 | 0.924602 | 0.034 | 0 | 0 |
| Synthesis of wybutosine at G37 of tRNA(Phe) | R-HSA-6782861 | 0.924602 | 0.034 | 0 | 0 |
| Caspase activation via Death Receptors in the presence of ligand | R-HSA-140534 | 0.924602 | 0.034 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 0.924602 | 0.034 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 0.925956 | 0.033 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 0.926071 | 0.033 | 0 | 0 |
| Signaling by BMP | R-HSA-201451 | 0.926071 | 0.033 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in Cytochrome C Release | R-HSA-6803204 | 0.926071 | 0.033 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 0.927145 | 0.033 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 0.928576 | 0.032 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 0.929956 | 0.032 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 0.929956 | 0.032 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 0.931576 | 0.031 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 0.933449 | 0.030 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 0.933749 | 0.030 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 0.933749 | 0.030 | 0 | 0 |
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | R-HSA-975110 | 0.933749 | 0.030 | 0 | 0 |
| STAT5 activation downstream of FLT3 ITD mutants | R-HSA-9702518 | 0.933749 | 0.030 | 0 | 0 |
| Passive transport by Aquaporins | R-HSA-432047 | 0.933749 | 0.030 | 0 | 0 |
| Galactose catabolism | R-HSA-70370 | 0.933749 | 0.030 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 0.933749 | 0.030 | 0 | 0 |
| Response to metal ions | R-HSA-5660526 | 0.933749 | 0.030 | 0 | 0 |
| Defects of contact activation system (CAS) and kallikrein/kinin system (KKS) | R-HSA-9651496 | 0.933749 | 0.030 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 0.935506 | 0.029 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 0.935642 | 0.029 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 0.935642 | 0.029 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 0.935642 | 0.029 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 0.935642 | 0.029 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 0.935764 | 0.029 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 0.935764 | 0.029 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 0.936152 | 0.029 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 0.936917 | 0.028 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 0.937660 | 0.028 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 0.937660 | 0.028 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 0.937660 | 0.028 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 0.937660 | 0.028 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 0.937660 | 0.028 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 0.937991 | 0.028 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 0.938287 | 0.028 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 0.940125 | 0.027 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 0.940248 | 0.027 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 0.940695 | 0.027 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 0.940925 | 0.026 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 0.941101 | 0.026 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 0.941374 | 0.026 | 0 | 0 |
| Phospholipase C-mediated cascade: FGFR1 | R-HSA-5654219 | 0.941787 | 0.026 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 0.941787 | 0.026 | 0 | 0 |
| Glycogen storage diseases | R-HSA-3229121 | 0.941787 | 0.026 | 0 | 0 |
| Catecholamine biosynthesis | R-HSA-209905 | 0.941787 | 0.026 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 0.941787 | 0.026 | 0 | 0 |
| Sulfide oxidation to sulfate | R-HSA-1614517 | 0.941787 | 0.026 | 0 | 0 |
| GDP-fucose biosynthesis | R-HSA-6787639 | 0.941787 | 0.026 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 0.941787 | 0.026 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 0.941968 | 0.026 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 0.944116 | 0.025 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 0.944165 | 0.025 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 0.946630 | 0.024 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 0.946630 | 0.024 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 0.946630 | 0.024 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 0.946630 | 0.024 | 0 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 0.946791 | 0.024 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 0.946897 | 0.024 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 0.947775 | 0.023 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 0.948850 | 0.023 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 0.948850 | 0.023 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 0.948850 | 0.023 | 0 | 0 |
| Cytosolic iron-sulfur cluster assembly | R-HSA-2564830 | 0.948850 | 0.023 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 0.948850 | 0.023 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 0.950695 | 0.022 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 0.950831 | 0.022 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 0.950941 | 0.022 | 0 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 0.951214 | 0.022 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 0.954316 | 0.020 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 0.955057 | 0.020 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 0.955057 | 0.020 | 0 | 0 |
| Diseases of hemostasis | R-HSA-9671793 | 0.955057 | 0.020 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 0.955480 | 0.020 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 0.955851 | 0.020 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 0.955851 | 0.020 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 0.956538 | 0.019 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 0.958135 | 0.019 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 0.959352 | 0.018 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 0.959880 | 0.018 | 0 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 0.960271 | 0.018 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 0.960351 | 0.018 | 0 | 0 |
| Phospholipase C-mediated cascade; FGFR2 | R-HSA-5654221 | 0.960511 | 0.017 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 0.960511 | 0.017 | 0 | 0 |
| Pregnenolone biosynthesis | R-HSA-196108 | 0.960511 | 0.017 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 0.960511 | 0.017 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 0.960511 | 0.017 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 0.960511 | 0.017 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 0.960511 | 0.017 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 0.960511 | 0.017 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 0.960511 | 0.017 | 0 | 0 |
| Eicosanoid ligand-binding receptors | R-HSA-391903 | 0.960511 | 0.017 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 0.960979 | 0.017 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 0.961658 | 0.017 | 0 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 0.961658 | 0.017 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 0.962725 | 0.016 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 0.962725 | 0.016 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 0.962725 | 0.016 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 0.963562 | 0.016 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 0.963562 | 0.016 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 0.963974 | 0.016 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 0.964213 | 0.016 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 0.964983 | 0.015 | 0 | 0 |
| Heme degradation | R-HSA-189483 | 0.964983 | 0.015 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 0.965186 | 0.015 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 0.965186 | 0.015 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 0.965303 | 0.015 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 0.965303 | 0.015 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 0.965303 | 0.015 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 0.965303 | 0.015 | 0 | 0 |
| Intrinsic Pathway of Fibrin Clot Formation | R-HSA-140837 | 0.965303 | 0.015 | 0 | 0 |
| Phenylalanine metabolism | R-HSA-8964208 | 0.965303 | 0.015 | 0 | 0 |
| PD-L1(CD274) glycosylation and translocation to plasma membrane | R-HSA-9931295 | 0.965303 | 0.015 | 0 | 0 |
| Vitamin C (ascorbate) metabolism | R-HSA-196836 | 0.965303 | 0.015 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 0.965303 | 0.015 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 0.965555 | 0.015 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 0.965817 | 0.015 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 0.966390 | 0.015 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 0.966924 | 0.015 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 0.966924 | 0.015 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 0.966950 | 0.015 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 0.967918 | 0.014 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 0.968590 | 0.014 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 0.968590 | 0.014 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 0.968590 | 0.014 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 0.968590 | 0.014 | 0 | 0 |
| RA biosynthesis pathway | R-HSA-5365859 | 0.968590 | 0.014 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 0.968590 | 0.014 | 0 | 0 |
| SHC-mediated cascade:FGFR4 | R-HSA-5654719 | 0.969514 | 0.013 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 0.969514 | 0.013 | 0 | 0 |
| FRS-mediated FGFR3 signaling | R-HSA-5654706 | 0.969514 | 0.013 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 0.969992 | 0.013 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 0.969992 | 0.013 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 0.969992 | 0.013 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 0.969992 | 0.013 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 0.969992 | 0.013 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 0.970642 | 0.013 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 0.971370 | 0.013 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 0.971370 | 0.013 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 0.971370 | 0.013 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 0.971837 | 0.012 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 0.972403 | 0.012 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 0.973164 | 0.012 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 0.973170 | 0.012 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 0.973214 | 0.012 | 0 | 0 |
| Fructose metabolism | R-HSA-5652084 | 0.973214 | 0.012 | 0 | 0 |
| Cholesterol biosynthesis via lathosterol | R-HSA-6807062 | 0.973214 | 0.012 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 0.973214 | 0.012 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 0.974759 | 0.011 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 0.974759 | 0.011 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 0.974877 | 0.011 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 0.975337 | 0.011 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 0.975493 | 0.011 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 0.975493 | 0.011 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 0.976465 | 0.010 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 0.976465 | 0.010 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 0.976465 | 0.010 | 0 | 0 |
| Formation of the ureteric bud | R-HSA-9830674 | 0.976465 | 0.010 | 0 | 0 |
| Synthesis of pyrophosphates in the cytosol | R-HSA-1855167 | 0.976465 | 0.010 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 0.976465 | 0.010 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 0.976575 | 0.010 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 0.976958 | 0.010 | 0 | 0 |
| Voltage gated Potassium channels | R-HSA-1296072 | 0.977387 | 0.010 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 0.977626 | 0.010 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 0.977658 | 0.010 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 0.977658 | 0.010 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 0.977936 | 0.010 | 0 | 0 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 0.978664 | 0.009 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 0.979322 | 0.009 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 0.979322 | 0.009 | 0 | 0 |
| Synthesis of dolichyl-phosphate | R-HSA-446199 | 0.979322 | 0.009 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 0.979322 | 0.009 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 0.979583 | 0.009 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 0.980372 | 0.009 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 0.981438 | 0.008 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 0.981637 | 0.008 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 0.981690 | 0.008 | 0 | 0 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 0.981730 | 0.008 | 0 | 0 |
| FRS-mediated FGFR1 signaling | R-HSA-5654693 | 0.981832 | 0.008 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 0.981832 | 0.008 | 0 | 0 |
| Alpha-oxidation of phytanate | R-HSA-389599 | 0.981832 | 0.008 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 0.981832 | 0.008 | 0 | 0 |
| Fertilization | R-HSA-1187000 | 0.981832 | 0.008 | 0 | 0 |
| Retinoid cycle disease events | R-HSA-2453864 | 0.981832 | 0.008 | 0 | 0 |
| Diseases associated with visual transduction | R-HSA-2474795 | 0.981832 | 0.008 | 0 | 0 |
| Diseases of the neuronal system | R-HSA-9675143 | 0.981832 | 0.008 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 0.981832 | 0.008 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 0.981871 | 0.008 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 0.981874 | 0.008 | 1 | 1 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 0.981996 | 0.008 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 0.982721 | 0.008 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 0.983105 | 0.007 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 0.983435 | 0.007 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 0.983777 | 0.007 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 0.983777 | 0.007 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 0.983777 | 0.007 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 0.983777 | 0.007 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 0.983777 | 0.007 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 0.983777 | 0.007 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 0.983777 | 0.007 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 0.984037 | 0.007 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 0.984037 | 0.007 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 0.984037 | 0.007 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 0.984037 | 0.007 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 0.984383 | 0.007 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 0.984424 | 0.007 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 0.984873 | 0.007 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 0.984971 | 0.007 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 0.985057 | 0.007 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 0.985487 | 0.006 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 0.985487 | 0.006 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 0.985487 | 0.006 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 0.985748 | 0.006 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 0.985908 | 0.006 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 0.985912 | 0.006 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 0.985912 | 0.006 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 0.985975 | 0.006 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 0.985975 | 0.006 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 0.985975 | 0.006 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 0.985975 | 0.006 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 0.986460 | 0.006 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 0.987021 | 0.006 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 0.987170 | 0.006 | 0 | 0 |
| FRS-mediated FGFR2 signaling | R-HSA-5654700 | 0.987678 | 0.005 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 0.987678 | 0.005 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 0.987678 | 0.005 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 0.987770 | 0.005 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 0.987848 | 0.005 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 0.988396 | 0.005 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 0.988396 | 0.005 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 0.988646 | 0.005 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 0.989129 | 0.005 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 0.989174 | 0.005 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 0.989174 | 0.005 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 0.989527 | 0.005 | 0 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 0.989587 | 0.005 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 0.990023 | 0.004 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 0.990340 | 0.004 | 0 | 0 |
| Neurotransmitter clearance | R-HSA-112311 | 0.990489 | 0.004 | 0 | 0 |
| Protein folding | R-HSA-391251 | 0.990589 | 0.004 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 0.990734 | 0.004 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 0.991098 | 0.004 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 0.991480 | 0.004 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 0.991644 | 0.004 | 0 | 0 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 0.991798 | 0.004 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 0.991877 | 0.004 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 0.991877 | 0.004 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 0.991877 | 0.004 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 0.992070 | 0.003 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 0.992111 | 0.003 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 0.992372 | 0.003 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 0.992658 | 0.003 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 0.992658 | 0.003 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 0.992674 | 0.003 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 0.992674 | 0.003 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 0.992674 | 0.003 | 0 | 0 |
| Defective B3GALTL causes PpS | R-HSA-5083635 | 0.993550 | 0.003 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 0.993550 | 0.003 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 0.993550 | 0.003 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 0.994028 | 0.003 | 0 | 0 |
| Glutamate and glutamine metabolism | R-HSA-8964539 | 0.994333 | 0.002 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 0.994359 | 0.002 | 1 | 0 |
| Hemostasis | R-HSA-109582 | 0.994603 | 0.002 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 0.994685 | 0.002 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 0.995022 | 0.002 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 0.995022 | 0.002 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 0.995022 | 0.002 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 0.995022 | 0.002 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 0.995313 | 0.002 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 0.995544 | 0.002 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 0.995626 | 0.002 | 0 | 0 |
| Synthesis of bile acids and bile salts via 24-hydroxycholesterol | R-HSA-193775 | 0.995626 | 0.002 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 0.995839 | 0.002 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 0.995934 | 0.002 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 0.996158 | 0.002 | 0 | 0 |
| Glycosphingolipid transport | R-HSA-9845576 | 0.996158 | 0.002 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 0.996216 | 0.002 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 0.996341 | 0.002 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 0.996602 | 0.001 | 0 | 0 |
| O-glycosylation of TSR domain-containing proteins | R-HSA-5173214 | 0.996624 | 0.001 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 0.996624 | 0.001 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 0.996624 | 0.001 | 0 | 0 |
| Phenylalanine and tyrosine metabolism | R-HSA-8963691 | 0.996624 | 0.001 | 0 | 0 |
| Beta-oxidation of very long chain fatty acids | R-HSA-390247 | 0.996624 | 0.001 | 0 | 0 |
| Lysine catabolism | R-HSA-71064 | 0.996624 | 0.001 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 0.996624 | 0.001 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 0.996624 | 0.001 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 0.996637 | 0.001 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 0.996637 | 0.001 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 0.996678 | 0.001 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 0.996686 | 0.001 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 0.996831 | 0.001 | 0 | 0 |
| Depurination | R-HSA-73927 | 0.997035 | 0.001 | 0 | 0 |
| Purine salvage | R-HSA-74217 | 0.997035 | 0.001 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 0.997062 | 0.001 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 0.997114 | 0.001 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 0.997211 | 0.001 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 0.997395 | 0.001 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 0.997395 | 0.001 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 0.997438 | 0.001 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 0.997650 | 0.001 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 0.997650 | 0.001 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 0.997687 | 0.001 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 0.997697 | 0.001 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 0.997697 | 0.001 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 0.997711 | 0.001 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 0.997711 | 0.001 | 0 | 0 |
| Tryptophan catabolism | R-HSA-71240 | 0.997711 | 0.001 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 0.997779 | 0.001 | 0 | 0 |
| Aflatoxin activation and detoxification | R-HSA-5423646 | 0.997989 | 0.001 | 0 | 0 |
| Early SARS-CoV-2 Infection Events | R-HSA-9772572 | 0.998136 | 0.001 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 0.998189 | 0.001 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 0.998234 | 0.001 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 0.998234 | 0.001 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 0.998330 | 0.001 | 0 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 0.998448 | 0.001 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 0.998523 | 0.001 | 0 | 0 |
| Glutathione conjugation | R-HSA-156590 | 0.998523 | 0.001 | 0 | 0 |
| Signaling by Retinoic Acid | R-HSA-5362517 | 0.998523 | 0.001 | 0 | 0 |
| Defensins | R-HSA-1461973 | 0.998637 | 0.001 | 0 | 0 |
| Endogenous sterols | R-HSA-211976 | 0.998685 | 0.001 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 0.998685 | 0.001 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 0.998803 | 0.001 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 0.998803 | 0.001 | 0 | 0 |
| Cobalamin (Cbl, vitamin B12) transport and metabolism | R-HSA-196741 | 0.998803 | 0.001 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 0.998839 | 0.001 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 0.998899 | 0.000 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 0.998916 | 0.000 | 0 | 0 |
| The canonical retinoid cycle in rods (twilight vision) | R-HSA-2453902 | 0.998948 | 0.000 | 0 | 0 |
| Degradation of cysteine and homocysteine | R-HSA-1614558 | 0.998948 | 0.000 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 0.999013 | 0.000 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 0.999013 | 0.000 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 0.999076 | 0.000 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 0.999108 | 0.000 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 0.999168 | 0.000 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 0.999188 | 0.000 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 0.999254 | 0.000 | 1 | 0 |
| Metabolism of steroid hormones | R-HSA-196071 | 0.999349 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 0.999363 | 0.000 | 1 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 0.999374 | 0.000 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 0.999432 | 0.000 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 0.999450 | 0.000 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 0.999517 | 0.000 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 0.999534 | 0.000 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 0.999549 | 0.000 | 0 | 0 |
| Immune System | R-HSA-168256 | 0.999556 | 0.000 | 1 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 0.999594 | 0.000 | 0 | 0 |
| Retinoid metabolism and transport | R-HSA-975634 | 0.999594 | 0.000 | 0 | 0 |
| Metabolism of porphyrins | R-HSA-189445 | 0.999594 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 0.999611 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 0.999619 | 0.000 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 0.999638 | 0.000 | 0 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 0.999649 | 0.000 | 0 | 0 |
| Glucuronidation | R-HSA-156588 | 0.999672 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 0.999679 | 0.000 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 0.999747 | 0.000 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 0.999769 | 0.000 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 0.999802 | 0.000 | 0 | 0 |
| Cholesterol biosynthesis | R-HSA-191273 | 0.999823 | 0.000 | 0 | 0 |
| Metabolic disorders of biological oxidation enzymes | R-HSA-5579029 | 0.999843 | 0.000 | 0 | 0 |
| Nucleotide salvage | R-HSA-8956321 | 0.999868 | 0.000 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 0.999875 | 0.000 | 0 | 0 |
| Metabolism of fat-soluble vitamins | R-HSA-6806667 | 0.999876 | 0.000 | 0 | 0 |
| Complex I biogenesis | R-HSA-6799198 | 0.999898 | 0.000 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 0.999898 | 0.000 | 0 | 0 |
| Xenobiotics | R-HSA-211981 | 0.999910 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 0.999915 | 0.000 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 0.999918 | 0.000 | 0 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 0.999922 | 0.000 | 0 | 0 |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | R-HSA-193368 | 0.999939 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 0.999939 | 0.000 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 0.999940 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 0.999947 | 0.000 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 0.999959 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 0.999959 | 0.000 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 0.999964 | 0.000 | 0 | 0 |
| Purine catabolism | R-HSA-74259 | 0.999968 | 0.000 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 0.999972 | 0.000 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 0.999981 | 0.000 | 0 | 0 |
| Antimicrobial peptides | R-HSA-6803157 | 0.999983 | 0.000 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 0.999985 | 0.000 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 0.999986 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 0.999986 | 0.000 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 0.999987 | 0.000 | 0 | 0 |
| Developmental Lineage of Pancreatic Acinar Cells | R-HSA-9925561 | 0.999987 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 0.999990 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 0.999993 | 0.000 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 0.999994 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 0.999994 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 0.999995 | 0.000 | 0 | 0 |
| Sulfur amino acid metabolism | R-HSA-1614635 | 0.999995 | 0.000 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 0.999995 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 0.999997 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 0.999997 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 0.999998 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 0.999998 | 0.000 | 0 | 0 |
| Translation | R-HSA-72766 | 0.999999 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 0.999999 | 0.000 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 0.999999 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 0.999999 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 1.000000 | 0.000 | 0 | 0 |
| Post-translational modification: synthesis of GPI-anchored proteins | R-HSA-163125 | 1.000000 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 1.000000 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 1.000000 | 0.000 | 0 | 0 |
| Initial triggering of complement | R-HSA-166663 | 1.000000 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 1.000000 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 1.000000 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 1.000000 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 1.000000 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 1.000000 | 0.000 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 1.000000 | 0.000 | 0 | 0 |
| Nucleotide catabolism | R-HSA-8956319 | 1.000000 | 0.000 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 1.000000 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 1.000000 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 1.000000 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 1.000000 | 0.000 | 0 | 0 |
| Cytochrome P450 - arranged by substrate type | R-HSA-211897 | 1.000000 | 0.000 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 1.000000 | 0.000 | 0 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 1.000000 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 1.000000 | 0.000 | 1 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 1.000000 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 1.000000 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 1.000000 | 0.000 | 0 | 0 |
| Disease | R-HSA-1643685 | 1.000000 | 0.000 | 1 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 1.000000 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000 | 0.000 | 0 | 0 |
| Phase II - Conjugation of compounds | R-HSA-156580 | 1.000000 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 1.000000 | 0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000 | -0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000 | -0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000 | -0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000 | -0.000 | 0 | 0 |
Top15 pathways (red highlights are reference pathways)
Compared with reference pathways
Motif of predicted substrate sequence
Reactome pathways of predicted substrates
Download
| name | reactome_id | p | -log10p | ref_path | ref_path_lowest |
|---|---|---|---|---|---|
| Cell Cycle | R-HSA-1640170 | 1.776357e-15 | 14.750 | 0 | 0 |
| Metabolism of RNA | R-HSA-8953854 | 4.251044e-13 | 12.372 | 0 | 0 |
| Cell Cycle Checkpoints | R-HSA-69620 | 8.052448e-13 | 12.094 | 0 | 0 |
| Cell Cycle, Mitotic | R-HSA-69278 | 4.371947e-12 | 11.359 | 0 | 0 |
| M Phase | R-HSA-68886 | 8.520185e-12 | 11.070 | 0 | 0 |
| Cell-Cell communication | R-HSA-1500931 | 2.924028e-11 | 10.534 | 0 | 0 |
| Apoptotic execution phase | R-HSA-75153 | 2.838085e-11 | 10.547 | 0 | 0 |
| Mitotic Prometaphase | R-HSA-68877 | 3.439649e-11 | 10.463 | 0 | 0 |
| GTP hydrolysis and joining of the 60S ribosomal subunit | R-HSA-72706 | 5.232204e-11 | 10.281 | 0 | 0 |
| Eukaryotic Translation Initiation | R-HSA-72613 | 1.443885e-10 | 9.840 | 0 | 0 |
| Cap-dependent Translation Initiation | R-HSA-72737 | 1.443885e-10 | 9.840 | 0 | 0 |
| L13a-mediated translational silencing of Ceruloplasmin expression | R-HSA-156827 | 6.596266e-10 | 9.181 | 0 | 0 |
| Resolution of Sister Chromatid Cohesion | R-HSA-2500257 | 1.380537e-09 | 8.860 | 0 | 0 |
| Nervous system development | R-HSA-9675108 | 1.473881e-09 | 8.832 | 0 | 0 |
| Axon guidance | R-HSA-422475 | 1.780397e-09 | 8.749 | 0 | 0 |
| Cellular responses to stress | R-HSA-2262752 | 2.648313e-09 | 8.577 | 1 | 0 |
| Cellular responses to stimuli | R-HSA-8953897 | 3.936276e-09 | 8.405 | 1 | 0 |
| Eukaryotic Translation Elongation | R-HSA-156842 | 6.153138e-09 | 8.211 | 0 | 0 |
| rRNA processing in the nucleus and cytosol | R-HSA-8868773 | 7.215861e-09 | 8.142 | 0 | 0 |
| Translocation of SLC2A4 (GLUT4) to the plasma membrane | R-HSA-1445148 | 7.234745e-09 | 8.141 | 0 | 0 |
| ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression | R-HSA-427389 | 7.840881e-09 | 8.106 | 0 | 0 |
| Major pathway of rRNA processing in the nucleolus and cytosol | R-HSA-6791226 | 9.177273e-09 | 8.037 | 0 | 0 |
| EML4 and NUDC in mitotic spindle formation | R-HSA-9648025 | 9.151503e-09 | 8.039 | 0 | 0 |
| Separation of Sister Chromatids | R-HSA-2467813 | 8.410032e-09 | 8.075 | 0 | 0 |
| G2/M DNA damage checkpoint | R-HSA-69473 | 9.346319e-09 | 8.029 | 0 | 0 |
| Negative Regulation of CDH1 Gene Transcription | R-HSA-9764725 | 1.410185e-08 | 7.851 | 0 | 0 |
| Formation of a pool of free 40S subunits | R-HSA-72689 | 1.483598e-08 | 7.829 | 0 | 0 |
| Positive epigenetic regulation of rRNA expression | R-HSA-5250913 | 1.674018e-08 | 7.776 | 0 | 0 |
| G2/M Checkpoints | R-HSA-69481 | 1.629647e-08 | 7.788 | 0 | 0 |
| Processing of Capped Intron-Containing Pre-mRNA | R-HSA-72203 | 2.437333e-08 | 7.613 | 0 | 0 |
| Mitotic Anaphase | R-HSA-68882 | 2.487575e-08 | 7.604 | 0 | 0 |
| Mitotic Metaphase and Anaphase | R-HSA-2555396 | 2.837690e-08 | 7.547 | 0 | 0 |
| Nonhomologous End-Joining (NHEJ) | R-HSA-5693571 | 3.288141e-08 | 7.483 | 0 | 0 |
| Regulation of Expression and Function of Type I Classical Cadherins | R-HSA-9764274 | 3.868428e-08 | 7.412 | 0 | 0 |
| Regulation of CDH1 Expression and Function | R-HSA-9764265 | 3.868428e-08 | 7.412 | 0 | 0 |
| mRNA Splicing - Major Pathway | R-HSA-72163 | 4.408860e-08 | 7.356 | 0 | 0 |
| Regulation of CDH1 Gene Transcription | R-HSA-9764560 | 4.948828e-08 | 7.305 | 0 | 0 |
| Cell junction organization | R-HSA-446728 | 4.951466e-08 | 7.305 | 0 | 0 |
| Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs) | R-HSA-9845323 | 5.718157e-08 | 7.243 | 0 | 0 |
| HDACs deacetylate histones | R-HSA-3214815 | 5.936372e-08 | 7.226 | 0 | 0 |
| mRNA Splicing | R-HSA-72172 | 1.875265e-07 | 6.727 | 0 | 0 |
| Regulation of endogenous retroelements | R-HSA-9842860 | 1.948446e-07 | 6.710 | 0 | 0 |
| Apoptotic cleavage of cellular proteins | R-HSA-111465 | 1.981889e-07 | 6.703 | 0 | 0 |
| Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation | R-HSA-8950505 | 2.031729e-07 | 6.692 | 0 | 0 |
| Peptide chain elongation | R-HSA-156902 | 2.780797e-07 | 6.556 | 0 | 0 |
| Nonsense-Mediated Decay (NMD) | R-HSA-927802 | 4.635537e-07 | 6.334 | 0 | 0 |
| Nonsense Mediated Decay (NMD) enhanced by the Exon Junction Complex (EJC) | R-HSA-975957 | 4.635537e-07 | 6.334 | 0 | 0 |
| Muscle contraction | R-HSA-397014 | 4.995079e-07 | 6.301 | 1 | 0 |
| Chromatin organization | R-HSA-4839726 | 5.582538e-07 | 6.253 | 0 | 0 |
| Influenza Infection | R-HSA-168255 | 5.678114e-07 | 6.246 | 0 | 0 |
| Nonsense Mediated Decay (NMD) independent of the Exon Junction Complex (EJC) | R-HSA-975956 | 6.080471e-07 | 6.216 | 0 | 0 |
| Interleukin-12 signaling | R-HSA-9020591 | 6.891289e-07 | 6.162 | 0 | 0 |
| Regulation of Homotypic Cell-Cell Adhesion | R-HSA-9759476 | 8.304458e-07 | 6.081 | 0 | 0 |
| rRNA processing | R-HSA-72312 | 9.510236e-07 | 6.022 | 0 | 0 |
| Adherens junctions interactions | R-HSA-418990 | 1.003111e-06 | 5.999 | 0 | 0 |
| RNA Polymerase I Transcription | R-HSA-73864 | 1.042891e-06 | 5.982 | 0 | 0 |
| Chromatin modifying enzymes | R-HSA-3247509 | 1.183972e-06 | 5.927 | 0 | 0 |
| Signaling by ROBO receptors | R-HSA-376176 | 1.896780e-06 | 5.722 | 0 | 0 |
| Apoptosis | R-HSA-109581 | 1.970893e-06 | 5.705 | 0 | 0 |
| Estrogen-dependent gene expression | R-HSA-9018519 | 2.036973e-06 | 5.691 | 0 | 0 |
| Smooth Muscle Contraction | R-HSA-445355 | 2.114853e-06 | 5.675 | 0 | 0 |
| Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks | R-HSA-5693565 | 2.375212e-06 | 5.624 | 0 | 0 |
| RNA Polymerase I Promoter Clearance | R-HSA-73854 | 2.268766e-06 | 5.644 | 0 | 0 |
| Signal Transduction | R-HSA-162582 | 2.409089e-06 | 5.618 | 1 | 0 |
| Interleukin-12 family signaling | R-HSA-447115 | 2.280725e-06 | 5.642 | 0 | 0 |
| Regulation of endogenous retroelements by the Human Silencing Hub (HUSH) complex | R-HSA-9843970 | 2.547008e-06 | 5.594 | 0 | 0 |
| Recruitment of NuMA to mitotic centrosomes | R-HSA-380320 | 2.737225e-06 | 5.563 | 0 | 0 |
| Cell-cell junction organization | R-HSA-421270 | 3.225591e-06 | 5.491 | 0 | 0 |
| Mitotic Spindle Checkpoint | R-HSA-69618 | 3.575297e-06 | 5.447 | 0 | 0 |
| DNA Double Strand Break Response | R-HSA-5693606 | 3.917281e-06 | 5.407 | 0 | 0 |
| Nucleosome assembly | R-HSA-774815 | 4.176788e-06 | 5.379 | 0 | 0 |
| Deposition of new CENPA-containing nucleosomes at the centromere | R-HSA-606279 | 4.176788e-06 | 5.379 | 0 | 0 |
| PELO:HBS1L and ABCE1 dissociate a ribosome on a non-stop mRNA | R-HSA-9954714 | 4.655427e-06 | 5.332 | 0 | 0 |
| SRP-dependent cotranslational protein targeting to membrane | R-HSA-1799339 | 4.624219e-06 | 5.335 | 0 | 0 |
| Eukaryotic Translation Termination | R-HSA-72764 | 4.451680e-06 | 5.351 | 0 | 0 |
| DNA Damage/Telomere Stress Induced Senescence | R-HSA-2559586 | 4.599060e-06 | 5.337 | 0 | 0 |
| Influenza Viral RNA Transcription and Replication | R-HSA-168273 | 4.739648e-06 | 5.324 | 0 | 0 |
| Amplification of signal from the kinetochores | R-HSA-141424 | 4.809369e-06 | 5.318 | 0 | 0 |
| Amplification of signal from unattached kinetochores via a MAD2 inhibitory signal | R-HSA-141444 | 4.809369e-06 | 5.318 | 0 | 0 |
| Signaling downstream of RAS mutants | R-HSA-9649948 | 5.366612e-06 | 5.270 | 1 | 1 |
| Paradoxical activation of RAF signaling by kinase inactive BRAF | R-HSA-6802955 | 5.366612e-06 | 5.270 | 1 | 1 |
| Signaling by moderate kinase activity BRAF mutants | R-HSA-6802946 | 5.366612e-06 | 5.270 | 1 | 1 |
| Signaling by RAS mutants | R-HSA-6802949 | 5.366612e-06 | 5.270 | 1 | 0 |
| Signaling by RAF1 mutants | R-HSA-9656223 | 5.814902e-06 | 5.235 | 1 | 1 |
| Response of EIF2AK4 (GCN2) to amino acid deficiency | R-HSA-9633012 | 6.799921e-06 | 5.167 | 0 | 0 |
| Post NMDA receptor activation events | R-HSA-438064 | 6.843418e-06 | 5.165 | 1 | 0 |
| Recycling pathway of L1 | R-HSA-437239 | 6.853130e-06 | 5.164 | 0 | 0 |
| Meiotic synapsis | R-HSA-1221632 | 7.664747e-06 | 5.116 | 0 | 0 |
| ESR-mediated signaling | R-HSA-8939211 | 7.520286e-06 | 5.124 | 0 | 0 |
| Signaling by BRAF and RAF1 fusions | R-HSA-6802952 | 8.569514e-06 | 5.067 | 1 | 1 |
| ZNF598 and the Ribosome-associated Quality Trigger (RQT) complex dissociate a ribosome stalled on a no-go mRNA | R-HSA-9954716 | 1.072037e-05 | 4.970 | 0 | 0 |
| TP53 Regulates Transcription of DNA Repair Genes | R-HSA-6796648 | 1.037092e-05 | 4.984 | 0 | 0 |
| Ribosomal scanning and start codon recognition | R-HSA-72702 | 1.474791e-05 | 4.831 | 0 | 0 |
| Mitotic Prophase | R-HSA-68875 | 1.574068e-05 | 4.803 | 0 | 0 |
| Regulation of expression of SLITs and ROBOs | R-HSA-9010553 | 1.837794e-05 | 4.736 | 0 | 0 |
| PRC2 methylates histones and DNA | R-HSA-212300 | 1.890620e-05 | 4.723 | 0 | 0 |
| Diseases of signal transduction by growth factor receptors and second messengers | R-HSA-5663202 | 2.134013e-05 | 4.671 | 1 | 0 |
| Formation of the beta-catenin:TCF transactivating complex | R-HSA-201722 | 2.228908e-05 | 4.652 | 0 | 0 |
| Activation of the mRNA upon binding of the cap-binding complex and eIFs, and subsequent binding to 43S | R-HSA-72662 | 2.228908e-05 | 4.652 | 0 | 0 |
| Regulation of endogenous retroelements by KRAB-ZFP proteins | R-HSA-9843940 | 2.238587e-05 | 4.650 | 0 | 0 |
| Prefoldin mediated transfer of substrate to CCT/TriC | R-HSA-389957 | 2.523526e-05 | 4.598 | 0 | 0 |
| B-WICH complex positively regulates rRNA expression | R-HSA-5250924 | 2.642733e-05 | 4.578 | 0 | 0 |
| SARS-CoV-1-host interactions | R-HSA-9692914 | 2.838193e-05 | 4.547 | 0 | 0 |
| Selenocysteine synthesis | R-HSA-2408557 | 3.126961e-05 | 4.505 | 0 | 0 |
| Translation initiation complex formation | R-HSA-72649 | 3.250911e-05 | 4.488 | 0 | 0 |
| Striated Muscle Contraction | R-HSA-390522 | 3.415758e-05 | 4.467 | 0 | 0 |
| Formation of tubulin folding intermediates by CCT/TriC | R-HSA-389960 | 3.486030e-05 | 4.458 | 0 | 0 |
| Developmental Lineage of Mammary Gland Myoepithelial Cells | R-HSA-9927432 | 3.550846e-05 | 4.450 | 0 | 0 |
| Formation of Senescence-Associated Heterochromatin Foci (SAHF) | R-HSA-2559584 | 4.044405e-05 | 4.393 | 0 | 0 |
| Recruitment of mitotic centrosome proteins and complexes | R-HSA-380270 | 3.819311e-05 | 4.418 | 0 | 0 |
| Apoptosis induced DNA fragmentation | R-HSA-140342 | 3.814703e-05 | 4.419 | 0 | 0 |
| Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex | R-HSA-75035 | 4.044405e-05 | 4.393 | 0 | 0 |
| Transcriptional Regulation by E2F6 | R-HSA-8953750 | 4.031117e-05 | 4.395 | 0 | 0 |
| Cellular Senescence | R-HSA-2559583 | 4.068716e-05 | 4.391 | 0 | 0 |
| Viral mRNA Translation | R-HSA-192823 | 4.165503e-05 | 4.380 | 0 | 0 |
| Centrosome maturation | R-HSA-380287 | 5.366633e-05 | 4.270 | 0 | 0 |
| Formation of the polybromo-BAF (pBAF) complex | R-HSA-9933939 | 6.233495e-05 | 4.205 | 0 | 0 |
| Cooperation of Prefoldin and TriC/CCT in actin and tubulin folding | R-HSA-389958 | 6.181035e-05 | 4.209 | 0 | 0 |
| Loss of proteins required for interphase microtubule organization from the centrosome | R-HSA-380284 | 5.814309e-05 | 4.236 | 0 | 0 |
| Loss of Nlp from mitotic centrosomes | R-HSA-380259 | 5.814309e-05 | 4.236 | 0 | 0 |
| HSF1-dependent transactivation | R-HSA-3371571 | 5.818245e-05 | 4.235 | 1 | 1 |
| Assembly of the pre-replicative complex | R-HSA-68867 | 5.841480e-05 | 4.233 | 0 | 0 |
| G2/M Transition | R-HSA-69275 | 7.442453e-05 | 4.128 | 0 | 0 |
| Assembly and cell surface presentation of NMDA receptors | R-HSA-9609736 | 8.065637e-05 | 4.093 | 1 | 1 |
| RNA Polymerase I Promoter Opening | R-HSA-73728 | 8.513760e-05 | 4.070 | 0 | 0 |
| Oncogenic MAPK signaling | R-HSA-6802957 | 9.412341e-05 | 4.026 | 1 | 0 |
| Ribosome-associated quality control | R-HSA-9948299 | 8.960195e-05 | 4.048 | 0 | 0 |
| Ribosome Quality Control (RQC) complex extracts and degrades nascent peptide | R-HSA-9954709 | 8.978761e-05 | 4.047 | 0 | 0 |
| Transcriptional regulation by small RNAs | R-HSA-5578749 | 9.347873e-05 | 4.029 | 0 | 0 |
| Activation of NMDA receptors and postsynaptic events | R-HSA-442755 | 9.243415e-05 | 4.034 | 1 | 0 |
| SARS-CoV-2 targets host intracellular signalling and regulatory pathways | R-HSA-9755779 | 9.344636e-05 | 4.029 | 0 | 0 |
| Mitotic G2-G2/M phases | R-HSA-453274 | 9.036231e-05 | 4.044 | 0 | 0 |
| SARS-CoV-1 targets host intracellular signalling and regulatory pathways | R-HSA-9735871 | 9.344636e-05 | 4.029 | 0 | 0 |
| AURKA Activation by TPX2 | R-HSA-8854518 | 9.872911e-05 | 4.006 | 0 | 0 |
| Regulation of MECP2 expression and activity | R-HSA-9022692 | 1.035996e-04 | 3.985 | 1 | 1 |
| Assembly of the ORC complex at the origin of replication | R-HSA-68616 | 1.035996e-04 | 3.985 | 0 | 0 |
| Cellular response to heat stress | R-HSA-3371556 | 1.065033e-04 | 3.973 | 1 | 0 |
| Programmed Cell Death | R-HSA-5357801 | 1.161125e-04 | 3.935 | 0 | 0 |
| VEGFA-VEGFR2 Pathway | R-HSA-4420097 | 1.212779e-04 | 3.916 | 0 | 0 |
| Defective pyroptosis | R-HSA-9710421 | 1.240988e-04 | 3.906 | 0 | 0 |
| EPH-Ephrin signaling | R-HSA-2682334 | 1.318768e-04 | 3.880 | 0 | 0 |
| Processing of DNA double-strand break ends | R-HSA-5693607 | 1.387745e-04 | 3.858 | 0 | 0 |
| DNA methylation | R-HSA-5334118 | 1.459755e-04 | 3.836 | 0 | 0 |
| Replacement of protamines by nucleosomes in the male pronucleus | R-HSA-9821993 | 1.542102e-04 | 3.812 | 0 | 0 |
| Inhibition of DNA recombination at telomere | R-HSA-9670095 | 1.810060e-04 | 3.742 | 0 | 0 |
| Nuclear Envelope Breakdown | R-HSA-2980766 | 1.811380e-04 | 3.742 | 0 | 0 |
| Viral Infection Pathways | R-HSA-9824446 | 1.973299e-04 | 3.705 | 0 | 0 |
| Long-term potentiation | R-HSA-9620244 | 2.035986e-04 | 3.691 | 1 | 1 |
| Regulation of PLK1 Activity at G2/M Transition | R-HSA-2565942 | 2.152043e-04 | 3.667 | 0 | 0 |
| Anchoring of the basal body to the plasma membrane | R-HSA-5620912 | 2.222990e-04 | 3.653 | 0 | 0 |
| NoRC negatively regulates rRNA expression | R-HSA-427413 | 2.230048e-04 | 3.652 | 0 | 0 |
| DNA Double-Strand Break Repair | R-HSA-5693532 | 2.244276e-04 | 3.649 | 0 | 0 |
| DNA Replication Pre-Initiation | R-HSA-69002 | 2.560787e-04 | 3.592 | 0 | 0 |
| Negative epigenetic regulation of rRNA expression | R-HSA-5250941 | 3.169574e-04 | 3.499 | 0 | 0 |
| Nuclear Envelope (NE) Reassembly | R-HSA-2995410 | 3.169574e-04 | 3.499 | 0 | 0 |
| L1CAM interactions | R-HSA-373760 | 3.172231e-04 | 3.499 | 0 | 0 |
| Signaling by high-kinase activity BRAF mutants | R-HSA-6802948 | 3.269648e-04 | 3.485 | 0 | 0 |
| Packaging Of Telomere Ends | R-HSA-171306 | 3.432184e-04 | 3.464 | 0 | 0 |
| Cohesin Loading onto Chromatin | R-HSA-2470946 | 4.026364e-04 | 3.395 | 0 | 0 |
| mTORC1-mediated signalling | R-HSA-166208 | 3.708782e-04 | 3.431 | 0 | 0 |
| Homology Directed Repair | R-HSA-5693538 | 3.969694e-04 | 3.401 | 0 | 0 |
| Cellular response to starvation | R-HSA-9711097 | 3.654661e-04 | 3.437 | 0 | 0 |
| Diseases of programmed cell death | R-HSA-9645723 | 4.259946e-04 | 3.371 | 0 | 0 |
| Signaling by VEGF | R-HSA-194138 | 4.265118e-04 | 3.370 | 0 | 0 |
| MITF-M-regulated melanocyte development | R-HSA-9730414 | 4.474413e-04 | 3.349 | 0 | 0 |
| Ion homeostasis | R-HSA-5578775 | 4.480257e-04 | 3.349 | 1 | 1 |
| HDR through Homologous Recombination (HRR) or Single Strand Annealing (SSA) | R-HSA-5693567 | 4.578588e-04 | 3.339 | 0 | 0 |
| Signaling by ALK fusions and activated point mutants | R-HSA-9725370 | 4.702050e-04 | 3.328 | 0 | 0 |
| Signaling by ALK in cancer | R-HSA-9700206 | 4.702050e-04 | 3.328 | 0 | 0 |
| Activation of BAD and translocation to mitochondria | R-HSA-111447 | 4.893820e-04 | 3.310 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected pyrimidine | R-HSA-110328 | 5.915887e-04 | 3.228 | 0 | 0 |
| Meiosis | R-HSA-1500620 | 6.243972e-04 | 3.205 | 0 | 0 |
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | R-HSA-5625886 | 7.255379e-04 | 3.139 | 0 | 0 |
| Formation of the ternary complex, and subsequently, the 43S complex | R-HSA-72695 | 7.023300e-04 | 3.153 | 0 | 0 |
| RNA Polymerase I Promoter Escape | R-HSA-73772 | 6.649160e-04 | 3.177 | 0 | 0 |
| Developmental Lineages of the Mammary Gland | R-HSA-9924644 | 6.888535e-04 | 3.162 | 0 | 0 |
| HCMV Early Events | R-HSA-9609690 | 7.203286e-04 | 3.142 | 0 | 0 |
| Apoptotic cleavage of cell adhesion proteins | R-HSA-351906 | 6.598607e-04 | 3.181 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in DNA replication, damage repair and senescence | R-HSA-9825895 | 6.598607e-04 | 3.181 | 0 | 0 |
| Developmental Biology | R-HSA-1266738 | 6.853641e-04 | 3.164 | 0 | 0 |
| Nephrin family interactions | R-HSA-373753 | 6.776919e-04 | 3.169 | 0 | 0 |
| MITF-M-dependent gene expression | R-HSA-9856651 | 7.247230e-04 | 3.140 | 0 | 0 |
| ATP-dependent chromatin remodelers | R-HSA-9932444 | 8.025931e-04 | 3.096 | 0 | 0 |
| SWI/SNF chromatin remodelers | R-HSA-9932451 | 8.025931e-04 | 3.096 | 0 | 0 |
| MAP2K and MAPK activation | R-HSA-5674135 | 8.726944e-04 | 3.059 | 0 | 0 |
| Epigenetic regulation of gene expression | R-HSA-212165 | 9.533724e-04 | 3.021 | 0 | 0 |
| HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand | R-HSA-3371497 | 1.016658e-03 | 2.993 | 0 | 0 |
| Transport of Mature Transcript to Cytoplasm | R-HSA-72202 | 1.039584e-03 | 2.983 | 0 | 0 |
| Gene Silencing by RNA | R-HSA-211000 | 1.060176e-03 | 2.975 | 0 | 0 |
| Recognition and association of DNA glycosylase with site containing an affected purine | R-HSA-110330 | 1.072428e-03 | 2.970 | 0 | 0 |
| SIRT1 negatively regulates rRNA expression | R-HSA-427359 | 1.076434e-03 | 2.968 | 0 | 0 |
| Negative regulation of NMDA receptor-mediated neuronal transmission | R-HSA-9617324 | 1.151921e-03 | 2.939 | 1 | 1 |
| Chromosome Maintenance | R-HSA-73886 | 1.184061e-03 | 2.927 | 0 | 0 |
| Microtubule-dependent trafficking of connexons from Golgi to the plasma membrane | R-HSA-190840 | 1.242960e-03 | 2.906 | 0 | 0 |
| Regulation of TP53 Activity through Acetylation | R-HSA-6804758 | 1.314376e-03 | 2.881 | 0 | 0 |
| Establishment of Sister Chromatid Cohesion | R-HSA-2468052 | 1.539285e-03 | 2.813 | 0 | 0 |
| Folding of actin by CCT/TriC | R-HSA-390450 | 1.539285e-03 | 2.813 | 0 | 0 |
| Regulation of CDH1 Function | R-HSA-9764561 | 1.451243e-03 | 2.838 | 0 | 0 |
| CaMK IV-mediated phosphorylation of CREB | R-HSA-111932 | 1.539285e-03 | 2.813 | 1 | 1 |
| Insulin-like Growth Factor-2 mRNA Binding Proteins (IGF2BPs/IMPs/VICKZs) bind RNA | R-HSA-428359 | 1.539285e-03 | 2.813 | 0 | 0 |
| Signaling by WNT | R-HSA-195721 | 1.654581e-03 | 2.781 | 0 | 0 |
| Depolymerization of the Nuclear Lamina | R-HSA-4419969 | 1.637360e-03 | 2.786 | 0 | 0 |
| Cilium Assembly | R-HSA-5617833 | 1.583732e-03 | 2.800 | 0 | 0 |
| Transport of connexons to the plasma membrane | R-HSA-190872 | 1.637360e-03 | 2.786 | 0 | 0 |
| TFAP2A acts as a transcriptional repressor during retinoic acid induced cell differentiation | R-HSA-8869496 | 1.701079e-03 | 2.769 | 0 | 0 |
| Factors involved in megakaryocyte development and platelet production | R-HSA-983231 | 1.730080e-03 | 2.762 | 0 | 0 |
| Translation | R-HSA-72766 | 1.784286e-03 | 2.749 | 0 | 0 |
| Transcriptional Regulation by TP53 | R-HSA-3700989 | 1.820836e-03 | 2.740 | 0 | 0 |
| Protein folding | R-HSA-391251 | 1.839634e-03 | 2.735 | 0 | 0 |
| Aggrephagy | R-HSA-9646399 | 1.853226e-03 | 2.732 | 0 | 0 |
| Attenuation phase | R-HSA-3371568 | 1.853226e-03 | 2.732 | 0 | 0 |
| E3 ubiquitin ligases ubiquitinate target proteins | R-HSA-8866654 | 1.858702e-03 | 2.731 | 0 | 0 |
| Regulation of PD-L1(CD274) transcription | R-HSA-9909649 | 1.967455e-03 | 2.706 | 0 | 0 |
| HATs acetylate histones | R-HSA-3214847 | 1.968398e-03 | 2.706 | 0 | 0 |
| Antiviral mechanism by IFN-stimulated genes | R-HSA-1169410 | 2.029615e-03 | 2.693 | 0 | 0 |
| Chaperonin-mediated protein folding | R-HSA-390466 | 2.128726e-03 | 2.672 | 0 | 0 |
| Chromatin modifications during the maternal to zygotic transition (MZT) | R-HSA-9821002 | 2.196716e-03 | 2.658 | 0 | 0 |
| Regulation of PTEN gene transcription | R-HSA-8943724 | 2.220553e-03 | 2.654 | 0 | 0 |
| Kinesins | R-HSA-983189 | 2.220553e-03 | 2.654 | 0 | 0 |
| Regulation of localization of FOXO transcription factors | R-HSA-9614399 | 2.222331e-03 | 2.653 | 0 | 0 |
| Formation of the embryonic stem cell BAF (esBAF) complex | R-HSA-9933946 | 2.290161e-03 | 2.640 | 0 | 0 |
| Cell-extracellular matrix interactions | R-HSA-446353 | 2.290161e-03 | 2.640 | 0 | 0 |
| Protein ubiquitination | R-HSA-8852135 | 2.517632e-03 | 2.599 | 0 | 0 |
| Developmental Cell Lineages of the Integumentary System | R-HSA-9734779 | 2.535138e-03 | 2.596 | 0 | 0 |
| RUNX1 regulates genes involved in megakaryocyte differentiation and platelet function | R-HSA-8936459 | 2.548078e-03 | 2.594 | 0 | 0 |
| Post-chaperonin tubulin folding pathway | R-HSA-389977 | 2.719431e-03 | 2.566 | 0 | 0 |
| Ca-dependent events | R-HSA-111996 | 3.039903e-03 | 2.517 | 1 | 0 |
| CaM pathway | R-HSA-111997 | 2.770310e-03 | 2.557 | 1 | 0 |
| Calmodulin induced events | R-HSA-111933 | 2.770310e-03 | 2.557 | 1 | 0 |
| HSF1 activation | R-HSA-3371511 | 2.770310e-03 | 2.557 | 0 | 0 |
| Intracellular signaling by second messengers | R-HSA-9006925 | 2.824431e-03 | 2.549 | 1 | 0 |
| RNA Polymerase I Transcription Initiation | R-HSA-73762 | 3.039903e-03 | 2.517 | 0 | 0 |
| Oxidative Stress Induced Senescence | R-HSA-2559580 | 2.682561e-03 | 2.571 | 0 | 0 |
| Cleavage of the damaged pyrimidine | R-HSA-110329 | 3.039903e-03 | 2.517 | 0 | 0 |
| Depyrimidination | R-HSA-73928 | 3.039903e-03 | 2.517 | 0 | 0 |
| Mitotic Telophase/Cytokinesis | R-HSA-68884 | 3.111989e-03 | 2.507 | 0 | 0 |
| COPI-dependent Golgi-to-ER retrograde traffic | R-HSA-6811434 | 3.132583e-03 | 2.504 | 0 | 0 |
| Cleavage of the damaged purine | R-HSA-110331 | 3.286853e-03 | 2.483 | 0 | 0 |
| Semaphorin interactions | R-HSA-373755 | 3.301387e-03 | 2.481 | 0 | 0 |
| DNA Replication | R-HSA-69306 | 3.557395e-03 | 2.449 | 0 | 0 |
| Depurination | R-HSA-73927 | 3.877914e-03 | 2.411 | 0 | 0 |
| Membrane Trafficking | R-HSA-199991 | 4.003441e-03 | 2.398 | 0 | 0 |
| RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known | R-HSA-8939243 | 4.153189e-03 | 2.382 | 0 | 0 |
| SARS-CoV-2-host interactions | R-HSA-9705683 | 4.182761e-03 | 2.379 | 0 | 0 |
| Meiotic recombination | R-HSA-912446 | 4.253374e-03 | 2.371 | 0 | 0 |
| Unblocking of NMDA receptors, glutamate binding and activation | R-HSA-438066 | 4.292417e-03 | 2.367 | 1 | 1 |
| Ras activation upon Ca2+ influx through NMDA receptor | R-HSA-442982 | 4.292417e-03 | 2.367 | 1 | 1 |
| S Phase | R-HSA-69242 | 4.517484e-03 | 2.345 | 0 | 0 |
| Transport of Mature mRNA Derived from an Intronless Transcript | R-HSA-159231 | 4.550836e-03 | 2.342 | 0 | 0 |
| Transport of Mature mRNA derived from an Intron-Containing Transcript | R-HSA-159236 | 4.643321e-03 | 2.333 | 0 | 0 |
| DAG and IP3 signaling | R-HSA-1489509 | 4.778292e-03 | 2.321 | 1 | 0 |
| Ub-specific processing proteases | R-HSA-5689880 | 5.010245e-03 | 2.300 | 0 | 0 |
| Signaling by Hippo | R-HSA-2028269 | 5.049376e-03 | 2.297 | 0 | 0 |
| Activation of AMPK downstream of NMDARs | R-HSA-9619483 | 5.215474e-03 | 2.283 | 0 | 0 |
| Transport of Mature mRNAs Derived from Intronless Transcripts | R-HSA-159234 | 5.313262e-03 | 2.275 | 0 | 0 |
| Signaling by ERBB2 | R-HSA-1227986 | 5.508343e-03 | 2.259 | 0 | 0 |
| Formation of the non-canonical BAF (ncBAF) complex | R-HSA-9933947 | 5.653176e-03 | 2.248 | 0 | 0 |
| Calcineurin activates NFAT | R-HSA-2025928 | 5.719545e-03 | 2.243 | 0 | 0 |
| SARS-CoV-1 Infection | R-HSA-9678108 | 5.755988e-03 | 2.240 | 0 | 0 |
| RAF activation | R-HSA-5673000 | 5.823306e-03 | 2.235 | 1 | 1 |
| VEGFR2 mediated vascular permeability | R-HSA-5218920 | 6.173108e-03 | 2.209 | 0 | 0 |
| PLC beta mediated events | R-HSA-112043 | 6.219453e-03 | 2.206 | 1 | 0 |
| RUNX1 regulates transcription of genes involved in differentiation of HSCs | R-HSA-8939236 | 6.799529e-03 | 2.168 | 0 | 0 |
| Transcriptional Regulation by MECP2 | R-HSA-8986944 | 7.052379e-03 | 2.152 | 1 | 0 |
| Signaling by ERBB2 in Cancer | R-HSA-1227990 | 7.431123e-03 | 2.129 | 0 | 0 |
| MTOR signalling | R-HSA-165159 | 8.217889e-03 | 2.085 | 0 | 0 |
| Downregulation of ERBB2 signaling | R-HSA-8863795 | 7.431123e-03 | 2.129 | 0 | 0 |
| Response to elevated platelet cytosolic Ca2+ | R-HSA-76005 | 7.940724e-03 | 2.100 | 0 | 0 |
| Platelet activation, signaling and aggregation | R-HSA-76002 | 8.049262e-03 | 2.094 | 0 | 0 |
| rRNA modification in the nucleus and cytosol | R-HSA-6790901 | 7.861428e-03 | 2.104 | 0 | 0 |
| Neurotransmitter receptors and postsynaptic signal transmission | R-HSA-112314 | 7.532749e-03 | 2.123 | 1 | 0 |
| The role of GTSE1 in G2/M progression after G2 checkpoint | R-HSA-8852276 | 7.002183e-03 | 2.155 | 0 | 0 |
| Deubiquitination | R-HSA-5688426 | 7.431180e-03 | 2.129 | 0 | 0 |
| Selenoamino acid metabolism | R-HSA-2408522 | 7.926881e-03 | 2.101 | 0 | 0 |
| Gap junction trafficking and regulation | R-HSA-157858 | 8.239483e-03 | 2.084 | 0 | 0 |
| Platelet degranulation | R-HSA-114608 | 8.664012e-03 | 2.062 | 0 | 0 |
| Trafficking of AMPA receptors | R-HSA-399719 | 8.777901e-03 | 2.057 | 1 | 1 |
| XBP1(S) activates chaperone genes | R-HSA-381038 | 9.125287e-03 | 2.040 | 0 | 0 |
| Regulation of mRNA stability by proteins that bind AU-rich elements | R-HSA-450531 | 9.342462e-03 | 2.030 | 0 | 0 |
| Neutrophil degranulation | R-HSA-6798695 | 9.414117e-03 | 2.026 | 0 | 0 |
| Sema4D in semaphorin signaling | R-HSA-400685 | 9.439918e-03 | 2.025 | 0 | 0 |
| Glycolysis | R-HSA-70171 | 9.454755e-03 | 2.024 | 0 | 0 |
| TCF dependent signaling in response to WNT | R-HSA-201681 | 9.728029e-03 | 2.012 | 0 | 0 |
| PKR-mediated signaling | R-HSA-9833482 | 9.744773e-03 | 2.011 | 0 | 0 |
| Formation of definitive endoderm | R-HSA-9823730 | 9.774275e-03 | 2.010 | 0 | 0 |
| Formation of neuronal progenitor and neuronal BAF (npBAF and nBAF) | R-HSA-9934037 | 9.774275e-03 | 2.010 | 0 | 0 |
| Sema4D induced cell migration and growth-cone collapse | R-HSA-416572 | 9.774275e-03 | 2.010 | 0 | 0 |
| Transcriptional regulation by RUNX1 | R-HSA-8878171 | 1.028583e-02 | 1.988 | 0 | 0 |
| Gap junction trafficking | R-HSA-190828 | 1.075265e-02 | 1.968 | 0 | 0 |
| Regulation of HSF1-mediated heat shock response | R-HSA-3371453 | 1.121849e-02 | 1.950 | 0 | 0 |
| MECP2 regulates neuronal receptors and channels | R-HSA-9022699 | 1.124547e-02 | 1.949 | 0 | 0 |
| Reproduction | R-HSA-1474165 | 1.168691e-02 | 1.932 | 0 | 0 |
| Senescence-Associated Secretory Phenotype (SASP) | R-HSA-2559582 | 1.181867e-02 | 1.927 | 0 | 0 |
| Loss of MECP2 binding ability to 5mC-DNA | R-HSA-9022538 | 1.182338e-02 | 1.927 | 0 | 0 |
| Sealing of the nuclear envelope (NE) by ESCRT-III | R-HSA-9668328 | 1.201667e-02 | 1.920 | 0 | 0 |
| Transport of the SLBP independent Mature mRNA | R-HSA-159227 | 1.201667e-02 | 1.920 | 0 | 0 |
| Glutamate binding, activation of AMPA receptors and synaptic plasticity | R-HSA-399721 | 1.201667e-02 | 1.920 | 1 | 0 |
| G-protein mediated events | R-HSA-112040 | 1.216522e-02 | 1.915 | 1 | 0 |
| NS1 Mediated Effects on Host Pathways | R-HSA-168276 | 1.229166e-02 | 1.910 | 0 | 0 |
| PTEN Regulation | R-HSA-6807070 | 1.317649e-02 | 1.880 | 0 | 0 |
| COPI-mediated anterograde transport | R-HSA-6807878 | 1.324763e-02 | 1.878 | 0 | 0 |
| Golgi-to-ER retrograde transport | R-HSA-8856688 | 1.348805e-02 | 1.870 | 0 | 0 |
| Condensation of Prophase Chromosomes | R-HSA-2299718 | 1.384684e-02 | 1.859 | 0 | 0 |
| Transport of the SLBP Dependant Mature mRNA | R-HSA-159230 | 1.393568e-02 | 1.856 | 0 | 0 |
| Reduction of cytosolic Ca++ levels | R-HSA-418359 | 1.395207e-02 | 1.855 | 0 | 0 |
| Interactions of Rev with host cellular proteins | R-HSA-177243 | 1.406298e-02 | 1.852 | 0 | 0 |
| Initiation of Nuclear Envelope (NE) Reformation | R-HSA-2995383 | 1.433876e-02 | 1.843 | 0 | 0 |
| Telomere Maintenance | R-HSA-157579 | 1.440460e-02 | 1.841 | 0 | 0 |
| Base-Excision Repair, AP Site Formation | R-HSA-73929 | 1.501968e-02 | 1.823 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere | R-HSA-9670621 | 1.525744e-02 | 1.817 | 0 | 0 |
| Alternative Lengthening of Telomeres (ALT) | R-HSA-9006821 | 1.525744e-02 | 1.817 | 0 | 0 |
| Diseases of Telomere Maintenance | R-HSA-9673013 | 1.525744e-02 | 1.817 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations | R-HSA-9670615 | 1.525744e-02 | 1.817 | 0 | 0 |
| Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations | R-HSA-9670613 | 1.525744e-02 | 1.817 | 0 | 0 |
| Loss of MECP2 binding ability to 5hmC-DNA | R-HSA-9022534 | 1.525744e-02 | 1.817 | 0 | 0 |
| IRE1alpha activates chaperones | R-HSA-381070 | 1.565838e-02 | 1.805 | 0 | 0 |
| Transcriptional regulation of granulopoiesis | R-HSA-9616222 | 1.586911e-02 | 1.799 | 0 | 0 |
| SARS-CoV-1 modulates host translation machinery | R-HSA-9735869 | 1.607228e-02 | 1.794 | 0 | 0 |
| CREB1 phosphorylation through the activation of CaMKII/CaMKK/CaMKIV cascasde | R-HSA-442729 | 2.031854e-02 | 1.692 | 0 | 0 |
| Type I hemidesmosome assembly | R-HSA-446107 | 2.031854e-02 | 1.692 | 0 | 0 |
| Chaperone Mediated Autophagy | R-HSA-9613829 | 2.193001e-02 | 1.659 | 0 | 0 |
| Signaling by cytosolic FGFR1 fusion mutants | R-HSA-1839117 | 2.193001e-02 | 1.659 | 0 | 0 |
| Ephrin signaling | R-HSA-3928664 | 2.193001e-02 | 1.659 | 0 | 0 |
| Signaling by ERBB2 KD Mutants | R-HSA-9664565 | 1.818701e-02 | 1.740 | 0 | 0 |
| SHC1 events in ERBB2 signaling | R-HSA-1250196 | 2.106505e-02 | 1.676 | 0 | 0 |
| Nuclear Pore Complex (NPC) Disassembly | R-HSA-3301854 | 1.843954e-02 | 1.734 | 0 | 0 |
| Host Interactions of HIV factors | R-HSA-162909 | 2.150068e-02 | 1.668 | 0 | 0 |
| Selective autophagy | R-HSA-9663891 | 2.190690e-02 | 1.659 | 0 | 0 |
| MAPK family signaling cascades | R-HSA-5683057 | 1.950227e-02 | 1.710 | 1 | 0 |
| Maternal to zygotic transition (MZT) | R-HSA-9816359 | 2.007527e-02 | 1.697 | 0 | 0 |
| Ion transport by P-type ATPases | R-HSA-936837 | 1.943076e-02 | 1.712 | 1 | 1 |
| Cargo trafficking to the periciliary membrane | R-HSA-5620920 | 1.810878e-02 | 1.742 | 0 | 0 |
| Activation of BH3-only proteins | R-HSA-114452 | 2.106505e-02 | 1.676 | 0 | 0 |
| SARS-CoV Infections | R-HSA-9679506 | 2.153547e-02 | 1.667 | 0 | 0 |
| Amyloid fiber formation | R-HSA-977225 | 2.194751e-02 | 1.659 | 0 | 0 |
| Signaling by Receptor Tyrosine Kinases | R-HSA-9006934 | 2.199146e-02 | 1.658 | 0 | 0 |
| HCMV Infection | R-HSA-9609646 | 2.244953e-02 | 1.649 | 0 | 0 |
| DNA Repair | R-HSA-73894 | 2.271260e-02 | 1.644 | 0 | 0 |
| Unfolded Protein Response (UPR) | R-HSA-381119 | 2.300701e-02 | 1.638 | 0 | 0 |
| Cytokine Signaling in Immune system | R-HSA-1280215 | 2.337825e-02 | 1.631 | 1 | 0 |
| Vpr-mediated nuclear import of PICs | R-HSA-180910 | 2.391659e-02 | 1.621 | 0 | 0 |
| Formation of the dystrophin-glycoprotein complex (DGC) | R-HSA-9913351 | 2.425154e-02 | 1.615 | 0 | 0 |
| Opioid Signalling | R-HSA-111885 | 2.486457e-02 | 1.604 | 1 | 0 |
| RAF/MAP kinase cascade | R-HSA-5673001 | 2.534744e-02 | 1.596 | 1 | 1 |
| Metabolism of non-coding RNA | R-HSA-194441 | 2.536946e-02 | 1.596 | 0 | 0 |
| snRNP Assembly | R-HSA-191859 | 2.536946e-02 | 1.596 | 0 | 0 |
| Signaling by Nuclear Receptors | R-HSA-9006931 | 2.553913e-02 | 1.593 | 0 | 0 |
| Base Excision Repair | R-HSA-73884 | 2.573395e-02 | 1.589 | 0 | 0 |
| Rap1 signalling | R-HSA-392517 | 2.624528e-02 | 1.581 | 0 | 0 |
| Hemostasis | R-HSA-109582 | 2.643530e-02 | 1.578 | 0 | 0 |
| GP1b-IX-V activation signalling | R-HSA-430116 | 2.679722e-02 | 1.572 | 0 | 0 |
| Unwinding of DNA | R-HSA-176974 | 2.679722e-02 | 1.572 | 0 | 0 |
| Rev-mediated nuclear export of HIV RNA | R-HSA-165054 | 2.705041e-02 | 1.568 | 0 | 0 |
| mRNA 3'-end processing | R-HSA-72187 | 2.718058e-02 | 1.566 | 0 | 0 |
| Interleukin-7 signaling | R-HSA-1266695 | 2.768188e-02 | 1.558 | 0 | 0 |
| Signal regulatory protein family interactions | R-HSA-391160 | 2.780307e-02 | 1.556 | 0 | 0 |
| Pre-NOTCH Transcription and Translation | R-HSA-1912408 | 2.782531e-02 | 1.556 | 0 | 0 |
| Interferon Signaling | R-HSA-913531 | 2.789884e-02 | 1.554 | 1 | 0 |
| Pre-NOTCH Expression and Processing | R-HSA-1912422 | 2.793149e-02 | 1.554 | 0 | 0 |
| Loss of Function of TGFBR1 in Cancer | R-HSA-3656534 | 2.834451e-02 | 1.548 | 0 | 0 |
| Loss of phosphorylation of MECP2 at T308 | R-HSA-9022535 | 2.834451e-02 | 1.548 | 0 | 0 |
| Toxicity of botulinum toxin type C (botC) | R-HSA-5250971 | 2.834451e-02 | 1.548 | 0 | 0 |
| Organelle biogenesis and maintenance | R-HSA-1852241 | 2.919151e-02 | 1.535 | 0 | 0 |
| Clathrin-mediated endocytosis | R-HSA-8856828 | 3.117907e-02 | 1.506 | 0 | 0 |
| Activation of ATR in response to replication stress | R-HSA-176187 | 3.160708e-02 | 1.500 | 0 | 0 |
| CREB1 phosphorylation through NMDA receptor-mediated activation of RAS signaling | R-HSA-442742 | 3.160708e-02 | 1.500 | 1 | 0 |
| Manipulation of host energy metabolism | R-HSA-9636667 | 3.230922e-02 | 1.491 | 0 | 0 |
| Breakdown of the nuclear lamina | R-HSA-352238 | 3.230922e-02 | 1.491 | 0 | 0 |
| Signaling by NOTCH | R-HSA-157118 | 3.266078e-02 | 1.486 | 0 | 0 |
| Sema3A PAK dependent Axon repulsion | R-HSA-399954 | 3.384825e-02 | 1.470 | 0 | 0 |
| Protein methylation | R-HSA-8876725 | 3.384825e-02 | 1.470 | 0 | 0 |
| MAPK1/MAPK3 signaling | R-HSA-5684996 | 3.397513e-02 | 1.469 | 1 | 0 |
| Interactions of Vpr with host cellular proteins | R-HSA-176033 | 3.416421e-02 | 1.466 | 0 | 0 |
| Positive Regulation of CDH1 Gene Transcription | R-HSA-9764790 | 3.437947e-02 | 1.464 | 0 | 0 |
| PI3K/AKT activation | R-HSA-198203 | 3.437947e-02 | 1.464 | 0 | 0 |
| MHC class II antigen presentation | R-HSA-2132295 | 3.508724e-02 | 1.455 | 0 | 0 |
| Association of TriC/CCT with target proteins during biosynthesis | R-HSA-390471 | 3.580206e-02 | 1.446 | 0 | 0 |
| Early Phase of HIV Life Cycle | R-HSA-162594 | 3.648260e-02 | 1.438 | 0 | 0 |
| Basigin interactions | R-HSA-210991 | 3.648260e-02 | 1.438 | 0 | 0 |
| COPI-independent Golgi-to-ER retrograde traffic | R-HSA-6811436 | 3.653347e-02 | 1.437 | 0 | 0 |
| EPHA-mediated growth cone collapse | R-HSA-3928663 | 3.677174e-02 | 1.434 | 0 | 0 |
| PKMTs methylate histone lysines | R-HSA-3214841 | 3.816422e-02 | 1.418 | 0 | 0 |
| Nuclear events stimulated by ALK signaling in cancer | R-HSA-9725371 | 3.950081e-02 | 1.403 | 0 | 0 |
| Regulation of cytoskeletal remodeling and cell spreading by IPP complex components | R-HSA-446388 | 3.956819e-02 | 1.403 | 0 | 0 |
| Intra-Golgi and retrograde Golgi-to-ER traffic | R-HSA-6811442 | 3.996685e-02 | 1.398 | 0 | 0 |
| Cooperation of PDCL (PhLP1) and TRiC/CCT in G-protein beta folding | R-HSA-6814122 | 4.035714e-02 | 1.394 | 0 | 0 |
| Nuclear import of Rev protein | R-HSA-180746 | 4.035714e-02 | 1.394 | 0 | 0 |
| Gap junction assembly | R-HSA-190861 | 4.035714e-02 | 1.394 | 0 | 0 |
| Signaling by Interleukins | R-HSA-449147 | 4.112009e-02 | 1.386 | 0 | 0 |
| Glucose metabolism | R-HSA-70326 | 4.129223e-02 | 1.384 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in cell cycle and proliferation | R-HSA-9825892 | 4.244054e-02 | 1.372 | 0 | 0 |
| Drug resistance in ERBB2 KD mutants | R-HSA-9665230 | 5.408542e-02 | 1.267 | 0 | 0 |
| Drug-mediated inhibition of ERBB2 signaling | R-HSA-9652282 | 5.408542e-02 | 1.267 | 0 | 0 |
| Resistance of ERBB2 KD mutants to tesevatinib | R-HSA-9665245 | 5.408542e-02 | 1.267 | 0 | 0 |
| Resistance of ERBB2 KD mutants to afatinib | R-HSA-9665249 | 5.408542e-02 | 1.267 | 0 | 0 |
| Resistance of ERBB2 KD mutants to lapatinib | R-HSA-9665251 | 5.408542e-02 | 1.267 | 0 | 0 |
| TGFBR1 LBD Mutants in Cancer | R-HSA-3656535 | 5.408542e-02 | 1.267 | 0 | 0 |
| Resistance of ERBB2 KD mutants to osimertinib | R-HSA-9665247 | 5.408542e-02 | 1.267 | 0 | 0 |
| Resistance of ERBB2 KD mutants to neratinib | R-HSA-9665246 | 5.408542e-02 | 1.267 | 0 | 0 |
| Resistance of ERBB2 KD mutants to AEE788 | R-HSA-9665250 | 5.408542e-02 | 1.267 | 0 | 0 |
| Resistance of ERBB2 KD mutants to trastuzumab | R-HSA-9665233 | 5.408542e-02 | 1.267 | 0 | 0 |
| Drug resistance in ERBB2 TMD/JMD mutants | R-HSA-9665737 | 5.408542e-02 | 1.267 | 0 | 0 |
| Resistance of ERBB2 KD mutants to sapitinib | R-HSA-9665244 | 5.408542e-02 | 1.267 | 0 | 0 |
| Signaling by LTK in cancer | R-HSA-9842640 | 5.270612e-02 | 1.278 | 0 | 0 |
| PI3K events in ERBB2 signaling | R-HSA-1963642 | 5.656943e-02 | 1.247 | 0 | 0 |
| FGFR2 alternative splicing | R-HSA-6803529 | 4.897580e-02 | 1.310 | 0 | 0 |
| Defective TPR may confer susceptibility towards thyroid papillary carcinoma (TPC) | R-HSA-5619107 | 5.375757e-02 | 1.270 | 0 | 0 |
| IP3 and IP4 transport between cytosol and nucleus | R-HSA-1855196 | 6.035042e-02 | 1.219 | 0 | 0 |
| IP6 and IP7 transport between cytosol and nucleus | R-HSA-1855229 | 6.035042e-02 | 1.219 | 0 | 0 |
| Developmental Lineage of Mammary Gland Luminal Epithelial Cells | R-HSA-9927418 | 4.709429e-02 | 1.327 | 0 | 0 |
| Formation of RNA Pol II elongation complex | R-HSA-112382 | 5.736542e-02 | 1.241 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex in Cancer | R-HSA-3304351 | 5.270612e-02 | 1.278 | 0 | 0 |
| Integration of provirus | R-HSA-162592 | 5.291438e-02 | 1.276 | 0 | 0 |
| PIP3 activates AKT signaling | R-HSA-1257604 | 4.707206e-02 | 1.327 | 0 | 0 |
| Beta-catenin independent WNT signaling | R-HSA-3858494 | 5.345086e-02 | 1.272 | 0 | 0 |
| Deactivation of the beta-catenin transactivating complex | R-HSA-3769402 | 5.627405e-02 | 1.250 | 0 | 0 |
| Regulation of TP53 Activity | R-HSA-5633007 | 4.869945e-02 | 1.312 | 0 | 0 |
| Nef and signal transduction | R-HSA-164944 | 5.270612e-02 | 1.278 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperone genes | R-HSA-381183 | 5.291438e-02 | 1.276 | 0 | 0 |
| Potential therapeutics for SARS | R-HSA-9679191 | 4.606936e-02 | 1.337 | 0 | 0 |
| RMTs methylate histone arginines | R-HSA-3214858 | 5.731180e-02 | 1.242 | 0 | 0 |
| Non-integrin membrane-ECM interactions | R-HSA-3000171 | 5.041682e-02 | 1.297 | 0 | 0 |
| ISG15 antiviral mechanism | R-HSA-1169408 | 5.041682e-02 | 1.297 | 0 | 0 |
| RNA Polymerase II Transcription Termination | R-HSA-73856 | 6.154354e-02 | 1.211 | 0 | 0 |
| RNA Polymerase II Transcription Elongation | R-HSA-75955 | 6.254117e-02 | 1.204 | 0 | 0 |
| Golgi Associated Vesicle Biogenesis | R-HSA-432722 | 6.254117e-02 | 1.204 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in pigmentation | R-HSA-9824585 | 6.291731e-02 | 1.201 | 0 | 0 |
| Signaling by ERBB2 TMD/JMD mutants | R-HSA-9665686 | 6.380924e-02 | 1.195 | 0 | 0 |
| Neurodegenerative Diseases | R-HSA-8863678 | 6.380924e-02 | 1.195 | 0 | 0 |
| Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models | R-HSA-8862803 | 6.380924e-02 | 1.195 | 0 | 0 |
| Loss of function of MECP2 in Rett syndrome | R-HSA-9005891 | 6.385783e-02 | 1.195 | 0 | 0 |
| Disorders of Nervous System Development | R-HSA-9697154 | 6.385783e-02 | 1.195 | 0 | 0 |
| Pervasive developmental disorders | R-HSA-9005895 | 6.385783e-02 | 1.195 | 0 | 0 |
| Signaling by ERBB2 ECD mutants | R-HSA-9665348 | 6.569632e-02 | 1.182 | 0 | 0 |
| GAB1 signalosome | R-HSA-180292 | 6.569632e-02 | 1.182 | 0 | 0 |
| DNA strand elongation | R-HSA-69190 | 6.741761e-02 | 1.171 | 0 | 0 |
| MET activates PI3K/AKT signaling | R-HSA-8851907 | 6.766267e-02 | 1.170 | 0 | 0 |
| SHOC2 M1731 mutant abolishes MRAS complex function | R-HSA-9726840 | 6.766267e-02 | 1.170 | 0 | 0 |
| Uptake and function of diphtheria toxin | R-HSA-5336415 | 6.766267e-02 | 1.170 | 0 | 0 |
| Transcriptional and post-translational regulation of MITF-M expression and activity | R-HSA-9856649 | 6.969882e-02 | 1.157 | 0 | 0 |
| trans-Golgi Network Vesicle Budding | R-HSA-199992 | 7.483045e-02 | 1.126 | 0 | 0 |
| IPs transport between nucleus and cytosol | R-HSA-1855170 | 7.496096e-02 | 1.125 | 0 | 0 |
| G-protein beta:gamma signalling | R-HSA-397795 | 7.496096e-02 | 1.125 | 0 | 0 |
| EPH-ephrin mediated repulsion of cells | R-HSA-3928665 | 7.514028e-02 | 1.124 | 0 | 0 |
| Nuclear signaling by ERBB4 | R-HSA-1251985 | 7.569800e-02 | 1.121 | 0 | 0 |
| CREB1 phosphorylation through the activation of Adenylate Cyclase | R-HSA-442720 | 7.588928e-02 | 1.120 | 0 | 0 |
| ATF6 (ATF6-alpha) activates chaperones | R-HSA-381033 | 7.588928e-02 | 1.120 | 0 | 0 |
| Response of endothelial cells to shear stress | R-HSA-9860931 | 7.596607e-02 | 1.119 | 0 | 0 |
| MET interacts with TNS proteins | R-HSA-8875513 | 7.961463e-02 | 1.099 | 0 | 0 |
| Signaling by cytosolic PDGFRA and PDGFRB fusion proteins | R-HSA-9673766 | 7.961463e-02 | 1.099 | 0 | 0 |
| MET activates PTPN11 | R-HSA-8865999 | 7.961463e-02 | 1.099 | 0 | 0 |
| Signaling by EGFR | R-HSA-177929 | 7.983120e-02 | 1.098 | 0 | 0 |
| Intrinsic Pathway for Apoptosis | R-HSA-109606 | 7.983120e-02 | 1.098 | 0 | 0 |
| Ca2+ pathway | R-HSA-4086398 | 8.019764e-02 | 1.096 | 0 | 0 |
| Switching of origins to a post-replicative state | R-HSA-69052 | 8.019764e-02 | 1.096 | 0 | 0 |
| Activation of anterior HOX genes in hindbrain development during early embryogenesis | R-HSA-5617472 | 8.042105e-02 | 1.095 | 0 | 0 |
| Activation of HOX genes during differentiation | R-HSA-5619507 | 8.042105e-02 | 1.095 | 0 | 0 |
| M-decay: degradation of maternal mRNAs by maternally stored factors | R-HSA-9820841 | 8.296638e-02 | 1.081 | 0 | 0 |
| Regulation of Glucokinase by Glucokinase Regulatory Protein | R-HSA-170822 | 8.298000e-02 | 1.081 | 0 | 0 |
| ROBO receptors bind AKAP5 | R-HSA-9010642 | 8.431466e-02 | 1.074 | 0 | 0 |
| Downregulation of ERBB4 signaling | R-HSA-1253288 | 8.431466e-02 | 1.074 | 0 | 0 |
| Formation of annular gap junctions | R-HSA-196025 | 8.431466e-02 | 1.074 | 0 | 0 |
| Signaling by MRAS-complex mutants | R-HSA-9660537 | 8.431466e-02 | 1.074 | 0 | 0 |
| Gain-of-function MRAS complexes activate RAF signaling | R-HSA-9726842 | 8.431466e-02 | 1.074 | 0 | 0 |
| Infectious disease | R-HSA-5663205 | 8.524227e-02 | 1.069 | 0 | 0 |
| Cellular responses to mechanical stimuli | R-HSA-9855142 | 8.526686e-02 | 1.069 | 0 | 0 |
| Transcription of E2F targets under negative control by DREAM complex | R-HSA-1362277 | 8.625371e-02 | 1.064 | 0 | 0 |
| Negative regulation of MET activity | R-HSA-6807004 | 8.625371e-02 | 1.064 | 0 | 0 |
| Signal transduction by L1 | R-HSA-445144 | 8.625371e-02 | 1.064 | 0 | 0 |
| Defective SFTPA2 causes IPF | R-HSA-5687868 | 8.871978e-02 | 1.052 | 0 | 0 |
| Formation of the canonical BAF (cBAF) complex | R-HSA-9933937 | 8.897174e-02 | 1.051 | 0 | 0 |
| ERBB2 Activates PTK6 Signaling | R-HSA-8847993 | 8.897174e-02 | 1.051 | 0 | 0 |
| Interaction between L1 and Ankyrins | R-HSA-445095 | 9.048419e-02 | 1.043 | 0 | 0 |
| Insulin processing | R-HSA-264876 | 9.048419e-02 | 1.043 | 0 | 0 |
| Defective Intrinsic Pathway for Apoptosis | R-HSA-9734009 | 9.048419e-02 | 1.043 | 0 | 0 |
| APC-Cdc20 mediated degradation of Nek2A | R-HSA-179409 | 9.765392e-02 | 1.010 | 0 | 0 |
| Activation of RAC1 downstream of NMDARs | R-HSA-9619229 | 1.025197e-01 | 0.989 | 0 | 0 |
| Gap junction degradation | R-HSA-190873 | 1.025197e-01 | 0.989 | 0 | 0 |
| ALK mutants bind TKIs | R-HSA-9700645 | 1.025197e-01 | 0.989 | 0 | 0 |
| Caspase-mediated cleavage of cytoskeletal proteins | R-HSA-264870 | 1.025197e-01 | 0.989 | 0 | 0 |
| HuR (ELAVL1) binds and stabilizes mRNA | R-HSA-450520 | 1.025197e-01 | 0.989 | 0 | 0 |
| ERBB2 Regulates Cell Motility | R-HSA-6785631 | 1.030582e-01 | 0.987 | 0 | 0 |
| MECP2 regulates transcription of genes involved in GABA signaling | R-HSA-9022927 | 1.080604e-01 | 0.966 | 0 | 0 |
| TGFBR1 KD Mutants in Cancer | R-HSA-3656532 | 1.080604e-01 | 0.966 | 0 | 0 |
| p75NTR negatively regulates cell cycle via SC1 | R-HSA-193670 | 1.080604e-01 | 0.966 | 0 | 0 |
| SARS-CoV-2 Infection | R-HSA-9694516 | 1.084847e-01 | 0.965 | 0 | 0 |
| G1/S Transition | R-HSA-69206 | 1.089196e-01 | 0.963 | 0 | 0 |
| Listeria monocytogenes entry into host cells | R-HSA-8876384 | 1.097726e-01 | 0.960 | 0 | 0 |
| Signaling by PDGFR in disease | R-HSA-9671555 | 1.097726e-01 | 0.960 | 0 | 0 |
| G1/S-Specific Transcription | R-HSA-69205 | 1.098524e-01 | 0.959 | 0 | 0 |
| DARPP-32 events | R-HSA-180024 | 1.111474e-01 | 0.954 | 0 | 0 |
| Platelet calcium homeostasis | R-HSA-418360 | 1.111474e-01 | 0.954 | 0 | 0 |
| Drug-mediated inhibition of MET activation | R-HSA-9734091 | 1.695731e-01 | 0.771 | 0 | 0 |
| Regulation of PAK-2p34 activity by PS-GAP/RHG10 | R-HSA-211728 | 1.695731e-01 | 0.771 | 0 | 0 |
| RPIA deficiency: failed conversion of R5P to RU5P | R-HSA-5659996 | 1.695731e-01 | 0.771 | 0 | 0 |
| Defective DNA double strand break response due to BARD1 loss of function | R-HSA-9699150 | 1.695731e-01 | 0.771 | 0 | 0 |
| RPIA deficiency: failed conversion of RU5P to R5P | R-HSA-6791461 | 1.695731e-01 | 0.771 | 0 | 0 |
| Defective DNA double strand break response due to BRCA1 loss of function | R-HSA-9663199 | 1.695731e-01 | 0.771 | 0 | 0 |
| IRS activation | R-HSA-74713 | 1.387051e-01 | 0.858 | 0 | 0 |
| SMAD2/3 Phosphorylation Motif Mutants in Cancer | R-HSA-3304356 | 1.387051e-01 | 0.858 | 0 | 0 |
| MECP2 regulates transcription of neuronal ligands | R-HSA-9022702 | 1.221227e-01 | 0.913 | 0 | 0 |
| 2-LTR circle formation | R-HSA-164843 | 1.221227e-01 | 0.913 | 0 | 0 |
| GRB2:SOS provides linkage to MAPK signaling for Integrins | R-HSA-354194 | 1.180930e-01 | 0.928 | 0 | 0 |
| Aberrant regulation of mitotic exit in cancer due to RB1 defects | R-HSA-9687136 | 1.180930e-01 | 0.928 | 0 | 0 |
| APOBEC3G mediated resistance to HIV-1 infection | R-HSA-180689 | 1.648725e-01 | 0.783 | 0 | 0 |
| PI3K events in ERBB4 signaling | R-HSA-1250342 | 1.648725e-01 | 0.783 | 0 | 0 |
| GRB2 events in ERBB2 signaling | R-HSA-1963640 | 1.340138e-01 | 0.873 | 0 | 0 |
| Inactivation of APC/C via direct inhibition of the APC/C complex | R-HSA-141430 | 1.340138e-01 | 0.873 | 0 | 0 |
| Signaling by EGFRvIII in Cancer | R-HSA-5637812 | 1.507527e-01 | 0.822 | 0 | 0 |
| Constitutive Signaling by EGFRvIII | R-HSA-5637810 | 1.507527e-01 | 0.822 | 0 | 0 |
| p130Cas linkage to MAPK signaling for integrins | R-HSA-372708 | 1.507527e-01 | 0.822 | 0 | 0 |
| Conversion from APC/C:Cdc20 to APC/C:Cdh1 in late anaphase | R-HSA-176407 | 1.507527e-01 | 0.822 | 0 | 0 |
| G beta:gamma signalling through PLC beta | R-HSA-418217 | 1.682377e-01 | 0.774 | 0 | 0 |
| Constitutive Signaling by AKT1 E17K in Cancer | R-HSA-5674400 | 1.360490e-01 | 0.866 | 0 | 0 |
| Deadenylation of mRNA | R-HSA-429947 | 1.501388e-01 | 0.824 | 0 | 0 |
| Carboxyterminal post-translational modifications of tubulin | R-HSA-8955332 | 1.447151e-01 | 0.839 | 0 | 0 |
| Degradation of CDH1 | R-HSA-9766229 | 1.656384e-01 | 0.781 | 0 | 0 |
| Integrin signaling | R-HSA-354192 | 1.588546e-01 | 0.799 | 0 | 0 |
| Activation of the pre-replicative complex | R-HSA-68962 | 1.223052e-01 | 0.913 | 0 | 0 |
| TGFBR3 expression | R-HSA-9839394 | 1.648121e-01 | 0.783 | 0 | 0 |
| Disorders of Developmental Biology | R-HSA-9675151 | 1.340138e-01 | 0.873 | 0 | 0 |
| EPHB-mediated forward signaling | R-HSA-3928662 | 1.159758e-01 | 0.936 | 0 | 0 |
| LGI-ADAM interactions | R-HSA-5682910 | 1.429619e-01 | 0.845 | 0 | 0 |
| KSRP (KHSRP) binds and destabilizes mRNA | R-HSA-450604 | 1.180930e-01 | 0.928 | 0 | 0 |
| HIV Life Cycle | R-HSA-162587 | 1.454944e-01 | 0.837 | 0 | 0 |
| PKA activation | R-HSA-163615 | 1.682377e-01 | 0.774 | 0 | 0 |
| Synthesis of DNA | R-HSA-69239 | 1.492044e-01 | 0.826 | 0 | 0 |
| HIV Infection | R-HSA-162906 | 1.232563e-01 | 0.909 | 0 | 0 |
| Pyrophosphate hydrolysis | R-HSA-71737 | 1.387051e-01 | 0.858 | 0 | 0 |
| Inhibition of the proteolytic activity of APC/C required for the onset of anaphase by mitotic spindle checkpoint components | R-HSA-141405 | 1.340138e-01 | 0.873 | 0 | 0 |
| Nectin/Necl trans heterodimerization | R-HSA-420597 | 1.387051e-01 | 0.858 | 0 | 0 |
| Diseases of mitotic cell cycle | R-HSA-9675126 | 1.461809e-01 | 0.835 | 0 | 0 |
| Developmental Cell Lineages | R-HSA-9734767 | 1.527056e-01 | 0.816 | 0 | 0 |
| PTK6 Regulates Proteins Involved in RNA Processing | R-HSA-8849468 | 1.387051e-01 | 0.858 | 0 | 0 |
| Acetylcholine regulates insulin secretion | R-HSA-399997 | 1.340138e-01 | 0.873 | 0 | 0 |
| FGFR1 mutant receptor activation | R-HSA-1839124 | 1.588546e-01 | 0.799 | 0 | 0 |
| Regulation of PD-L1(CD274) expression | R-HSA-9909648 | 1.296665e-01 | 0.887 | 0 | 0 |
| Regulation of T cell activation by CD28 family | R-HSA-388841 | 1.233949e-01 | 0.909 | 0 | 0 |
| ER to Golgi Anterograde Transport | R-HSA-199977 | 1.427637e-01 | 0.845 | 0 | 0 |
| Inhibition of PKR | R-HSA-169131 | 1.695731e-01 | 0.771 | 0 | 0 |
| Class I peroxisomal membrane protein import | R-HSA-9603798 | 1.180930e-01 | 0.928 | 0 | 0 |
| Presynaptic function of Kainate receptors | R-HSA-500657 | 1.682377e-01 | 0.774 | 0 | 0 |
| Intraflagellar transport | R-HSA-5620924 | 1.550079e-01 | 0.810 | 0 | 0 |
| Vesicle-mediated transport | R-HSA-5653656 | 1.342959e-01 | 0.872 | 0 | 0 |
| Signaling by TGFBR3 | R-HSA-9839373 | 1.347718e-01 | 0.870 | 0 | 0 |
| CD163 mediating an anti-inflammatory response | R-HSA-9662834 | 1.429619e-01 | 0.845 | 0 | 0 |
| Platelet sensitization by LDL | R-HSA-432142 | 1.682377e-01 | 0.774 | 0 | 0 |
| tRNA processing in the nucleus | R-HSA-6784531 | 1.224177e-01 | 0.912 | 0 | 0 |
| Cargo recognition for clathrin-mediated endocytosis | R-HSA-8856825 | 1.231636e-01 | 0.910 | 0 | 0 |
| Cardiac conduction | R-HSA-5576891 | 1.482276e-01 | 0.829 | 1 | 0 |
| Transcriptional Regulation by VENTX | R-HSA-8853884 | 1.634789e-01 | 0.787 | 0 | 0 |
| Mitotic G1 phase and G1/S transition | R-HSA-453279 | 1.372026e-01 | 0.863 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation by EBF2 | R-HSA-9844594 | 1.519299e-01 | 0.818 | 0 | 0 |
| Transcriptional regulation of brown and beige adipocyte differentiation | R-HSA-9843743 | 1.519299e-01 | 0.818 | 0 | 0 |
| Regulation of MITF-M dependent genes involved in invasion | R-HSA-9854909 | 1.387051e-01 | 0.858 | 0 | 0 |
| SARS-CoV-2 modulates host translation machinery | R-HSA-9754678 | 1.285798e-01 | 0.891 | 0 | 0 |
| Hedgehog 'off' state | R-HSA-5610787 | 1.585995e-01 | 0.800 | 0 | 0 |
| Gluconeogenesis | R-HSA-70263 | 1.550079e-01 | 0.810 | 0 | 0 |
| NRAGE signals death through JNK | R-HSA-193648 | 1.467941e-01 | 0.833 | 0 | 0 |
| Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors | R-HSA-8864260 | 1.159758e-01 | 0.936 | 0 | 0 |
| Transport of Ribonucleoproteins into the Host Nucleus | R-HSA-168271 | 1.634789e-01 | 0.787 | 0 | 0 |
| Cell death signalling via NRAGE, NRIF and NADE | R-HSA-204998 | 1.393812e-01 | 0.856 | 0 | 0 |
| p75 NTR receptor-mediated signalling | R-HSA-193704 | 1.512974e-01 | 0.820 | 0 | 0 |
| Signaling by ALK | R-HSA-201556 | 1.407772e-01 | 0.851 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in extracellular matrix, focal adhesion and epithelial-to-mesenchymal transition | R-HSA-9926550 | 1.682377e-01 | 0.774 | 0 | 0 |
| Assembly of Viral Components at the Budding Site | R-HSA-168316 | 1.387051e-01 | 0.858 | 0 | 0 |
| CDH11 homotypic and heterotypic interactions | R-HSA-9833576 | 1.709352e-01 | 0.767 | 0 | 0 |
| Noncanonical activation of NOTCH3 | R-HSA-9017802 | 1.709352e-01 | 0.767 | 0 | 0 |
| Loss of Function of SMAD2/3 in Cancer | R-HSA-3304349 | 1.709352e-01 | 0.767 | 0 | 0 |
| Defective CSF2RA causes SMDP4 | R-HSA-5688890 | 1.709352e-01 | 0.767 | 0 | 0 |
| Defective CSF2RB causes SMDP5 | R-HSA-5688849 | 1.709352e-01 | 0.767 | 0 | 0 |
| Loss of MECP2 binding ability to the NCoR/SMRT complex | R-HSA-9022537 | 1.709352e-01 | 0.767 | 0 | 0 |
| Toxicity of botulinum toxin type E (botE) | R-HSA-5250992 | 1.709352e-01 | 0.767 | 0 | 0 |
| Negative feedback regulation of MAPK pathway | R-HSA-5674499 | 1.709352e-01 | 0.767 | 0 | 0 |
| Epithelial-Mesenchymal Transition (EMT) during gastrulation | R-HSA-9758919 | 1.709352e-01 | 0.767 | 0 | 0 |
| Aryl hydrocarbon receptor signalling | R-HSA-8937144 | 1.709352e-01 | 0.767 | 0 | 0 |
| RUNX1 regulates expression of components of tight junctions | R-HSA-8935964 | 1.709352e-01 | 0.767 | 0 | 0 |
| Regulation of CDH19 Expression and Function | R-HSA-9764302 | 1.709352e-01 | 0.767 | 0 | 0 |
| DNA Damage Recognition in GG-NER | R-HSA-5696394 | 1.719856e-01 | 0.765 | 0 | 0 |
| Co-inhibition by PD-1 | R-HSA-389948 | 1.751952e-01 | 0.756 | 0 | 0 |
| Sensory processing of sound by inner hair cells of the cochlea | R-HSA-9662360 | 1.752229e-01 | 0.756 | 0 | 0 |
| Signaling by FGFR1 in disease | R-HSA-5655302 | 1.754065e-01 | 0.756 | 0 | 0 |
| Postmitotic nuclear pore complex (NPC) reformation | R-HSA-9615933 | 1.800273e-01 | 0.745 | 0 | 0 |
| G alpha (12/13) signalling events | R-HSA-416482 | 1.825464e-01 | 0.739 | 0 | 0 |
| Death Receptor Signaling | R-HSA-73887 | 1.851642e-01 | 0.732 | 0 | 0 |
| Dual Incision in GG-NER | R-HSA-5696400 | 1.855469e-01 | 0.732 | 0 | 0 |
| Developmental Lineage of Mammary Gland Alveolar Cells | R-HSA-9927426 | 1.855469e-01 | 0.732 | 0 | 0 |
| Pre-NOTCH Processing in Golgi | R-HSA-1912420 | 1.863940e-01 | 0.730 | 0 | 0 |
| Abortive elongation of HIV-1 transcript in the absence of Tat | R-HSA-167242 | 1.863940e-01 | 0.730 | 0 | 0 |
| AKT phosphorylates targets in the cytosol | R-HSA-198323 | 1.876910e-01 | 0.727 | 0 | 0 |
| Erythropoietin activates Phosphoinositide-3-kinase (PI3K) | R-HSA-9027276 | 1.876910e-01 | 0.727 | 0 | 0 |
| Z-decay: degradation of maternal mRNAs by zygotically expressed factors | R-HSA-9820865 | 1.876910e-01 | 0.727 | 0 | 0 |
| Constitutive Signaling by Overexpressed ERBB2 | R-HSA-9634285 | 1.876910e-01 | 0.727 | 0 | 0 |
| Signaling by LTK | R-HSA-9842663 | 1.876910e-01 | 0.727 | 0 | 0 |
| Glucagon-like Peptide-1 (GLP1) regulates insulin secretion | R-HSA-381676 | 1.876938e-01 | 0.727 | 0 | 0 |
| Downstream signaling events of B Cell Receptor (BCR) | R-HSA-1168372 | 1.948761e-01 | 0.710 | 0 | 0 |
| Tat-mediated HIV elongation arrest and recovery | R-HSA-167243 | 1.957411e-01 | 0.708 | 0 | 0 |
| Pausing and recovery of Tat-mediated HIV elongation | R-HSA-167238 | 1.957411e-01 | 0.708 | 0 | 0 |
| CD28 dependent PI3K/Akt signaling | R-HSA-389357 | 1.957411e-01 | 0.708 | 0 | 0 |
| Mitochondrial unfolded protein response (UPRmt) | R-HSA-9841251 | 1.957411e-01 | 0.708 | 0 | 0 |
| Viral Messenger RNA Synthesis | R-HSA-168325 | 1.974764e-01 | 0.704 | 0 | 0 |
| Autophagy | R-HSA-9612973 | 1.983450e-01 | 0.703 | 0 | 0 |
| Orc1 removal from chromatin | R-HSA-68949 | 1.994201e-01 | 0.700 | 0 | 0 |
| Uptake and actions of bacterial toxins | R-HSA-5339562 | 1.994201e-01 | 0.700 | 0 | 0 |
| SARS-CoV-1 activates/modulates innate immune responses | R-HSA-9692916 | 1.994201e-01 | 0.700 | 0 | 0 |
| Turbulent (oscillatory, disturbed) flow shear stress activates signaling by PIEZO1 and integrins in endothelial cells | R-HSA-9860927 | 1.995100e-01 | 0.700 | 0 | 0 |
| Formation of WDR5-containing histone-modifying complexes | R-HSA-9772755 | 1.995100e-01 | 0.700 | 0 | 0 |
| Transmission across Chemical Synapses | R-HSA-112315 | 2.006441e-01 | 0.698 | 1 | 0 |
| High laminar flow shear stress activates signaling by PIEZO1 and PECAM1:CDH5:KDR in endothelial cells | R-HSA-9856530 | 2.013768e-01 | 0.696 | 0 | 0 |
| Activation of NIMA Kinases NEK9, NEK6, NEK7 | R-HSA-2980767 | 2.042286e-01 | 0.690 | 0 | 0 |
| Autointegration results in viral DNA circles | R-HSA-177539 | 2.042286e-01 | 0.690 | 0 | 0 |
| Integration of viral DNA into host genomic DNA | R-HSA-175567 | 2.042286e-01 | 0.690 | 0 | 0 |
| APC/C-mediated degradation of cell cycle proteins | R-HSA-174143 | 2.050493e-01 | 0.688 | 0 | 0 |
| Regulation of mitotic cell cycle | R-HSA-453276 | 2.050493e-01 | 0.688 | 0 | 0 |
| Protein hydroxylation | R-HSA-9629569 | 2.051450e-01 | 0.688 | 0 | 0 |
| Nucleotide Excision Repair | R-HSA-5696398 | 2.060705e-01 | 0.686 | 0 | 0 |
| Formation of axial mesoderm | R-HSA-9796292 | 2.112575e-01 | 0.675 | 0 | 0 |
| APC:Cdc20 mediated degradation of cell cycle proteins prior to satisfation of the cell cycle checkpoint | R-HSA-179419 | 2.112610e-01 | 0.675 | 0 | 0 |
| APC/C:Cdh1 mediated degradation of Cdc20 and other APC/C:Cdh1 targeted proteins in late mitosis/early G1 | R-HSA-174178 | 2.112610e-01 | 0.675 | 0 | 0 |
| HIV elongation arrest and recovery | R-HSA-167287 | 2.119081e-01 | 0.674 | 0 | 0 |
| Pausing and recovery of HIV elongation | R-HSA-167290 | 2.119081e-01 | 0.674 | 0 | 0 |
| Activation of kainate receptors upon glutamate binding | R-HSA-451326 | 2.119081e-01 | 0.674 | 0 | 0 |
| Phase 0 - rapid depolarisation | R-HSA-5576892 | 2.119081e-01 | 0.674 | 1 | 1 |
| Regulation of TP53 Degradation | R-HSA-6804757 | 2.138448e-01 | 0.670 | 0 | 0 |
| AUF1 (hnRNP D0) binds and destabilizes mRNA | R-HSA-450408 | 2.138448e-01 | 0.670 | 0 | 0 |
| RET signaling | R-HSA-8853659 | 2.138448e-01 | 0.670 | 0 | 0 |
| Cyclin A:Cdk2-associated events at S phase entry | R-HSA-69656 | 2.154403e-01 | 0.667 | 0 | 0 |
| Regulation of insulin secretion | R-HSA-422356 | 2.199449e-01 | 0.658 | 0 | 0 |
| Gene expression (Transcription) | R-HSA-74160 | 2.235089e-01 | 0.651 | 1 | 0 |
| Macroautophagy | R-HSA-1632852 | 2.235819e-01 | 0.651 | 0 | 0 |
| Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | R-HSA-1236382 | 2.244135e-01 | 0.649 | 0 | 0 |
| Signaling by Ligand-Responsive EGFR Variants in Cancer | R-HSA-5637815 | 2.244135e-01 | 0.649 | 0 | 0 |
| PKA-mediated phosphorylation of CREB | R-HSA-111931 | 2.244135e-01 | 0.649 | 0 | 0 |
| NEP/NS2 Interacts with the Cellular Export Machinery | R-HSA-168333 | 2.265062e-01 | 0.645 | 0 | 0 |
| Regulation of CDH11 Expression and Function | R-HSA-9759475 | 2.284823e-01 | 0.641 | 0 | 0 |
| Interactions of Tat with host cellular proteins | R-HSA-176034 | 2.432572e-01 | 0.614 | 0 | 0 |
| Defective SLC6A2 causes orthostatic intolerance (OI) | R-HSA-5619109 | 2.432572e-01 | 0.614 | 0 | 0 |
| SMAD4 MH2 Domain Mutants in Cancer | R-HSA-3311021 | 2.432572e-01 | 0.614 | 0 | 0 |
| IKBKB deficiency causes SCID | R-HSA-5602636 | 2.432572e-01 | 0.614 | 0 | 0 |
| IKBKG deficiency causes anhidrotic ectodermal dysplasia with immunodeficiency (EDA-ID) (via TLR) | R-HSA-5603027 | 2.432572e-01 | 0.614 | 0 | 0 |
| Signaling by TCF7L2 mutants | R-HSA-5339700 | 2.432572e-01 | 0.614 | 0 | 0 |
| SMAD2/3 MH2 Domain Mutants in Cancer | R-HSA-3315487 | 2.432572e-01 | 0.614 | 0 | 0 |
| Defective GFPT1 causes CMSTA1 | R-HSA-4085023 | 2.432572e-01 | 0.614 | 0 | 0 |
| Defective SLC12A6 causes agenesis of the corpus callosum, with peripheral neuropathy (ACCPN) | R-HSA-5619039 | 2.432572e-01 | 0.614 | 0 | 0 |
| Loss of Function of SMAD4 in Cancer | R-HSA-3304347 | 2.432572e-01 | 0.614 | 0 | 0 |
| TWIK-releated acid-sensitive K+ channel (TASK) | R-HSA-1299316 | 2.432572e-01 | 0.614 | 0 | 0 |
| Defective SLC4A4 causes renal tubular acidosis, proximal, with ocular abnormalities and mental retardation (pRTA-OA) | R-HSA-5619054 | 2.432572e-01 | 0.614 | 0 | 0 |
| Stimulation of the cell death response by PAK-2p34 | R-HSA-211736 | 3.104072e-01 | 0.508 | 0 | 0 |
| Defective SLC6A5 causes hyperekplexia 3 (HKPX3) | R-HSA-5619089 | 3.104072e-01 | 0.508 | 0 | 0 |
| TGFBR2 Kinase Domain Mutants in Cancer | R-HSA-3645790 | 3.104072e-01 | 0.508 | 0 | 0 |
| MECP2 regulates transcription factors | R-HSA-9022707 | 2.381434e-01 | 0.623 | 0 | 0 |
| NOSTRIN mediated eNOS trafficking | R-HSA-203641 | 2.381434e-01 | 0.623 | 0 | 0 |
| SOS-mediated signalling | R-HSA-112412 | 2.381434e-01 | 0.623 | 0 | 0 |
| Axonal growth stimulation | R-HSA-209563 | 3.716022e-01 | 0.430 | 0 | 0 |
| Invadopodia formation | R-HSA-8941237 | 3.716022e-01 | 0.430 | 0 | 0 |
| Formyl peptide receptors bind formyl peptides and many other ligands | R-HSA-444473 | 2.723076e-01 | 0.565 | 0 | 0 |
| Activated NTRK2 signals through PI3K | R-HSA-9028335 | 2.723076e-01 | 0.565 | 0 | 0 |
| MET receptor recycling | R-HSA-8875656 | 2.723076e-01 | 0.565 | 0 | 0 |
| PLCG1 events in ERBB2 signaling | R-HSA-1251932 | 4.273700e-01 | 0.369 | 0 | 0 |
| Defective LFNG causes SCDO3 | R-HSA-5083630 | 4.273700e-01 | 0.369 | 0 | 0 |
| InlB-mediated entry of Listeria monocytogenes into host cell | R-HSA-8875360 | 2.600254e-01 | 0.585 | 0 | 0 |
| TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) | R-HSA-2173791 | 2.600254e-01 | 0.585 | 0 | 0 |
| Binding and entry of HIV virion | R-HSA-173107 | 3.401934e-01 | 0.468 | 0 | 0 |
| MET activates RAP1 and RAC1 | R-HSA-8875555 | 3.401934e-01 | 0.468 | 0 | 0 |
| Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1 | R-HSA-1362300 | 2.849419e-01 | 0.545 | 0 | 0 |
| Phosphorylation of the APC/C | R-HSA-176412 | 2.849419e-01 | 0.545 | 0 | 0 |
| Developmental Lineage of Mammary Stem Cells | R-HSA-9938206 | 2.641957e-01 | 0.578 | 0 | 0 |
| G beta:gamma signalling through CDC42 | R-HSA-8964616 | 3.100387e-01 | 0.509 | 0 | 0 |
| SHC1 events in ERBB4 signaling | R-HSA-1250347 | 3.100387e-01 | 0.509 | 0 | 0 |
| InlA-mediated entry of Listeria monocytogenes into host cells | R-HSA-8876493 | 3.734454e-01 | 0.428 | 0 | 0 |
| NF-kB activation through FADD/RIP-1 pathway mediated by caspase-8 and -10 | R-HSA-933543 | 3.734454e-01 | 0.428 | 0 | 0 |
| PCNA-Dependent Long Patch Base Excision Repair | R-HSA-5651801 | 3.603069e-01 | 0.443 | 0 | 0 |
| RNA Polymerase III Transcription Termination | R-HSA-73980 | 3.603069e-01 | 0.443 | 0 | 0 |
| Autodegradation of Cdh1 by Cdh1:APC/C | R-HSA-174084 | 2.400206e-01 | 0.620 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176409 | 2.357160e-01 | 0.628 | 0 | 0 |
| Activation of APC/C and APC/C:Cdc20 mediated degradation of mitotic proteins | R-HSA-176814 | 2.482954e-01 | 0.605 | 0 | 0 |
| Signaling by EGFR in Cancer | R-HSA-1643713 | 3.466822e-01 | 0.460 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Cyclin B | R-HSA-174048 | 3.852704e-01 | 0.414 | 0 | 0 |
| Polymerase switching | R-HSA-69091 | 4.377042e-01 | 0.359 | 0 | 0 |
| Leading Strand Synthesis | R-HSA-69109 | 4.377042e-01 | 0.359 | 0 | 0 |
| Scavenging by Class F Receptors | R-HSA-3000484 | 4.377042e-01 | 0.359 | 0 | 0 |
| Signaling by ERBB4 | R-HSA-1236394 | 2.368335e-01 | 0.626 | 0 | 0 |
| Dual incision in TC-NER | R-HSA-6782135 | 2.740674e-01 | 0.562 | 0 | 0 |
| Formation of the HIV-1 Early Elongation Complex | R-HSA-167158 | 3.883049e-01 | 0.411 | 0 | 0 |
| Formation of the Early Elongation Complex | R-HSA-113418 | 3.883049e-01 | 0.411 | 0 | 0 |
| Developmental Lineage of Pancreatic Ductal Cells | R-HSA-9925563 | 2.908527e-01 | 0.536 | 0 | 0 |
| Cdc20:Phospho-APC/C mediated degradation of Cyclin A | R-HSA-174184 | 3.255202e-01 | 0.487 | 0 | 0 |
| Lagging Strand Synthesis | R-HSA-69186 | 4.344102e-01 | 0.362 | 0 | 0 |
| mRNA Splicing - Minor Pathway | R-HSA-72165 | 3.869753e-01 | 0.412 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in GG-NER | R-HSA-5696397 | 4.584368e-01 | 0.339 | 0 | 0 |
| Gap-filling DNA repair synthesis and ligation in TC-NER | R-HSA-6782210 | 3.849624e-01 | 0.415 | 0 | 0 |
| APC/C:Cdc20 mediated degradation of Securin | R-HSA-174154 | 4.032969e-01 | 0.394 | 0 | 0 |
| Formation of HIV-1 elongation complex containing HIV-1 Tat | R-HSA-167200 | 4.245089e-01 | 0.372 | 0 | 0 |
| Transcription-Coupled Nucleotide Excision Repair (TC-NER) | R-HSA-6781827 | 3.670601e-01 | 0.435 | 0 | 0 |
| Regulation of activated PAK-2p34 by proteasome mediated degradation | R-HSA-211733 | 4.499041e-01 | 0.347 | 0 | 0 |
| HIV Transcription Elongation | R-HSA-167169 | 4.424655e-01 | 0.354 | 0 | 0 |
| Tat-mediated elongation of the HIV-1 transcript | R-HSA-167246 | 4.424655e-01 | 0.354 | 0 | 0 |
| Formation of HIV elongation complex in the absence of HIV Tat | R-HSA-167152 | 4.424655e-01 | 0.354 | 0 | 0 |
| PI3K/AKT Signaling in Cancer | R-HSA-2219528 | 2.516061e-01 | 0.599 | 0 | 0 |
| Signaling by MET | R-HSA-6806834 | 4.319833e-01 | 0.365 | 0 | 0 |
| Global Genome Nucleotide Excision Repair (GG-NER) | R-HSA-5696399 | 2.413811e-01 | 0.617 | 0 | 0 |
| EGFR downregulation | R-HSA-182971 | 4.499041e-01 | 0.347 | 0 | 0 |
| Myogenesis | R-HSA-525793 | 3.466822e-01 | 0.460 | 0 | 0 |
| Regulation of APC/C activators between G1/S and early anaphase | R-HSA-176408 | 3.275421e-01 | 0.485 | 0 | 0 |
| G0 and Early G1 | R-HSA-1538133 | 2.801778e-01 | 0.553 | 0 | 0 |
| EGFR Transactivation by Gastrin | R-HSA-2179392 | 3.401934e-01 | 0.468 | 0 | 0 |
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | R-HSA-2173796 | 3.883118e-01 | 0.411 | 0 | 0 |
| DAP12 signaling | R-HSA-2424491 | 4.295498e-01 | 0.367 | 0 | 0 |
| Germ layer formation at gastrulation | R-HSA-9754189 | 3.852704e-01 | 0.414 | 0 | 0 |
| Platelet Aggregation (Plug Formation) | R-HSA-76009 | 3.706497e-01 | 0.431 | 0 | 0 |
| Toxicity of botulinum toxin type A (botA) | R-HSA-5250968 | 3.064102e-01 | 0.514 | 0 | 0 |
| Regulation of CDH11 function | R-HSA-9762292 | 3.401934e-01 | 0.468 | 0 | 0 |
| POLB-Dependent Long Patch Base Excision Repair | R-HSA-110362 | 4.059947e-01 | 0.391 | 0 | 0 |
| Formation of Incision Complex in GG-NER | R-HSA-5696395 | 2.742753e-01 | 0.562 | 0 | 0 |
| Co-inhibition by CTLA4 | R-HSA-389513 | 4.099980e-01 | 0.387 | 0 | 0 |
| activated TAK1 mediates p38 MAPK activation | R-HSA-450302 | 4.584368e-01 | 0.339 | 0 | 0 |
| Sensing of DNA Double Strand Breaks | R-HSA-5693548 | 4.059947e-01 | 0.391 | 0 | 0 |
| RNA Polymerase II Pre-transcription Events | R-HSA-674695 | 2.368335e-01 | 0.626 | 0 | 0 |
| Generation of second messenger molecules | R-HSA-202433 | 4.424655e-01 | 0.354 | 0 | 0 |
| Regulation of gap junction activity | R-HSA-191650 | 4.273700e-01 | 0.369 | 0 | 0 |
| G beta:gamma signalling through PI3Kgamma | R-HSA-392451 | 2.845591e-01 | 0.546 | 0 | 0 |
| RNA Polymerase I Transcription Termination | R-HSA-73863 | 3.675136e-01 | 0.435 | 0 | 0 |
| Resolution of AP sites via the multiple-nucleotide patch replacement pathway | R-HSA-110373 | 3.466822e-01 | 0.460 | 0 | 0 |
| ER-Phagosome pathway | R-HSA-1236974 | 3.061310e-01 | 0.514 | 0 | 0 |
| Late Phase of HIV Life Cycle | R-HSA-162599 | 4.179435e-01 | 0.379 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 1 | R-HSA-418592 | 3.051404e-01 | 0.516 | 0 | 0 |
| Regulation of TP53 Expression and Degradation | R-HSA-6806003 | 2.587682e-01 | 0.587 | 0 | 0 |
| Repression of WNT target genes | R-HSA-4641265 | 4.377042e-01 | 0.359 | 0 | 0 |
| Fcgamma receptor (FCGR) dependent phagocytosis | R-HSA-2029480 | 4.311698e-01 | 0.365 | 0 | 0 |
| Signaling by TGF-beta Receptor Complex | R-HSA-170834 | 4.211537e-01 | 0.376 | 0 | 0 |
| Glycogen breakdown (glycogenolysis) | R-HSA-70221 | 3.258702e-01 | 0.487 | 0 | 0 |
| CLEC7A (Dectin-1) induces NFAT activation | R-HSA-5607763 | 2.354178e-01 | 0.628 | 0 | 0 |
| Regulation of CDH1 mRNA translation by microRNAs | R-HSA-9764562 | 2.354178e-01 | 0.628 | 0 | 0 |
| TNFR1-mediated ceramide production | R-HSA-5626978 | 4.273700e-01 | 0.369 | 0 | 0 |
| Butyrate Response Factor 1 (BRF1) binds and destabilizes mRNA | R-HSA-450385 | 2.600254e-01 | 0.585 | 0 | 0 |
| Formation of the posterior neural plate | R-HSA-9832991 | 3.734454e-01 | 0.428 | 0 | 0 |
| Metalloprotease DUBs | R-HSA-5689901 | 3.466822e-01 | 0.460 | 0 | 0 |
| Epigenetic regulation by WDR5-containing histone modifying complexes | R-HSA-9917777 | 2.550200e-01 | 0.593 | 0 | 0 |
| Lysosome Vesicle Biogenesis | R-HSA-432720 | 3.701425e-01 | 0.432 | 0 | 0 |
| Signaling by FLT3 fusion proteins | R-HSA-9703465 | 3.466822e-01 | 0.460 | 0 | 0 |
| Activated NTRK3 signals through PI3K | R-HSA-9603381 | 2.381434e-01 | 0.623 | 0 | 0 |
| WNT5A-dependent internalization of FZD4 | R-HSA-5099900 | 2.849419e-01 | 0.545 | 0 | 0 |
| Metabolism of nitric oxide: NOS3 activation and regulation | R-HSA-202131 | 2.435059e-01 | 0.613 | 0 | 0 |
| Deadenylation-dependent mRNA decay | R-HSA-429914 | 4.297711e-01 | 0.367 | 0 | 0 |
| TCR signaling | R-HSA-202403 | 3.480646e-01 | 0.458 | 0 | 0 |
| eNOS activation | R-HSA-203615 | 3.338546e-01 | 0.476 | 0 | 0 |
| p53-Independent G1/S DNA Damage Checkpoint | R-HSA-69613 | 3.706497e-01 | 0.431 | 0 | 0 |
| Ubiquitin-Mediated Degradation of Phosphorylated Cdc25A | R-HSA-69601 | 3.706497e-01 | 0.431 | 0 | 0 |
| Co-stimulation by CD28 | R-HSA-389356 | 2.677759e-01 | 0.572 | 0 | 0 |
| GPVI-mediated activation cascade | R-HSA-114604 | 3.701425e-01 | 0.432 | 0 | 0 |
| Loss of Function of TGFBR2 in Cancer | R-HSA-3642278 | 3.104072e-01 | 0.508 | 0 | 0 |
| Localization of the PINCH-ILK-PARVIN complex to focal adhesions | R-HSA-446343 | 3.104072e-01 | 0.508 | 0 | 0 |
| MET activates STAT3 | R-HSA-8875791 | 3.716022e-01 | 0.430 | 0 | 0 |
| Co-stimulation by ICOS | R-HSA-9927354 | 2.723076e-01 | 0.565 | 0 | 0 |
| SARS-CoV-2 targets PDZ proteins in cell-cell junction | R-HSA-9705677 | 4.273700e-01 | 0.369 | 0 | 0 |
| AKT-mediated inactivation of FOXO1A | R-HSA-211163 | 4.273700e-01 | 0.369 | 0 | 0 |
| WNT5A-dependent internalization of FZD2, FZD5 and ROR2 | R-HSA-5140745 | 3.401934e-01 | 0.468 | 0 | 0 |
| PKA activation in glucagon signalling | R-HSA-164378 | 3.603069e-01 | 0.443 | 0 | 0 |
| VLDLR internalisation and degradation | R-HSA-8866427 | 4.377042e-01 | 0.359 | 0 | 0 |
| CDK-mediated phosphorylation and removal of Cdc6 | R-HSA-69017 | 3.551235e-01 | 0.450 | 0 | 0 |
| Retrograde transport at the Trans-Golgi-Network | R-HSA-6811440 | 4.032969e-01 | 0.394 | 0 | 0 |
| Negative regulation of NOTCH4 signaling | R-HSA-9604323 | 4.424655e-01 | 0.354 | 0 | 0 |
| PI3K Cascade | R-HSA-109704 | 4.519683e-01 | 0.345 | 0 | 0 |
| Extra-nuclear estrogen signaling | R-HSA-9009391 | 2.477302e-01 | 0.606 | 0 | 0 |
| Regulation of Expression and Function of Type II Classical Cadherins | R-HSA-9764260 | 2.979111e-01 | 0.526 | 0 | 0 |
| HDMs demethylate histones | R-HSA-3214842 | 3.258702e-01 | 0.487 | 0 | 0 |
| Polo-like kinase mediated events | R-HSA-156711 | 3.603069e-01 | 0.443 | 0 | 0 |
| Adaptive Immune System | R-HSA-1280218 | 3.580075e-01 | 0.446 | 0 | 0 |
| PCP/CE pathway | R-HSA-4086400 | 2.817461e-01 | 0.550 | 0 | 0 |
| Platelet homeostasis | R-HSA-418346 | 3.067818e-01 | 0.513 | 0 | 0 |
| Antigen processing-Cross presentation | R-HSA-1236975 | 3.272742e-01 | 0.485 | 0 | 0 |
| Interferon gamma signaling | R-HSA-877300 | 3.822783e-01 | 0.418 | 1 | 1 |
| Signal attenuation | R-HSA-74749 | 3.401934e-01 | 0.468 | 0 | 0 |
| Diseases associated with surfactant metabolism | R-HSA-5687613 | 4.377042e-01 | 0.359 | 0 | 0 |
| TBC/RABGAPs | R-HSA-8854214 | 3.381019e-01 | 0.471 | 0 | 0 |
| Negative regulation of MAPK pathway | R-HSA-5675221 | 3.058934e-01 | 0.514 | 0 | 0 |
| RNA Polymerase II Transcription | R-HSA-73857 | 4.565200e-01 | 0.341 | 1 | 0 |
| CHL1 interactions | R-HSA-447041 | 2.381434e-01 | 0.623 | 0 | 0 |
| Activation of the AP-1 family of transcription factors | R-HSA-450341 | 3.064102e-01 | 0.514 | 0 | 0 |
| NOTCH4 Activation and Transmission of Signal to the Nucleus | R-HSA-9013700 | 3.064102e-01 | 0.514 | 0 | 0 |
| Neurotoxicity of clostridium toxins | R-HSA-168799 | 2.641957e-01 | 0.578 | 0 | 0 |
| The role of Nef in HIV-1 replication and disease pathogenesis | R-HSA-164952 | 2.845591e-01 | 0.546 | 0 | 0 |
| TNFR1-induced NF-kappa-B signaling pathway | R-HSA-5357956 | 3.675136e-01 | 0.435 | 0 | 0 |
| Integration of energy metabolism | R-HSA-163685 | 4.523400e-01 | 0.345 | 0 | 0 |
| TGFBR3 regulates TGF-beta signaling | R-HSA-9839389 | 2.381434e-01 | 0.623 | 0 | 0 |
| Downregulation of ERBB2:ERBB3 signaling | R-HSA-1358803 | 4.377042e-01 | 0.359 | 0 | 0 |
| Rab regulation of trafficking | R-HSA-9007101 | 4.435661e-01 | 0.353 | 0 | 0 |
| HCMV Late Events | R-HSA-9610379 | 3.645251e-01 | 0.438 | 0 | 0 |
| FOXO-mediated transcription of cell cycle genes | R-HSA-9617828 | 4.584368e-01 | 0.339 | 0 | 0 |
| Signaling by PTK6 | R-HSA-8848021 | 3.412029e-01 | 0.467 | 0 | 0 |
| Signaling by Non-Receptor Tyrosine Kinases | R-HSA-9006927 | 3.412029e-01 | 0.467 | 0 | 0 |
| Intracellular oxygen transport | R-HSA-8981607 | 3.716022e-01 | 0.430 | 0 | 0 |
| ARMS-mediated activation | R-HSA-170984 | 3.064102e-01 | 0.514 | 0 | 0 |
| NADE modulates death signalling | R-HSA-205025 | 4.273700e-01 | 0.369 | 0 | 0 |
| Cross-presentation of particulate exogenous antigens (phagosomes) | R-HSA-1236973 | 3.401934e-01 | 0.468 | 0 | 0 |
| Estrogen-dependent nuclear events downstream of ESR-membrane signaling | R-HSA-9634638 | 2.845591e-01 | 0.546 | 0 | 0 |
| Glucagon signaling in metabolic regulation | R-HSA-163359 | 3.158183e-01 | 0.501 | 0 | 0 |
| Creatine metabolism | R-HSA-71288 | 4.099980e-01 | 0.387 | 0 | 0 |
| Aberrant regulation of mitotic cell cycle due to RB1 defects | R-HSA-9687139 | 4.295498e-01 | 0.367 | 0 | 0 |
| MAPK6/MAPK4 signaling | R-HSA-5687128 | 3.651231e-01 | 0.438 | 0 | 0 |
| Signaling by NTRK1 (TRKA) | R-HSA-187037 | 4.583925e-01 | 0.339 | 0 | 0 |
| SARS-CoV-2 activates/modulates innate and adaptive immune responses | R-HSA-9705671 | 2.388604e-01 | 0.622 | 0 | 0 |
| Regulation of PTEN stability and activity | R-HSA-8948751 | 3.402808e-01 | 0.468 | 0 | 0 |
| Signaling by FGFR in disease | R-HSA-1226099 | 3.541553e-01 | 0.451 | 0 | 0 |
| Signaling by NOTCH4 | R-HSA-9013694 | 3.541553e-01 | 0.451 | 0 | 0 |
| EGR2 and SOX10-mediated initiation of Schwann cell myelination | R-HSA-9619665 | 3.158183e-01 | 0.501 | 0 | 0 |
| TP53 Regulates Metabolic Genes | R-HSA-5628897 | 3.065943e-01 | 0.513 | 0 | 0 |
| Histamine receptors | R-HSA-390650 | 3.716022e-01 | 0.430 | 0 | 0 |
| TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain | R-HSA-6804115 | 2.641957e-01 | 0.578 | 0 | 0 |
| Suppression of apoptosis | R-HSA-9635465 | 3.734454e-01 | 0.428 | 0 | 0 |
| PECAM1 interactions | R-HSA-210990 | 3.734454e-01 | 0.428 | 0 | 0 |
| Immune System | R-HSA-168256 | 2.900827e-01 | 0.537 | 1 | 0 |
| Signaling by FGFR2 | R-HSA-5654738 | 4.319833e-01 | 0.365 | 0 | 0 |
| STAT3 nuclear events downstream of ALK signaling | R-HSA-9701898 | 2.600254e-01 | 0.585 | 0 | 0 |
| Mechanical load activates signaling by PIEZO1 and integrins in osteocytes | R-HSA-9856532 | 3.852704e-01 | 0.414 | 0 | 0 |
| Syndecan interactions | R-HSA-3000170 | 2.845591e-01 | 0.546 | 0 | 0 |
| TP53 Regulates Transcription of Cell Cycle Genes | R-HSA-6791312 | 2.610853e-01 | 0.583 | 0 | 0 |
| Activation, myristolyation of BID and translocation to mitochondria | R-HSA-75108 | 3.104072e-01 | 0.508 | 0 | 0 |
| Role of ABL in ROBO-SLIT signaling | R-HSA-428890 | 2.381434e-01 | 0.623 | 0 | 0 |
| Interleukin-18 signaling | R-HSA-9012546 | 2.723076e-01 | 0.565 | 0 | 0 |
| NFE2L2 regulating MDR associated enzymes | R-HSA-9818032 | 3.064102e-01 | 0.514 | 0 | 0 |
| Assembly and release of respiratory syncytial virus (RSV) virions | R-HSA-9820962 | 3.401934e-01 | 0.468 | 0 | 0 |
| NFE2L2 regulates pentose phosphate pathway genes | R-HSA-9818028 | 4.059947e-01 | 0.391 | 0 | 0 |
| Sodium/Calcium exchangers | R-HSA-425561 | 4.059947e-01 | 0.391 | 0 | 0 |
| Synthesis of IP3 and IP4 in the cytosol | R-HSA-1855204 | 2.979111e-01 | 0.526 | 0 | 0 |
| Sensory processing of sound | R-HSA-9659379 | 2.933474e-01 | 0.533 | 0 | 0 |
| Regulation of CDH11 gene transcription | R-HSA-9762293 | 3.064102e-01 | 0.514 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9694631 | 3.852704e-01 | 0.414 | 0 | 0 |
| Signaling by Hedgehog | R-HSA-5358351 | 3.703835e-01 | 0.431 | 0 | 0 |
| RUNX3 Regulates Immune Response and Cell Migration | R-HSA-8949275 | 2.381434e-01 | 0.623 | 0 | 0 |
| Respiratory syncytial virus genome replication | R-HSA-9834752 | 3.064102e-01 | 0.514 | 0 | 0 |
| IRF3-mediated induction of type I IFN | R-HSA-3270619 | 2.600254e-01 | 0.585 | 0 | 0 |
| Export of Viral Ribonucleoproteins from Nucleus | R-HSA-168274 | 2.400206e-01 | 0.620 | 0 | 0 |
| VxPx cargo-targeting to cilium | R-HSA-5620916 | 4.099980e-01 | 0.387 | 0 | 0 |
| BBSome-mediated cargo-targeting to cilium | R-HSA-5620922 | 4.099980e-01 | 0.387 | 0 | 0 |
| Expression of BMAL (ARNTL), CLOCK, and NPAS2 | R-HSA-9931509 | 4.245089e-01 | 0.372 | 0 | 0 |
| Cyclin E associated events during G1/S transition | R-HSA-69202 | 4.380297e-01 | 0.358 | 0 | 0 |
| Ion channel transport | R-HSA-983712 | 3.806632e-01 | 0.419 | 1 | 0 |
| FOXO-mediated transcription | R-HSA-9614085 | 4.444578e-01 | 0.352 | 0 | 0 |
| Specification of primordial germ cells | R-HSA-9827857 | 3.351967e-01 | 0.475 | 0 | 0 |
| Interleukin-4 and Interleukin-13 signaling | R-HSA-6785807 | 2.482768e-01 | 0.605 | 0 | 0 |
| Butyrophilin (BTN) family interactions | R-HSA-8851680 | 3.064102e-01 | 0.514 | 0 | 0 |
| Sensory processing of sound by outer hair cells of the cochlea | R-HSA-9662361 | 2.482954e-01 | 0.605 | 0 | 0 |
| Other interleukin signaling | R-HSA-449836 | 3.852704e-01 | 0.414 | 0 | 0 |
| NOTCH4 Intracellular Domain Regulates Transcription | R-HSA-9013695 | 4.344102e-01 | 0.362 | 0 | 0 |
| Signaling by Leptin | R-HSA-2586552 | 3.401934e-01 | 0.468 | 0 | 0 |
| STING mediated induction of host immune responses | R-HSA-1834941 | 3.852704e-01 | 0.414 | 0 | 0 |
| Interleukin-37 signaling | R-HSA-9008059 | 4.295498e-01 | 0.367 | 0 | 0 |
| IRS-related events triggered by IGF1R | R-HSA-2428928 | 4.594331e-01 | 0.338 | 0 | 0 |
| SPOP-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929491 | 4.602836e-01 | 0.337 | 0 | 0 |
| Resolution of Abasic Sites (AP sites) | R-HSA-73933 | 4.602836e-01 | 0.337 | 0 | 0 |
| HDR through MMEJ (alt-NHEJ) | R-HSA-5685939 | 4.684668e-01 | 0.329 | 0 | 0 |
| Frs2-mediated activation | R-HSA-170968 | 4.684668e-01 | 0.329 | 0 | 0 |
| Maturation of nucleoprotein | R-HSA-9683610 | 4.684668e-01 | 0.329 | 0 | 0 |
| Signaling by membrane-tethered fusions of PDGFRA or PDGFRB | R-HSA-9673768 | 4.781917e-01 | 0.320 | 0 | 0 |
| Post-transcriptional silencing by small RNAs | R-HSA-426496 | 4.781917e-01 | 0.320 | 0 | 0 |
| LRR FLII-interacting protein 1 (LRRFIP1) activates type I IFN production | R-HSA-3134973 | 4.781917e-01 | 0.320 | 0 | 0 |
| Muscarinic acetylcholine receptors | R-HSA-390648 | 4.781917e-01 | 0.320 | 0 | 0 |
| Biosynthesis of DPAn-3-derived 13-series resolvins | R-HSA-9026403 | 4.781917e-01 | 0.320 | 0 | 0 |
| NrCAM interactions | R-HSA-447038 | 4.781917e-01 | 0.320 | 0 | 0 |
| Co-inhibition by BTLA | R-HSA-9927353 | 4.781917e-01 | 0.320 | 0 | 0 |
| Phosphorylation and nuclear translocation of BMAL1 (ARNTL) and CLOCK | R-HSA-9931529 | 4.781917e-01 | 0.320 | 0 | 0 |
| Negative regulation of the PI3K/AKT network | R-HSA-199418 | 4.788009e-01 | 0.320 | 0 | 0 |
| Notch-HLH transcription pathway | R-HSA-350054 | 4.820166e-01 | 0.317 | 0 | 0 |
| Downregulation of TGF-beta receptor signaling | R-HSA-2173788 | 4.820166e-01 | 0.317 | 0 | 0 |
| NOTCH3 Activation and Transmission of Signal to the Nucleus | R-HSA-9013507 | 4.820166e-01 | 0.317 | 0 | 0 |
| LDL clearance | R-HSA-8964038 | 4.820166e-01 | 0.317 | 0 | 0 |
| Inositol phosphate metabolism | R-HSA-1483249 | 4.827804e-01 | 0.316 | 0 | 0 |
| Signaling by TGFB family members | R-HSA-9006936 | 4.874088e-01 | 0.312 | 0 | 0 |
| G1/S DNA Damage Checkpoints | R-HSA-69615 | 4.887474e-01 | 0.311 | 0 | 0 |
| Resolution of D-loop Structures through Holliday Junction Intermediates | R-HSA-5693568 | 4.898583e-01 | 0.310 | 0 | 0 |
| Nuclear RNA decay | R-HSA-9930044 | 4.898583e-01 | 0.310 | 0 | 0 |
| Cardiogenesis | R-HSA-9733709 | 4.898583e-01 | 0.310 | 0 | 0 |
| Cyclin A/B1/B2 associated events during G2/M transition | R-HSA-69273 | 4.898583e-01 | 0.310 | 0 | 0 |
| Retrograde neurotrophin signalling | R-HSA-177504 | 4.982007e-01 | 0.303 | 0 | 0 |
| Malate-aspartate shuttle | R-HSA-9856872 | 4.982007e-01 | 0.303 | 0 | 0 |
| Regulation of KIT signaling | R-HSA-1433559 | 4.982007e-01 | 0.303 | 0 | 0 |
| Signaling by FGFR4 in disease | R-HSA-5655291 | 4.982007e-01 | 0.303 | 0 | 0 |
| Constitutive Signaling by Aberrant PI3K in Cancer | R-HSA-2219530 | 4.993863e-01 | 0.302 | 0 | 0 |
| Regulation of actin dynamics for phagocytic cup formation | R-HSA-2029482 | 5.014436e-01 | 0.300 | 0 | 0 |
| IGF1R signaling cascade | R-HSA-2428924 | 5.032305e-01 | 0.298 | 0 | 0 |
| Interleukin receptor SHC signaling | R-HSA-912526 | 5.050964e-01 | 0.297 | 0 | 0 |
| Growth hormone receptor signaling | R-HSA-982772 | 5.050964e-01 | 0.297 | 0 | 0 |
| Regulation of CDH1 posttranslational processing and trafficking to plasma membrane | R-HSA-9768727 | 5.093827e-01 | 0.293 | 0 | 0 |
| Resolution of D-Loop Structures | R-HSA-5693537 | 5.093827e-01 | 0.293 | 0 | 0 |
| TGF-beta receptor signaling activates SMADs | R-HSA-2173789 | 5.126133e-01 | 0.290 | 0 | 0 |
| Signaling by SCF-KIT | R-HSA-1433557 | 5.126133e-01 | 0.290 | 0 | 0 |
| Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | R-HSA-2404192 | 5.175760e-01 | 0.286 | 0 | 0 |
| Plus-strand DNA synthesis | R-HSA-164525 | 5.245056e-01 | 0.280 | 0 | 0 |
| Nef Mediated CD8 Down-regulation | R-HSA-182218 | 5.245056e-01 | 0.280 | 0 | 0 |
| Phosphorylation of Emi1 | R-HSA-176417 | 5.245056e-01 | 0.280 | 0 | 0 |
| PKB-mediated events | R-HSA-109703 | 5.245056e-01 | 0.280 | 0 | 0 |
| PDE3B signalling | R-HSA-165160 | 5.245056e-01 | 0.280 | 0 | 0 |
| Signaling by Overexpressed Wild-Type EGFR in Cancer | R-HSA-5638302 | 5.245056e-01 | 0.280 | 0 | 0 |
| Inhibition of Signaling by Overexpressed EGFR | R-HSA-5638303 | 5.245056e-01 | 0.280 | 0 | 0 |
| Loss-of-function mutations in DLD cause MSUD3/DLDD | R-HSA-9907570 | 5.245056e-01 | 0.280 | 0 | 0 |
| Loss-of-function mutations in DBT cause MSUD2 | R-HSA-9865113 | 5.245056e-01 | 0.280 | 0 | 0 |
| PKA-mediated phosphorylation of key metabolic factors | R-HSA-163358 | 5.245056e-01 | 0.280 | 0 | 0 |
| Pentose phosphate pathway disease | R-HSA-6791465 | 5.245056e-01 | 0.280 | 0 | 0 |
| CDC6 association with the ORC:origin complex | R-HSA-68689 | 5.245056e-01 | 0.280 | 0 | 0 |
| IkBA variant leads to EDA-ID | R-HSA-5603029 | 5.245056e-01 | 0.280 | 0 | 0 |
| Cam-PDE 1 activation | R-HSA-111957 | 5.245056e-01 | 0.280 | 0 | 0 |
| Synthesis of PS | R-HSA-1483101 | 5.245056e-01 | 0.280 | 0 | 0 |
| Intestinal hexose absorption | R-HSA-8981373 | 5.245056e-01 | 0.280 | 0 | 0 |
| Signalling to p38 via RIT and RIN | R-HSA-187706 | 5.245056e-01 | 0.280 | 0 | 0 |
| Release of apoptotic factors from the mitochondria | R-HSA-111457 | 5.245056e-01 | 0.280 | 0 | 0 |
| SLC15A4:TASL-dependent IRF5 activation | R-HSA-9860276 | 5.245056e-01 | 0.280 | 0 | 0 |
| TYSND1 cleaves peroxisomal proteins | R-HSA-9033500 | 5.245056e-01 | 0.280 | 0 | 0 |
| SMAC, XIAP-regulated apoptotic response | R-HSA-111469 | 5.245056e-01 | 0.280 | 0 | 0 |
| Processive synthesis on the lagging strand | R-HSA-69183 | 5.268464e-01 | 0.278 | 0 | 0 |
| G beta:gamma signalling through BTK | R-HSA-8964315 | 5.268464e-01 | 0.278 | 0 | 0 |
| DCC mediated attractive signaling | R-HSA-418885 | 5.268464e-01 | 0.278 | 0 | 0 |
| Tristetraprolin (TTP, ZFP36) binds and destabilizes mRNA | R-HSA-450513 | 5.268464e-01 | 0.278 | 0 | 0 |
| Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants | R-HSA-9673767 | 5.268464e-01 | 0.278 | 0 | 0 |
| Signaling by PDGFRA extracellular domain mutants | R-HSA-9673770 | 5.268464e-01 | 0.278 | 0 | 0 |
| Formation of the anterior neural plate | R-HSA-9823739 | 5.268464e-01 | 0.278 | 0 | 0 |
| TRAF6 mediated NF-kB activation | R-HSA-933542 | 5.276312e-01 | 0.278 | 0 | 0 |
| Recognition of DNA damage by PCNA-containing replication complex | R-HSA-110314 | 5.276312e-01 | 0.278 | 0 | 0 |
| CD209 (DC-SIGN) signaling | R-HSA-5621575 | 5.276312e-01 | 0.278 | 0 | 0 |
| Signal amplification | R-HSA-392518 | 5.285611e-01 | 0.277 | 0 | 0 |
| Regulation of TLR by endogenous ligand | R-HSA-5686938 | 5.285611e-01 | 0.277 | 0 | 0 |
| Calnexin/calreticulin cycle | R-HSA-901042 | 5.285611e-01 | 0.277 | 0 | 0 |
| MLL4 and MLL3 complexes regulate expression of PPARG target genes in adipogenesis and hepatic steatosis | R-HSA-9841922 | 5.380677e-01 | 0.269 | 0 | 0 |
| Epigenetic regulation of adipogenesis genes by MLL3 and MLL4 complexes | R-HSA-9851695 | 5.380677e-01 | 0.269 | 0 | 0 |
| Epigenetic regulation of gene expression by MLL3 and MLL4 complexes | R-HSA-9818564 | 5.380677e-01 | 0.269 | 0 | 0 |
| HDR through Homologous Recombination (HRR) | R-HSA-5685942 | 5.457952e-01 | 0.263 | 0 | 0 |
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | R-HSA-2173793 | 5.458687e-01 | 0.263 | 0 | 0 |
| TNF signaling | R-HSA-75893 | 5.458687e-01 | 0.263 | 0 | 0 |
| Fanconi Anemia Pathway | R-HSA-6783310 | 5.463076e-01 | 0.263 | 0 | 0 |
| ADORA2B mediated anti-inflammatory cytokines production | R-HSA-9660821 | 5.463076e-01 | 0.263 | 0 | 0 |
| Asymmetric localization of PCP proteins | R-HSA-4608870 | 5.463076e-01 | 0.263 | 0 | 0 |
| Vasopressin regulates renal water homeostasis via Aquaporins | R-HSA-432040 | 5.463076e-01 | 0.263 | 0 | 0 |
| SCF-beta-TrCP mediated degradation of Emi1 | R-HSA-174113 | 5.473653e-01 | 0.262 | 0 | 0 |
| Regulation of Apoptosis | R-HSA-169911 | 5.473653e-01 | 0.262 | 0 | 0 |
| Oncogene Induced Senescence | R-HSA-2559585 | 5.473653e-01 | 0.262 | 0 | 0 |
| Tight junction interactions | R-HSA-420029 | 5.495832e-01 | 0.260 | 0 | 0 |
| VEGFR2 mediated cell proliferation | R-HSA-5218921 | 5.495832e-01 | 0.260 | 0 | 0 |
| PIWI-interacting RNA (piRNA) biogenesis | R-HSA-5601884 | 5.495832e-01 | 0.260 | 0 | 0 |
| Regulation of glycolysis by fructose 2,6-bisphosphate metabolism | R-HSA-9634600 | 5.543627e-01 | 0.256 | 0 | 0 |
| Prolonged ERK activation events | R-HSA-169893 | 5.543627e-01 | 0.256 | 0 | 0 |
| Fatty Acids bound to GPR40 (FFAR1) regulate insulin secretion | R-HSA-434316 | 5.543627e-01 | 0.256 | 0 | 0 |
| Activation of SMO | R-HSA-5635838 | 5.543627e-01 | 0.256 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest | R-HSA-6804116 | 5.543627e-01 | 0.256 | 0 | 0 |
| Virus Assembly and Release | R-HSA-168268 | 5.543627e-01 | 0.256 | 0 | 0 |
| IRS-mediated signalling | R-HSA-112399 | 5.608398e-01 | 0.251 | 0 | 0 |
| Formation of TC-NER Pre-Incision Complex | R-HSA-6781823 | 5.627316e-01 | 0.250 | 0 | 0 |
| Regulation of TNFR1 signaling | R-HSA-5357905 | 5.627316e-01 | 0.250 | 0 | 0 |
| RNA Polymerase III Abortive And Retractive Initiation | R-HSA-749476 | 5.657703e-01 | 0.247 | 0 | 0 |
| RNA Polymerase III Transcription | R-HSA-74158 | 5.657703e-01 | 0.247 | 0 | 0 |
| FLT3 signaling in disease | R-HSA-9682385 | 5.657703e-01 | 0.247 | 0 | 0 |
| PTK6 promotes HIF1A stabilization | R-HSA-8857538 | 5.667114e-01 | 0.247 | 0 | 0 |
| Erythropoietin activates STAT5 | R-HSA-9027283 | 5.667114e-01 | 0.247 | 0 | 0 |
| RUNX3 regulates YAP1-mediated transcription | R-HSA-8951671 | 5.667114e-01 | 0.247 | 0 | 0 |
| Uncoating of the HIV Virion | R-HSA-162585 | 5.667114e-01 | 0.247 | 0 | 0 |
| H139Hfs13* PPM1K causes a mild variant of MSUD | R-HSA-9912529 | 5.667114e-01 | 0.247 | 0 | 0 |
| Branched-chain ketoacid dehydrogenase kinase deficiency | R-HSA-9912481 | 5.667114e-01 | 0.247 | 0 | 0 |
| RAS signaling downstream of NF1 loss-of-function variants | R-HSA-6802953 | 5.667114e-01 | 0.247 | 0 | 0 |
| E2F-enabled inhibition of pre-replication complex formation | R-HSA-113507 | 5.667114e-01 | 0.247 | 0 | 0 |
| Loss-of-function mutations in BCKDHA or BCKDHB cause MSUD | R-HSA-9865125 | 5.667114e-01 | 0.247 | 0 | 0 |
| Defective SLC16A1 causes symptomatic deficiency in lactate transport (SDLT) | R-HSA-5619070 | 5.667114e-01 | 0.247 | 0 | 0 |
| MET Receptor Activation | R-HSA-6806942 | 5.667114e-01 | 0.247 | 0 | 0 |
| Toxicity of botulinum toxin type F (botF) | R-HSA-5250981 | 5.667114e-01 | 0.247 | 0 | 0 |
| Toxicity of botulinum toxin type D (botD) | R-HSA-5250955 | 5.667114e-01 | 0.247 | 0 | 0 |
| G2/M DNA replication checkpoint | R-HSA-69478 | 5.667114e-01 | 0.247 | 0 | 0 |
| Neurofascin interactions | R-HSA-447043 | 5.667114e-01 | 0.247 | 0 | 0 |
| VLDL assembly | R-HSA-8866423 | 5.667114e-01 | 0.247 | 0 | 0 |
| Transport to the Golgi and subsequent modification | R-HSA-948021 | 5.771310e-01 | 0.239 | 0 | 0 |
| Signaling by NTRKs | R-HSA-166520 | 5.775978e-01 | 0.238 | 0 | 0 |
| Processing of Intronless Pre-mRNAs | R-HSA-77595 | 5.807245e-01 | 0.236 | 0 | 0 |
| TRAF3-dependent IRF activation pathway | R-HSA-918233 | 5.807245e-01 | 0.236 | 0 | 0 |
| TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest | R-HSA-6804114 | 5.807245e-01 | 0.236 | 0 | 0 |
| TFAP2 (AP-2) family regulates transcription of growth factors and their receptors | R-HSA-8866910 | 5.807245e-01 | 0.236 | 0 | 0 |
| Gastrulation | R-HSA-9758941 | 5.868059e-01 | 0.232 | 0 | 0 |
| Synthesis of active ubiquitin: roles of E1 and E2 enzymes | R-HSA-8866652 | 5.916207e-01 | 0.228 | 0 | 0 |
| GPER1 signaling | R-HSA-9634597 | 5.946454e-01 | 0.226 | 0 | 0 |
| MET promotes cell motility | R-HSA-8875878 | 6.012998e-01 | 0.221 | 0 | 0 |
| RUNX3 regulates WNT signaling | R-HSA-8951430 | 6.051732e-01 | 0.218 | 0 | 0 |
| PP2A-mediated dephosphorylation of key metabolic factors | R-HSA-163767 | 6.051732e-01 | 0.218 | 0 | 0 |
| Binding of TCF/LEF:CTNNB1 to target gene promoters | R-HSA-4411364 | 6.051732e-01 | 0.218 | 0 | 0 |
| IFNG signaling activates MAPKs | R-HSA-9732724 | 6.051732e-01 | 0.218 | 0 | 0 |
| Recycling of eIF2:GDP | R-HSA-72731 | 6.051732e-01 | 0.218 | 0 | 0 |
| Pre-NOTCH Processing in the Endoplasmic Reticulum | R-HSA-1912399 | 6.051732e-01 | 0.218 | 0 | 0 |
| Disinhibition of SNARE formation | R-HSA-114516 | 6.051732e-01 | 0.218 | 0 | 0 |
| Insulin effects increased synthesis of Xylulose-5-Phosphate | R-HSA-163754 | 6.051732e-01 | 0.218 | 0 | 0 |
| Nef Mediated CD4 Down-regulation | R-HSA-167590 | 6.051732e-01 | 0.218 | 0 | 0 |
| VLDL clearance | R-HSA-8964046 | 6.051732e-01 | 0.218 | 0 | 0 |
| LDL remodeling | R-HSA-8964041 | 6.051732e-01 | 0.218 | 0 | 0 |
| Regulation of PTEN localization | R-HSA-8948747 | 6.051732e-01 | 0.218 | 0 | 0 |
| Cation-coupled Chloride cotransporters | R-HSA-426117 | 6.051732e-01 | 0.218 | 0 | 0 |
| POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation | R-HSA-2892245 | 6.051732e-01 | 0.218 | 0 | 0 |
| Displacement of DNA glycosylase by APEX1 | R-HSA-110357 | 6.051732e-01 | 0.218 | 0 | 0 |
| Regulation of NPAS4 gene expression | R-HSA-9768759 | 6.059199e-01 | 0.218 | 0 | 0 |
| Modulation of host responses by IFN-stimulated genes | R-HSA-9909505 | 6.059199e-01 | 0.218 | 0 | 0 |
| Choline catabolism | R-HSA-6798163 | 6.059199e-01 | 0.218 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH3 (MutSbeta) | R-HSA-5358606 | 6.059199e-01 | 0.218 | 0 | 0 |
| Mismatch repair (MMR) directed by MSH2:MSH6 (MutSalpha) | R-HSA-5358565 | 6.059199e-01 | 0.218 | 0 | 0 |
| Stabilization of p53 | R-HSA-69541 | 6.183906e-01 | 0.209 | 0 | 0 |
| GSK3B-mediated proteasomal degradation of PD-L1(CD274) | R-HSA-9929356 | 6.183906e-01 | 0.209 | 0 | 0 |
| Differentiation of Keratinocytes in Interfollicular Epidermis in Mammalian Skin | R-HSA-9725554 | 6.183906e-01 | 0.209 | 0 | 0 |
| Respiratory syncytial virus (RSV) genome replication, transcription and translation | R-HSA-9820965 | 6.183906e-01 | 0.209 | 0 | 0 |
| PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling | R-HSA-6811558 | 6.194031e-01 | 0.208 | 0 | 0 |
| Regulation of RAS by GAPs | R-HSA-5658442 | 6.252183e-01 | 0.204 | 0 | 0 |
| Azathioprine ADME | R-HSA-9748787 | 6.252183e-01 | 0.204 | 0 | 0 |
| Trafficking of GluR2-containing AMPA receptors | R-HSA-416993 | 6.299484e-01 | 0.201 | 0 | 0 |
| Serotonin Neurotransmitter Release Cycle | R-HSA-181429 | 6.299484e-01 | 0.201 | 0 | 0 |
| Regulation of TP53 Activity through Methylation | R-HSA-6804760 | 6.299484e-01 | 0.201 | 0 | 0 |
| Nephron development | R-HSA-9831926 | 6.299484e-01 | 0.201 | 0 | 0 |
| Mismatch Repair | R-HSA-5358508 | 6.299484e-01 | 0.201 | 0 | 0 |
| Tie2 Signaling | R-HSA-210993 | 6.299484e-01 | 0.201 | 0 | 0 |
| Signaling by Erythropoietin | R-HSA-9006335 | 6.310330e-01 | 0.200 | 0 | 0 |
| Late endosomal microautophagy | R-HSA-9615710 | 6.310330e-01 | 0.200 | 0 | 0 |
| MAPK targets/ Nuclear events mediated by MAP kinases | R-HSA-450282 | 6.310330e-01 | 0.200 | 0 | 0 |
| Heme signaling | R-HSA-9707616 | 6.318908e-01 | 0.199 | 0 | 0 |
| Regulation of RUNX3 expression and activity | R-HSA-8941858 | 6.350146e-01 | 0.197 | 0 | 0 |
| Glycogen metabolism | R-HSA-8982491 | 6.350146e-01 | 0.197 | 0 | 0 |
| Activation of NF-kappaB in B cells | R-HSA-1169091 | 6.399732e-01 | 0.194 | 0 | 0 |
| Reverse Transcription of HIV RNA | R-HSA-162589 | 6.402229e-01 | 0.194 | 0 | 0 |
| Minus-strand DNA synthesis | R-HSA-164516 | 6.402229e-01 | 0.194 | 0 | 0 |
| EGFR interacts with phospholipase C-gamma | R-HSA-212718 | 6.402229e-01 | 0.194 | 0 | 0 |
| phospho-PLA2 pathway | R-HSA-111995 | 6.402229e-01 | 0.194 | 0 | 0 |
| Regulation of NPAS4 mRNA translation | R-HSA-9768778 | 6.402229e-01 | 0.194 | 0 | 0 |
| Axonal growth inhibition (RHOA activation) | R-HSA-193634 | 6.402229e-01 | 0.194 | 0 | 0 |
| TGFBR3 PTM regulation | R-HSA-9839383 | 6.402229e-01 | 0.194 | 0 | 0 |
| Regulation of TBK1, IKKε-mediated activation of IRF3, IRF7 upon TLR3 ligation | R-HSA-9828211 | 6.402229e-01 | 0.194 | 0 | 0 |
| SLC-mediated bile acid transport | R-HSA-9958517 | 6.402229e-01 | 0.194 | 0 | 0 |
| Adrenoceptors | R-HSA-390696 | 6.402229e-01 | 0.194 | 0 | 0 |
| PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 | R-HSA-8849469 | 6.402229e-01 | 0.194 | 0 | 0 |
| Intestinal absorption | R-HSA-8963676 | 6.402229e-01 | 0.194 | 0 | 0 |
| Interleukin-23 signaling | R-HSA-9020933 | 6.402229e-01 | 0.194 | 0 | 0 |
| Disease | R-HSA-1643685 | 6.464473e-01 | 0.189 | 1 | 0 |
| Thrombin signalling through proteinase activated receptors (PARs) | R-HSA-456926 | 6.497229e-01 | 0.187 | 0 | 0 |
| GABA synthesis, release, reuptake and degradation | R-HSA-888590 | 6.497229e-01 | 0.187 | 0 | 0 |
| Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation | R-HSA-1474151 | 6.497229e-01 | 0.187 | 0 | 0 |
| RORA,B,C and NR1D1 (REV-ERBA) regulate gene expression | R-HSA-9933387 | 6.497229e-01 | 0.187 | 0 | 0 |
| PI-3K cascade:FGFR3 | R-HSA-5654710 | 6.528184e-01 | 0.185 | 0 | 0 |
| Impaired BRCA2 binding to PALB2 | R-HSA-9709603 | 6.528184e-01 | 0.185 | 0 | 0 |
| Prostacyclin signalling through prostacyclin receptor | R-HSA-392851 | 6.528184e-01 | 0.185 | 0 | 0 |
| Gastrin-CREB signalling pathway via PKC and MAPK | R-HSA-881907 | 6.528184e-01 | 0.185 | 0 | 0 |
| Signaling by FGFR2 IIIa TM | R-HSA-8851708 | 6.528184e-01 | 0.185 | 0 | 0 |
| Regulation of signaling by CBL | R-HSA-912631 | 6.528184e-01 | 0.185 | 0 | 0 |
| Generic Transcription Pathway | R-HSA-212436 | 6.531281e-01 | 0.185 | 1 | 0 |
| Neurexins and neuroligins | R-HSA-6794361 | 6.543620e-01 | 0.184 | 0 | 0 |
| Regulation of TP53 Activity through Phosphorylation | R-HSA-6804756 | 6.559536e-01 | 0.183 | 0 | 0 |
| Insulin receptor signalling cascade | R-HSA-74751 | 6.583424e-01 | 0.182 | 0 | 0 |
| CLEC7A (Dectin-1) signaling | R-HSA-5607764 | 6.611792e-01 | 0.180 | 0 | 0 |
| UCH proteinases | R-HSA-5689603 | 6.626793e-01 | 0.179 | 0 | 0 |
| Neuronal System | R-HSA-112316 | 6.635286e-01 | 0.178 | 1 | 0 |
| Degradation of GLI1 by the proteasome | R-HSA-5610780 | 6.668257e-01 | 0.176 | 0 | 0 |
| GLI3 is processed to GLI3R by the proteasome | R-HSA-5610785 | 6.668257e-01 | 0.176 | 0 | 0 |
| Degradation of GLI2 by the proteasome | R-HSA-5610783 | 6.668257e-01 | 0.176 | 0 | 0 |
| Evasion by RSV of host interferon responses | R-HSA-9833109 | 6.677276e-01 | 0.175 | 0 | 0 |
| Lipophagy | R-HSA-9613354 | 6.721631e-01 | 0.173 | 0 | 0 |
| AKT phosphorylates targets in the nucleus | R-HSA-198693 | 6.721631e-01 | 0.173 | 0 | 0 |
| p75NTR regulates axonogenesis | R-HSA-193697 | 6.721631e-01 | 0.173 | 0 | 0 |
| Inactivation of CDC42 and RAC1 | R-HSA-428543 | 6.721631e-01 | 0.173 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex | R-HSA-937042 | 6.721631e-01 | 0.173 | 0 | 0 |
| Regulation of signaling by NODAL | R-HSA-1433617 | 6.721631e-01 | 0.173 | 0 | 0 |
| WNT mediated activation of DVL | R-HSA-201688 | 6.721631e-01 | 0.173 | 0 | 0 |
| Regulation of NPAS4 gene transcription | R-HSA-9768777 | 6.721631e-01 | 0.173 | 0 | 0 |
| Regulated proteolysis of p75NTR | R-HSA-193692 | 6.721631e-01 | 0.173 | 0 | 0 |
| Zinc influx into cells by the SLC39 gene family | R-HSA-442380 | 6.721631e-01 | 0.173 | 0 | 0 |
| Cellular response to mitochondrial stress | R-HSA-9840373 | 6.721631e-01 | 0.173 | 0 | 0 |
| PI-3K cascade:FGFR4 | R-HSA-5654720 | 6.745462e-01 | 0.171 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to PALB2 loss of function | R-HSA-9701193 | 6.745462e-01 | 0.171 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA1 binding function | R-HSA-9704331 | 6.745462e-01 | 0.171 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA1 loss of function | R-HSA-9701192 | 6.745462e-01 | 0.171 | 0 | 0 |
| Defective HDR through Homologous Recombination Repair (HRR) due to PALB2 loss of BRCA2/RAD51/RAD51C binding function | R-HSA-9704646 | 6.745462e-01 | 0.171 | 0 | 0 |
| Insertion of tail-anchored proteins into the endoplasmic reticulum membrane | R-HSA-9609523 | 6.745462e-01 | 0.171 | 0 | 0 |
| Signaling by NODAL | R-HSA-1181150 | 6.745462e-01 | 0.171 | 0 | 0 |
| Common Pathway of Fibrin Clot Formation | R-HSA-140875 | 6.745462e-01 | 0.171 | 0 | 0 |
| Cytosolic tRNA aminoacylation | R-HSA-379716 | 6.820005e-01 | 0.166 | 0 | 0 |
| Interleukin-3, Interleukin-5 and GM-CSF signaling | R-HSA-512988 | 6.820005e-01 | 0.166 | 0 | 0 |
| Signaling by FGFR | R-HSA-190236 | 6.820144e-01 | 0.166 | 0 | 0 |
| Downregulation of SMAD2/3:SMAD4 transcriptional activity | R-HSA-2173795 | 6.850459e-01 | 0.164 | 0 | 0 |
| Regulation of ornithine decarboxylase (ODC) | R-HSA-350562 | 6.850459e-01 | 0.164 | 0 | 0 |
| Integrin cell surface interactions | R-HSA-216083 | 6.860023e-01 | 0.164 | 0 | 0 |
| MyD88 deficiency (TLR2/4) | R-HSA-5602498 | 6.951545e-01 | 0.158 | 0 | 0 |
| NOTCH2 Activation and Transmission of Signal to the Nucleus | R-HSA-2979096 | 6.951545e-01 | 0.158 | 0 | 0 |
| G-protein activation | R-HSA-202040 | 6.951545e-01 | 0.158 | 0 | 0 |
| ADP signalling through P2Y purinoceptor 12 | R-HSA-392170 | 6.951545e-01 | 0.158 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in apoptosis | R-HSA-9824594 | 6.951545e-01 | 0.158 | 0 | 0 |
| Acetylcholine Neurotransmitter Release Cycle | R-HSA-264642 | 6.951545e-01 | 0.158 | 0 | 0 |
| JNK (c-Jun kinases) phosphorylation and activation mediated by activated human TAK1 | R-HSA-450321 | 6.951545e-01 | 0.158 | 0 | 0 |
| ERK/MAPK targets | R-HSA-198753 | 6.951545e-01 | 0.158 | 0 | 0 |
| G alpha (z) signalling events | R-HSA-418597 | 6.952704e-01 | 0.158 | 0 | 0 |
| Signaling by NOTCH3 | R-HSA-9012852 | 6.952704e-01 | 0.158 | 0 | 0 |
| Response of Mtb to phagocytosis | R-HSA-9637690 | 6.966836e-01 | 0.157 | 0 | 0 |
| Metabolism of proteins | R-HSA-392499 | 6.976454e-01 | 0.156 | 0 | 0 |
| Downstream TCR signaling | R-HSA-202424 | 6.994560e-01 | 0.155 | 0 | 0 |
| Erythropoietin activates Phospholipase C gamma (PLCG) | R-HSA-9027277 | 7.012694e-01 | 0.154 | 0 | 0 |
| Activation of Ca-permeable Kainate Receptor | R-HSA-451308 | 7.012694e-01 | 0.154 | 0 | 0 |
| TICAM1,TRAF6-dependent induction of TAK1 complex | R-HSA-9014325 | 7.012694e-01 | 0.154 | 0 | 0 |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | R-HSA-2151209 | 7.012694e-01 | 0.154 | 0 | 0 |
| CASP4 inflammasome assembly | R-HSA-9948001 | 7.012694e-01 | 0.154 | 0 | 0 |
| Tandem pore domain potassium channels | R-HSA-1296346 | 7.012694e-01 | 0.154 | 0 | 0 |
| Interleukin-27 signaling | R-HSA-9020956 | 7.012694e-01 | 0.154 | 0 | 0 |
| Receptor Mediated Mitophagy | R-HSA-8934903 | 7.012694e-01 | 0.154 | 0 | 0 |
| Maturation of spike protein | R-HSA-9683686 | 7.012694e-01 | 0.154 | 0 | 0 |
| KEAP1-NFE2L2 pathway | R-HSA-9755511 | 7.016533e-01 | 0.154 | 0 | 0 |
| Detoxification of Reactive Oxygen Species | R-HSA-3299685 | 7.081408e-01 | 0.150 | 0 | 0 |
| Proteasome assembly | R-HSA-9907900 | 7.108743e-01 | 0.148 | 0 | 0 |
| DAP12 interactions | R-HSA-2172127 | 7.108743e-01 | 0.148 | 0 | 0 |
| Netrin-1 signaling | R-HSA-373752 | 7.108743e-01 | 0.148 | 0 | 0 |
| Surfactant metabolism | R-HSA-5683826 | 7.108743e-01 | 0.148 | 0 | 0 |
| Adipogenesis | R-HSA-9843745 | 7.110346e-01 | 0.148 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 2 Promoter | R-HSA-76066 | 7.146706e-01 | 0.146 | 0 | 0 |
| IRAK4 deficiency (TLR2/4) | R-HSA-5603041 | 7.146706e-01 | 0.146 | 0 | 0 |
| Signaling by NTRK3 (TRKC) | R-HSA-9034015 | 7.146706e-01 | 0.146 | 0 | 0 |
| Effects of PIP2 hydrolysis | R-HSA-114508 | 7.176362e-01 | 0.144 | 0 | 0 |
| Vpu mediated degradation of CD4 | R-HSA-180534 | 7.176362e-01 | 0.144 | 0 | 0 |
| Miscellaneous transport and binding events | R-HSA-5223345 | 7.176362e-01 | 0.144 | 0 | 0 |
| Regulation of CDH11 mRNA translation by microRNAs | R-HSA-9759811 | 7.277931e-01 | 0.138 | 0 | 0 |
| Truncations of AMER1 destabilize the destruction complex | R-HSA-5467348 | 7.277931e-01 | 0.138 | 0 | 0 |
| APC truncation mutants have impaired AXIN binding | R-HSA-5467337 | 7.277931e-01 | 0.138 | 0 | 0 |
| AXIN missense mutants destabilize the destruction complex | R-HSA-5467340 | 7.277931e-01 | 0.138 | 0 | 0 |
| Ionotropic activity of kainate receptors | R-HSA-451306 | 7.277931e-01 | 0.138 | 0 | 0 |
| Signaling by APC mutants | R-HSA-4839744 | 7.277931e-01 | 0.138 | 0 | 0 |
| vRNA Synthesis | R-HSA-192814 | 7.277931e-01 | 0.138 | 0 | 0 |
| vRNP Assembly | R-HSA-192905 | 7.277931e-01 | 0.138 | 0 | 0 |
| Chylomicron assembly | R-HSA-8963888 | 7.277931e-01 | 0.138 | 0 | 0 |
| Bicarbonate transporters | R-HSA-425381 | 7.277931e-01 | 0.138 | 0 | 0 |
| Alpha-protein kinase 1 signaling pathway | R-HSA-9645460 | 7.277931e-01 | 0.138 | 0 | 0 |
| Biosynthesis of DPAn-3-derived maresins | R-HSA-9026290 | 7.277931e-01 | 0.138 | 0 | 0 |
| RUNX2 regulates genes involved in cell migration | R-HSA-8941332 | 7.277931e-01 | 0.138 | 0 | 0 |
| Dissolution of Fibrin Clot | R-HSA-75205 | 7.277931e-01 | 0.138 | 0 | 0 |
| Signaling by Insulin receptor | R-HSA-74752 | 7.296608e-01 | 0.137 | 0 | 0 |
| Degradation of beta-catenin by the destruction complex | R-HSA-195253 | 7.302901e-01 | 0.137 | 0 | 0 |
| Cytosolic sensors of pathogen-associated DNA | R-HSA-1834949 | 7.302901e-01 | 0.137 | 0 | 0 |
| NOD1/2 Signaling Pathway | R-HSA-168638 | 7.329214e-01 | 0.135 | 0 | 0 |
| Antigen Presentation: Folding, assembly and peptide loading of class I MHC | R-HSA-983170 | 7.329214e-01 | 0.135 | 0 | 0 |
| Mitophagy | R-HSA-5205647 | 7.329214e-01 | 0.135 | 0 | 0 |
| Autodegradation of the E3 ubiquitin ligase COP1 | R-HSA-349425 | 7.329214e-01 | 0.135 | 0 | 0 |
| Ubiquitin-dependent degradation of Cyclin D | R-HSA-75815 | 7.329214e-01 | 0.135 | 0 | 0 |
| BMAL1:CLOCK,NPAS2 activates circadian expression | R-HSA-1368108 | 7.329214e-01 | 0.135 | 0 | 0 |
| PI-3K cascade:FGFR1 | R-HSA-5654689 | 7.331261e-01 | 0.135 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 1 Promoter | R-HSA-76061 | 7.331261e-01 | 0.135 | 0 | 0 |
| Regulation of IFNA/IFNB signaling | R-HSA-912694 | 7.331261e-01 | 0.135 | 0 | 0 |
| Dopamine Neurotransmitter Release Cycle | R-HSA-212676 | 7.331261e-01 | 0.135 | 0 | 0 |
| Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants | R-HSA-9670439 | 7.331261e-01 | 0.135 | 0 | 0 |
| Regulation of MITF-M-dependent genes involved in lysosome biogenesis and autophagy | R-HSA-9857377 | 7.331261e-01 | 0.135 | 0 | 0 |
| TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain | R-HSA-6803205 | 7.331261e-01 | 0.135 | 0 | 0 |
| Signaling by KIT in disease | R-HSA-9669938 | 7.331261e-01 | 0.135 | 0 | 0 |
| Inactivation, recovery and regulation of the phototransduction cascade | R-HSA-2514859 | 7.377834e-01 | 0.132 | 0 | 0 |
| Presynaptic phase of homologous DNA pairing and strand exchange | R-HSA-5693616 | 7.475463e-01 | 0.126 | 0 | 0 |
| Signalling to ERKs | R-HSA-187687 | 7.475463e-01 | 0.126 | 0 | 0 |
| FBXL7 down-regulates AURKA during mitotic entry and in early mitosis | R-HSA-8854050 | 7.475463e-01 | 0.126 | 0 | 0 |
| Synthesis of PC | R-HSA-1483191 | 7.505085e-01 | 0.125 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE | R-HSA-77075 | 7.505553e-01 | 0.125 | 0 | 0 |
| RNA Pol II CTD phosphorylation and interaction with CE during HIV infection | R-HSA-167160 | 7.505553e-01 | 0.125 | 0 | 0 |
| Free fatty acids regulate insulin secretion | R-HSA-400451 | 7.505553e-01 | 0.125 | 0 | 0 |
| Nuclear Events (kinase and transcription factor activation) | R-HSA-198725 | 7.517364e-01 | 0.124 | 0 | 0 |
| Sema4D mediated inhibition of cell attachment and migration | R-HSA-416550 | 7.519633e-01 | 0.124 | 0 | 0 |
| Synthesis of diphthamide-EEF2 | R-HSA-5358493 | 7.519633e-01 | 0.124 | 0 | 0 |
| Signaling by GSK3beta mutants | R-HSA-5339716 | 7.519633e-01 | 0.124 | 0 | 0 |
| Proton-coupled monocarboxylate transport | R-HSA-433692 | 7.519633e-01 | 0.124 | 0 | 0 |
| Plasmalogen biosynthesis | R-HSA-75896 | 7.519633e-01 | 0.124 | 0 | 0 |
| ERKs are inactivated | R-HSA-202670 | 7.519633e-01 | 0.124 | 0 | 0 |
| Signaling by AMER1 mutants | R-HSA-4839748 | 7.519633e-01 | 0.124 | 0 | 0 |
| Signaling by AXIN mutants | R-HSA-4839735 | 7.519633e-01 | 0.124 | 0 | 0 |
| Regulation of TBK1, IKKε (IKBKE)-mediated activation of IRF3, IRF7 | R-HSA-9824878 | 7.519633e-01 | 0.124 | 0 | 0 |
| Activation of RAC1 | R-HSA-428540 | 7.519633e-01 | 0.124 | 0 | 0 |
| Condensation of Prometaphase Chromosomes | R-HSA-2514853 | 7.519633e-01 | 0.124 | 0 | 0 |
| TICAM1-dependent activation of IRF3/IRF7 | R-HSA-9013973 | 7.519633e-01 | 0.124 | 0 | 0 |
| tRNA Aminoacylation | R-HSA-379724 | 7.557659e-01 | 0.122 | 0 | 0 |
| DDX58/IFIH1-mediated induction of interferon-alpha/beta | R-HSA-168928 | 7.577383e-01 | 0.120 | 0 | 0 |
| Protein-protein interactions at synapses | R-HSA-6794362 | 7.592056e-01 | 0.120 | 0 | 0 |
| Vif-mediated degradation of APOBEC3G | R-HSA-180585 | 7.615231e-01 | 0.118 | 0 | 0 |
| NGF-stimulated transcription | R-HSA-9031628 | 7.627540e-01 | 0.118 | 0 | 0 |
| Respiratory Syncytial Virus Infection Pathway | R-HSA-9820952 | 7.662471e-01 | 0.116 | 0 | 0 |
| MAP kinase activation | R-HSA-450294 | 7.667150e-01 | 0.115 | 0 | 0 |
| Aquaporin-mediated transport | R-HSA-445717 | 7.667150e-01 | 0.115 | 0 | 0 |
| Thromboxane signalling through TP receptor | R-HSA-428930 | 7.669950e-01 | 0.115 | 0 | 0 |
| Processing of Capped Intronless Pre-mRNA | R-HSA-75067 | 7.669950e-01 | 0.115 | 0 | 0 |
| Norepinephrine Neurotransmitter Release Cycle | R-HSA-181430 | 7.669950e-01 | 0.115 | 0 | 0 |
| Mitochondrial RNA degradation | R-HSA-9836573 | 7.669950e-01 | 0.115 | 0 | 0 |
| Plasma lipoprotein assembly | R-HSA-8963898 | 7.669950e-01 | 0.115 | 0 | 0 |
| RAB GEFs exchange GTP for GDP on RABs | R-HSA-8876198 | 7.685788e-01 | 0.114 | 0 | 0 |
| MET activates RAS signaling | R-HSA-8851805 | 7.739886e-01 | 0.111 | 0 | 0 |
| NOTCH2 intracellular domain regulates transcription | R-HSA-2197563 | 7.739886e-01 | 0.111 | 0 | 0 |
| Maple Syrup Urine Disease | R-HSA-9865114 | 7.739886e-01 | 0.111 | 0 | 0 |
| Signaling by CTNNB1 phospho-site mutants | R-HSA-4839743 | 7.739886e-01 | 0.111 | 0 | 0 |
| CTNNB1 T41 mutants aren't phosphorylated | R-HSA-5358752 | 7.739886e-01 | 0.111 | 0 | 0 |
| CTNNB1 S37 mutants aren't phosphorylated | R-HSA-5358749 | 7.739886e-01 | 0.111 | 0 | 0 |
| CTNNB1 S45 mutants aren't phosphorylated | R-HSA-5358751 | 7.739886e-01 | 0.111 | 0 | 0 |
| CTNNB1 S33 mutants aren't phosphorylated | R-HSA-5358747 | 7.739886e-01 | 0.111 | 0 | 0 |
| GRB2 events in EGFR signaling | R-HSA-179812 | 7.739886e-01 | 0.111 | 0 | 0 |
| Advanced glycosylation endproduct receptor signaling | R-HSA-879415 | 7.739886e-01 | 0.111 | 0 | 0 |
| Biosynthesis of DPAn-3-derived protectins and resolvins | R-HSA-9026286 | 7.739886e-01 | 0.111 | 0 | 0 |
| Trafficking and processing of endosomal TLR | R-HSA-1679131 | 7.739886e-01 | 0.111 | 0 | 0 |
| IRAK1 recruits IKK complex | R-HSA-937039 | 7.739886e-01 | 0.111 | 0 | 0 |
| IRAK1 recruits IKK complex upon TLR7/8 or 9 stimulation | R-HSA-975144 | 7.739886e-01 | 0.111 | 0 | 0 |
| Regulation of IFNG signaling | R-HSA-877312 | 7.739886e-01 | 0.111 | 0 | 0 |
| Phosphorylation and nuclear translocation of the CRY:PER:kinase complex | R-HSA-9931530 | 7.739886e-01 | 0.111 | 0 | 0 |
| Interleukin-35 Signalling | R-HSA-8984722 | 7.739886e-01 | 0.111 | 0 | 0 |
| Reversal of alkylation damage by DNA dioxygenases | R-HSA-73943 | 7.739886e-01 | 0.111 | 0 | 0 |
| OAS antiviral response | R-HSA-8983711 | 7.739886e-01 | 0.111 | 0 | 0 |
| p53-Dependent G1/S DNA damage checkpoint | R-HSA-69580 | 7.745264e-01 | 0.111 | 0 | 0 |
| p53-Dependent G1 DNA Damage Response | R-HSA-69563 | 7.745264e-01 | 0.111 | 0 | 0 |
| N-glycan trimming in the ER and Calnexin/Calreticulin cycle | R-HSA-532668 | 7.745264e-01 | 0.111 | 0 | 0 |
| Degradation of DVL | R-HSA-4641258 | 7.748655e-01 | 0.111 | 0 | 0 |
| Degradation of AXIN | R-HSA-4641257 | 7.748655e-01 | 0.111 | 0 | 0 |
| GSK3B and BTRC:CUL1-mediated-degradation of NFE2L2 | R-HSA-9762114 | 7.748655e-01 | 0.111 | 0 | 0 |
| Ovarian tumor domain proteases | R-HSA-5689896 | 7.748655e-01 | 0.111 | 0 | 0 |
| RNA polymerase II transcribes snRNA genes | R-HSA-6807505 | 7.776826e-01 | 0.109 | 0 | 0 |
| PI-3K cascade:FGFR2 | R-HSA-5654695 | 7.824835e-01 | 0.107 | 0 | 0 |
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | R-HSA-997272 | 7.824835e-01 | 0.107 | 0 | 0 |
| G protein gated Potassium channels | R-HSA-1296059 | 7.824835e-01 | 0.107 | 0 | 0 |
| Activation of G protein gated Potassium channels | R-HSA-1296041 | 7.824835e-01 | 0.107 | 0 | 0 |
| Resolution of D-loop Structures through Synthesis-Dependent Strand Annealing (SDSA) | R-HSA-5693554 | 7.824835e-01 | 0.107 | 0 | 0 |
| Polymerase switching on the C-strand of the telomere | R-HSA-174411 | 7.824835e-01 | 0.107 | 0 | 0 |
| MicroRNA (miRNA) biogenesis | R-HSA-203927 | 7.824835e-01 | 0.107 | 0 | 0 |
| Transcriptional regulation by RUNX3 | R-HSA-8878159 | 7.836838e-01 | 0.106 | 0 | 0 |
| Signaling by FGFR2 in disease | R-HSA-5655253 | 7.858333e-01 | 0.105 | 0 | 0 |
| Leishmania phagocytosis | R-HSA-9664417 | 7.875406e-01 | 0.104 | 0 | 0 |
| Parasite infection | R-HSA-9664407 | 7.875406e-01 | 0.104 | 0 | 0 |
| FCGR3A-mediated phagocytosis | R-HSA-9664422 | 7.875406e-01 | 0.104 | 0 | 0 |
| Homologous DNA Pairing and Strand Exchange | R-HSA-5693579 | 7.875889e-01 | 0.104 | 0 | 0 |
| Post-translational protein phosphorylation | R-HSA-8957275 | 7.918625e-01 | 0.101 | 0 | 0 |
| Microbial factors inhibit CASP4 activity | R-HSA-9956593 | 7.940594e-01 | 0.100 | 0 | 0 |
| Golgi Cisternae Pericentriolar Stack Reorganization | R-HSA-162658 | 7.940594e-01 | 0.100 | 0 | 0 |
| NFE2L2 regulating tumorigenic genes | R-HSA-9818030 | 7.940594e-01 | 0.100 | 0 | 0 |
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | R-HSA-5676594 | 7.940594e-01 | 0.100 | 0 | 0 |
| CD28 dependent Vav1 pathway | R-HSA-389359 | 7.940594e-01 | 0.100 | 0 | 0 |
| Regulation of TP53 Activity through Association with Co-factors | R-HSA-6804759 | 7.940594e-01 | 0.100 | 0 | 0 |
| The phototransduction cascade | R-HSA-2514856 | 7.966832e-01 | 0.099 | 0 | 0 |
| Hedgehog ligand biogenesis | R-HSA-5358346 | 7.966832e-01 | 0.099 | 0 | 0 |
| MET activates PTK2 signaling | R-HSA-8874081 | 7.970599e-01 | 0.099 | 0 | 0 |
| Adrenaline,noradrenaline inhibits insulin secretion | R-HSA-400042 | 7.970599e-01 | 0.099 | 0 | 0 |
| Regulation of RUNX1 Expression and Activity | R-HSA-8934593 | 7.970599e-01 | 0.099 | 0 | 0 |
| Glutamate Neurotransmitter Release Cycle | R-HSA-210500 | 7.970599e-01 | 0.099 | 0 | 0 |
| Activated NOTCH1 Transmits Signal to the Nucleus | R-HSA-2122948 | 7.970599e-01 | 0.099 | 0 | 0 |
| Phosphorylated BMAL1:CLOCK (ARNTL:CLOCK) activates expression of core clock genes | R-HSA-9931510 | 7.970599e-01 | 0.099 | 0 | 0 |
| Cross-presentation of soluble exogenous antigens (endosomes) | R-HSA-1236978 | 7.997097e-01 | 0.097 | 0 | 0 |
| Plasma lipoprotein clearance | R-HSA-8964043 | 7.997097e-01 | 0.097 | 0 | 0 |
| Nuclear events mediated by NFE2L2 | R-HSA-9759194 | 8.028726e-01 | 0.095 | 0 | 0 |
| Transcriptional Regulation by NPAS4 | R-HSA-9634815 | 8.070853e-01 | 0.093 | 0 | 0 |
| Processive synthesis on the C-strand of the telomere | R-HSA-174414 | 8.107641e-01 | 0.091 | 0 | 0 |
| Cristae formation | R-HSA-8949613 | 8.107641e-01 | 0.091 | 0 | 0 |
| Phosphorylation of CD3 and TCR zeta chains | R-HSA-202427 | 8.107641e-01 | 0.091 | 0 | 0 |
| Disassembly of the destruction complex and recruitment of AXIN to the membrane | R-HSA-4641262 | 8.107641e-01 | 0.091 | 0 | 0 |
| Signaling by FGFR3 in disease | R-HSA-5655332 | 8.107641e-01 | 0.091 | 0 | 0 |
| Signaling by NTRK2 (TRKB) | R-HSA-9006115 | 8.107641e-01 | 0.091 | 0 | 0 |
| Diseases of Immune System | R-HSA-5260271 | 8.112452e-01 | 0.091 | 0 | 0 |
| Diseases associated with the TLR signaling cascade | R-HSA-5602358 | 8.112452e-01 | 0.091 | 0 | 0 |
| Interleukin-2 family signaling | R-HSA-451927 | 8.112452e-01 | 0.091 | 0 | 0 |
| Removal of the Flap Intermediate | R-HSA-69166 | 8.123488e-01 | 0.090 | 0 | 0 |
| BCKDH synthesizes BCAA-CoA from KIC, KMVA, KIV | R-HSA-9859138 | 8.123488e-01 | 0.090 | 0 | 0 |
| cGMP effects | R-HSA-418457 | 8.123488e-01 | 0.090 | 0 | 0 |
| CRMPs in Sema3A signaling | R-HSA-399956 | 8.123488e-01 | 0.090 | 0 | 0 |
| YAP1- and WWTR1 (TAZ)-stimulated gene expression | R-HSA-2032785 | 8.123488e-01 | 0.090 | 0 | 0 |
| IRAK2 mediated activation of TAK1 complex upon TLR7/8 or 9 stimulation | R-HSA-975163 | 8.123488e-01 | 0.090 | 0 | 0 |
| Hydrolysis of LPC | R-HSA-1483115 | 8.123488e-01 | 0.090 | 0 | 0 |
| Biosynthesis of E-series 18(R)-resolvins | R-HSA-9023661 | 8.123488e-01 | 0.090 | 0 | 0 |
| MAP3K8 (TPL2)-dependent MAPK1/3 activation | R-HSA-5684264 | 8.123488e-01 | 0.090 | 0 | 0 |
| Physiological factors | R-HSA-5578768 | 8.123488e-01 | 0.090 | 0 | 0 |
| Respiratory syncytial virus genome transcription | R-HSA-9828642 | 8.123488e-01 | 0.090 | 0 | 0 |
| NRIF signals cell death from the nucleus | R-HSA-205043 | 8.123488e-01 | 0.090 | 0 | 0 |
| Non-canonical inflammasome activation | R-HSA-9686114 | 8.123488e-01 | 0.090 | 0 | 0 |
| HDL assembly | R-HSA-8963896 | 8.123488e-01 | 0.090 | 0 | 0 |
| Acyl chain remodeling of CL | R-HSA-1482798 | 8.123488e-01 | 0.090 | 0 | 0 |
| Zinc transporters | R-HSA-435354 | 8.123488e-01 | 0.090 | 0 | 0 |
| Extracellular matrix organization | R-HSA-1474244 | 8.159653e-01 | 0.088 | 0 | 0 |
| Amino acids regulate mTORC1 | R-HSA-9639288 | 8.170497e-01 | 0.088 | 0 | 0 |
| Purine ribonucleoside monophosphate biosynthesis | R-HSA-73817 | 8.222133e-01 | 0.085 | 0 | 0 |
| Hh mutants are degraded by ERAD | R-HSA-5362768 | 8.222133e-01 | 0.085 | 0 | 0 |
| NIK-->noncanonical NF-kB signaling | R-HSA-5676590 | 8.222133e-01 | 0.085 | 0 | 0 |
| PINK1-PRKN Mediated Mitophagy | R-HSA-5205685 | 8.236360e-01 | 0.084 | 0 | 0 |
| Insulin receptor recycling | R-HSA-77387 | 8.236360e-01 | 0.084 | 0 | 0 |
| Competing endogenous RNAs (ceRNAs) regulate PTEN translation | R-HSA-8948700 | 8.290149e-01 | 0.081 | 0 | 0 |
| Erythropoietin activates RAS | R-HSA-9027284 | 8.290149e-01 | 0.081 | 0 | 0 |
| Beta-catenin phosphorylation cascade | R-HSA-196299 | 8.290149e-01 | 0.081 | 0 | 0 |
| SHC1 events in EGFR signaling | R-HSA-180336 | 8.290149e-01 | 0.081 | 0 | 0 |
| RNA Polymerase III Chain Elongation | R-HSA-73780 | 8.290149e-01 | 0.081 | 0 | 0 |
| Translesion synthesis by REV1 | R-HSA-110312 | 8.290149e-01 | 0.081 | 0 | 0 |
| TRAF6-mediated induction of TAK1 complex within TLR4 complex | R-HSA-937072 | 8.290149e-01 | 0.081 | 0 | 0 |
| RIP-mediated NFkB activation via ZBP1 | R-HSA-1810476 | 8.290149e-01 | 0.081 | 0 | 0 |
| Signaling by Activin | R-HSA-1502540 | 8.290149e-01 | 0.081 | 0 | 0 |
| p38MAPK events | R-HSA-171007 | 8.290149e-01 | 0.081 | 0 | 0 |
| TICAM1, RIP1-mediated IKK complex recruitment | R-HSA-168927 | 8.290149e-01 | 0.081 | 0 | 0 |
| Spry regulation of FGF signaling | R-HSA-1295596 | 8.290149e-01 | 0.081 | 0 | 0 |
| DNA Damage Reversal | R-HSA-73942 | 8.290149e-01 | 0.081 | 0 | 0 |
| Signaling by the B Cell Receptor (BCR) | R-HSA-983705 | 8.305069e-01 | 0.081 | 0 | 0 |
| Telomere C-strand (Lagging Strand) Synthesis | R-HSA-174417 | 8.326328e-01 | 0.080 | 0 | 0 |
| Degradation of CRY and PER proteins | R-HSA-9932298 | 8.326328e-01 | 0.080 | 0 | 0 |
| FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes | R-HSA-9615017 | 8.326328e-01 | 0.080 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9683701 | 8.326328e-01 | 0.080 | 0 | 0 |
| Transcriptional activation of mitochondrial biogenesis | R-HSA-2151201 | 8.328696e-01 | 0.079 | 0 | 0 |
| Transcription of the HIV genome | R-HSA-167172 | 8.331036e-01 | 0.079 | 0 | 0 |
| Impaired BRCA2 binding to RAD51 | R-HSA-9709570 | 8.357153e-01 | 0.078 | 0 | 0 |
| mRNA Capping | R-HSA-72086 | 8.357153e-01 | 0.078 | 0 | 0 |
| Termination of translesion DNA synthesis | R-HSA-5656169 | 8.357153e-01 | 0.078 | 0 | 0 |
| Downstream signaling of activated FGFR3 | R-HSA-5654708 | 8.357153e-01 | 0.078 | 0 | 0 |
| Endosomal Sorting Complex Required For Transport (ESCRT) | R-HSA-917729 | 8.357153e-01 | 0.078 | 0 | 0 |
| Glucagon-type ligand receptors | R-HSA-420092 | 8.357153e-01 | 0.078 | 0 | 0 |
| Class I MHC mediated antigen processing & presentation | R-HSA-983169 | 8.408923e-01 | 0.075 | 0 | 0 |
| Translesion synthesis by POLI | R-HSA-5656121 | 8.442018e-01 | 0.074 | 0 | 0 |
| Defective GALNT3 causes HFTC | R-HSA-5083625 | 8.442018e-01 | 0.074 | 0 | 0 |
| Defective GALNT12 causes CRCS1 | R-HSA-5083636 | 8.442018e-01 | 0.074 | 0 | 0 |
| Entry of Influenza Virion into Host Cell via Endocytosis | R-HSA-168275 | 8.442018e-01 | 0.074 | 0 | 0 |
| Phase 4 - resting membrane potential | R-HSA-5576886 | 8.442018e-01 | 0.074 | 0 | 0 |
| Regulation of NF-kappa B signaling | R-HSA-9758274 | 8.442018e-01 | 0.074 | 0 | 0 |
| Receptor-type tyrosine-protein phosphatases | R-HSA-388844 | 8.442018e-01 | 0.074 | 0 | 0 |
| SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion | R-HSA-399955 | 8.442018e-01 | 0.074 | 0 | 0 |
| RNA Polymerase III Transcription Initiation | R-HSA-76046 | 8.470412e-01 | 0.072 | 0 | 0 |
| Downstream signaling of activated FGFR4 | R-HSA-5654716 | 8.470412e-01 | 0.072 | 0 | 0 |
| Energy dependent regulation of mTOR by LKB1-AMPK | R-HSA-380972 | 8.470412e-01 | 0.072 | 0 | 0 |
| NOTCH3 Intracellular Domain Regulates Transcription | R-HSA-9013508 | 8.470412e-01 | 0.072 | 0 | 0 |
| Cellular response to chemical stress | R-HSA-9711123 | 8.481631e-01 | 0.072 | 0 | 0 |
| Interleukin-17 signaling | R-HSA-448424 | 8.489644e-01 | 0.071 | 0 | 0 |
| Signaling by FGFR4 | R-HSA-5654743 | 8.519019e-01 | 0.070 | 0 | 0 |
| Hh mutants abrogate ligand secretion | R-HSA-5387390 | 8.519019e-01 | 0.070 | 0 | 0 |
| Hedgehog 'on' state | R-HSA-5632684 | 8.564143e-01 | 0.067 | 0 | 0 |
| Mitochondrial biogenesis | R-HSA-1592230 | 8.568604e-01 | 0.067 | 0 | 0 |
| Respiratory syncytial virus (RSV) attachment and entry | R-HSA-9820960 | 8.576523e-01 | 0.067 | 0 | 0 |
| Negative regulators of DDX58/IFIH1 signaling | R-HSA-936440 | 8.576523e-01 | 0.067 | 0 | 0 |
| Cargo concentration in the ER | R-HSA-5694530 | 8.576523e-01 | 0.067 | 0 | 0 |
| Molecules associated with elastic fibres | R-HSA-2129379 | 8.576523e-01 | 0.067 | 0 | 0 |
| Downstream signal transduction | R-HSA-186763 | 8.576523e-01 | 0.067 | 0 | 0 |
| Translesion synthesis by POLK | R-HSA-5655862 | 8.580406e-01 | 0.066 | 0 | 0 |
| Antigen processing: Ub, ATP-independent proteasomal degradation | R-HSA-9912633 | 8.580406e-01 | 0.066 | 0 | 0 |
| mRNA decay by 5' to 3' exoribonuclease | R-HSA-430039 | 8.580406e-01 | 0.066 | 0 | 0 |
| Fibronectin matrix formation | R-HSA-1566977 | 8.580406e-01 | 0.066 | 0 | 0 |
| tRNA modification in the mitochondrion | R-HSA-6787450 | 8.580406e-01 | 0.066 | 0 | 0 |
| Coenzyme A biosynthesis | R-HSA-196783 | 8.580406e-01 | 0.066 | 0 | 0 |
| Activation of IRF3, IRF7 mediated by TBK1, IKKε (IKBKE) | R-HSA-936964 | 8.580406e-01 | 0.066 | 0 | 0 |
| Amine ligand-binding receptors | R-HSA-375280 | 8.607901e-01 | 0.065 | 0 | 0 |
| SCF(Skp2)-mediated degradation of p27/p21 | R-HSA-187577 | 8.607901e-01 | 0.065 | 0 | 0 |
| Interleukin-1 family signaling | R-HSA-446652 | 8.637644e-01 | 0.064 | 0 | 0 |
| Signaling by WNT in cancer | R-HSA-4791275 | 8.675860e-01 | 0.062 | 0 | 0 |
| Inwardly rectifying K+ channels | R-HSA-1296065 | 8.675860e-01 | 0.062 | 0 | 0 |
| Developmental Lineage of Multipotent Pancreatic Progenitor Cells | R-HSA-9937080 | 8.675860e-01 | 0.062 | 0 | 0 |
| Regulation of PD-L1(CD274) Post-translational modification | R-HSA-9909615 | 8.678372e-01 | 0.062 | 0 | 0 |
| Extension of Telomeres | R-HSA-180786 | 8.682623e-01 | 0.061 | 0 | 0 |
| Assembly of collagen fibrils and other multimeric structures | R-HSA-2022090 | 8.682623e-01 | 0.061 | 0 | 0 |
| Signaling by FGFR3 | R-HSA-5654741 | 8.692063e-01 | 0.061 | 0 | 0 |
| Defective CFTR causes cystic fibrosis | R-HSA-5678895 | 8.692063e-01 | 0.061 | 0 | 0 |
| Dectin-1 mediated noncanonical NF-kB signaling | R-HSA-5607761 | 8.692063e-01 | 0.061 | 0 | 0 |
| Somitogenesis | R-HSA-9824272 | 8.692063e-01 | 0.061 | 0 | 0 |
| Removal of the Flap Intermediate from the C-strand | R-HSA-174437 | 8.706509e-01 | 0.060 | 0 | 0 |
| Defective C1GALT1C1 causes TNPS | R-HSA-5083632 | 8.706509e-01 | 0.060 | 0 | 0 |
| Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters | R-HSA-164938 | 8.706509e-01 | 0.060 | 0 | 0 |
| Biosynthesis of aspirin-triggered D-series resolvins | R-HSA-9020265 | 8.706509e-01 | 0.060 | 0 | 0 |
| Elevation of cytosolic Ca2+ levels | R-HSA-139853 | 8.706509e-01 | 0.060 | 0 | 0 |
| Regulation of FZD by ubiquitination | R-HSA-4641263 | 8.706509e-01 | 0.060 | 0 | 0 |
| Uptake and function of anthrax toxins | R-HSA-5210891 | 8.706509e-01 | 0.060 | 0 | 0 |
| HDR through Single Strand Annealing (SSA) | R-HSA-5685938 | 8.768790e-01 | 0.057 | 0 | 0 |
| Circadian clock | R-HSA-9909396 | 8.793311e-01 | 0.056 | 0 | 0 |
| Synaptic adhesion-like molecules | R-HSA-8849932 | 8.821417e-01 | 0.054 | 0 | 0 |
| Biosynthesis of Lipoxins (LX) | R-HSA-2142700 | 8.821417e-01 | 0.054 | 0 | 0 |
| ZBP1(DAI) mediated induction of type I IFNs | R-HSA-1606322 | 8.821417e-01 | 0.054 | 0 | 0 |
| Apoptotic factor-mediated response | R-HSA-111471 | 8.821417e-01 | 0.054 | 0 | 0 |
| Toll Like Receptor TLR1:TLR2 Cascade | R-HSA-168179 | 8.833536e-01 | 0.054 | 0 | 0 |
| Toll Like Receptor 2 (TLR2) Cascade | R-HSA-181438 | 8.833536e-01 | 0.054 | 0 | 0 |
| TAK1-dependent IKK and NF-kappa-B activation | R-HSA-445989 | 8.847000e-01 | 0.053 | 0 | 0 |
| NFE2L2 regulating anti-oxidant/detoxification enzymes | R-HSA-9818027 | 8.855667e-01 | 0.053 | 0 | 0 |
| Mitochondrial protein import | R-HSA-1268020 | 8.888896e-01 | 0.051 | 0 | 0 |
| Synthesis of PIPs at the plasma membrane | R-HSA-1660499 | 8.888896e-01 | 0.051 | 0 | 0 |
| Signaling by PDGF | R-HSA-186797 | 8.888896e-01 | 0.051 | 0 | 0 |
| ABC-family proteins mediated transport | R-HSA-382556 | 8.891692e-01 | 0.051 | 0 | 0 |
| Metal ion SLC transporters | R-HSA-425410 | 8.918153e-01 | 0.050 | 0 | 0 |
| tRNA processing | R-HSA-72306 | 8.922458e-01 | 0.050 | 0 | 0 |
| Translesion Synthesis by POLH | R-HSA-110320 | 8.926123e-01 | 0.049 | 0 | 0 |
| IKK complex recruitment mediated by RIP1 | R-HSA-937041 | 8.926123e-01 | 0.049 | 0 | 0 |
| mRNA decay by 3' to 5' exoribonuclease | R-HSA-429958 | 8.926123e-01 | 0.049 | 0 | 0 |
| E2F mediated regulation of DNA replication | R-HSA-113510 | 8.926123e-01 | 0.049 | 0 | 0 |
| Synthesis of 5-eicosatetraenoic acids | R-HSA-2142688 | 8.926123e-01 | 0.049 | 0 | 0 |
| The NLRP3 inflammasome | R-HSA-844456 | 8.926123e-01 | 0.049 | 0 | 0 |
| Signaling by NOTCH2 | R-HSA-1980145 | 8.936832e-01 | 0.049 | 0 | 0 |
| Diseases of DNA Double-Strand Break Repair | R-HSA-9675136 | 8.936832e-01 | 0.049 | 0 | 0 |
| Defective homologous recombination repair (HRR) due to BRCA2 loss of function | R-HSA-9701190 | 8.936832e-01 | 0.049 | 0 | 0 |
| NPAS4 regulates expression of target genes | R-HSA-9768919 | 8.936832e-01 | 0.049 | 0 | 0 |
| Translation of Structural Proteins | R-HSA-9694635 | 8.949171e-01 | 0.048 | 0 | 0 |
| Activation of gene expression by SREBF (SREBP) | R-HSA-2426168 | 8.951088e-01 | 0.048 | 0 | 0 |
| C-type lectin receptors (CLRs) | R-HSA-5621481 | 8.961217e-01 | 0.048 | 0 | 0 |
| DNA Damage Bypass | R-HSA-73893 | 8.985341e-01 | 0.046 | 0 | 0 |
| Chemokine receptors bind chemokines | R-HSA-380108 | 8.985341e-01 | 0.046 | 0 | 0 |
| Nucleotide-binding domain, leucine rich repeat containing receptor (NLR) signaling pathways | R-HSA-168643 | 9.010199e-01 | 0.045 | 0 | 0 |
| Downstream signaling of activated FGFR2 | R-HSA-5654696 | 9.012615e-01 | 0.045 | 0 | 0 |
| Downstream signaling of activated FGFR1 | R-HSA-5654687 | 9.012615e-01 | 0.045 | 0 | 0 |
| PERK regulates gene expression | R-HSA-381042 | 9.012615e-01 | 0.045 | 0 | 0 |
| Transferrin endocytosis and recycling | R-HSA-917977 | 9.012615e-01 | 0.045 | 0 | 0 |
| Toll Like Receptor 4 (TLR4) Cascade | R-HSA-166016 | 9.018146e-01 | 0.045 | 0 | 0 |
| Regulation of PD-L1(CD274) translation | R-HSA-9909620 | 9.021533e-01 | 0.045 | 0 | 0 |
| Formation of ATP by chemiosmotic coupling | R-HSA-163210 | 9.021533e-01 | 0.045 | 0 | 0 |
| Mitochondrial iron-sulfur cluster biogenesis | R-HSA-1362409 | 9.021533e-01 | 0.045 | 0 | 0 |
| Wax and plasmalogen biosynthesis | R-HSA-8848584 | 9.021533e-01 | 0.045 | 0 | 0 |
| Acyl chain remodelling of PI | R-HSA-1482922 | 9.021533e-01 | 0.045 | 0 | 0 |
| Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | R-HSA-381426 | 9.022183e-01 | 0.045 | 0 | 0 |
| Triglyceride catabolism | R-HSA-163560 | 9.083331e-01 | 0.042 | 0 | 0 |
| Formation of Fibrin Clot (Clotting Cascade) | R-HSA-140877 | 9.083331e-01 | 0.042 | 0 | 0 |
| FGFR2 mutant receptor activation | R-HSA-1839126 | 9.083331e-01 | 0.042 | 0 | 0 |
| Matriglycan biosynthesis on DAG1 | R-HSA-9939291 | 9.108471e-01 | 0.041 | 0 | 0 |
| TNFR1-induced proapoptotic signaling | R-HSA-5357786 | 9.108471e-01 | 0.041 | 0 | 0 |
| Biosynthesis of E-series 18(S)-resolvins | R-HSA-9018896 | 9.108471e-01 | 0.041 | 0 | 0 |
| Signalling to RAS | R-HSA-167044 | 9.108471e-01 | 0.041 | 0 | 0 |
| Phenylalanine metabolism | R-HSA-8964208 | 9.108471e-01 | 0.041 | 0 | 0 |
| Zygotic genome activation (ZGA) | R-HSA-9819196 | 9.108471e-01 | 0.041 | 0 | 0 |
| Acyl chain remodelling of PG | R-HSA-1482925 | 9.108471e-01 | 0.041 | 0 | 0 |
| Oxygen-dependent proline hydroxylation of Hypoxia-inducible Factor Alpha | R-HSA-1234176 | 9.108546e-01 | 0.041 | 0 | 0 |
| TRAF6 mediated IRF7 activation | R-HSA-933541 | 9.149281e-01 | 0.039 | 0 | 0 |
| Developmental Cell Lineages of the Exocrine Pancreas | R-HSA-9820448 | 9.164067e-01 | 0.038 | 0 | 0 |
| AMPK-induced ERAD and lysosome mediated degradation of PD-L1(CD274) | R-HSA-9931269 | 9.164910e-01 | 0.038 | 0 | 0 |
| Toll Like Receptor 3 (TLR3) Cascade | R-HSA-168164 | 9.166344e-01 | 0.038 | 0 | 0 |
| Peptide hormone metabolism | R-HSA-2980736 | 9.185254e-01 | 0.037 | 0 | 0 |
| Fc epsilon receptor (FCERI) signaling | R-HSA-2454202 | 9.186006e-01 | 0.037 | 0 | 0 |
| Serine metabolism | R-HSA-977347 | 9.187690e-01 | 0.037 | 0 | 0 |
| Mitochondrial calcium ion transport | R-HSA-8949215 | 9.187690e-01 | 0.037 | 0 | 0 |
| Metabolism of Angiotensinogen to Angiotensins | R-HSA-2022377 | 9.187690e-01 | 0.037 | 0 | 0 |
| Ribavirin ADME | R-HSA-9755088 | 9.187690e-01 | 0.037 | 0 | 0 |
| Assembly Of The HIV Virion | R-HSA-175474 | 9.187690e-01 | 0.037 | 0 | 0 |
| Mitochondrial protein degradation | R-HSA-9837999 | 9.196606e-01 | 0.036 | 0 | 0 |
| Collagen formation | R-HSA-1474290 | 9.196606e-01 | 0.036 | 0 | 0 |
| Protein localization | R-HSA-9609507 | 9.197548e-01 | 0.036 | 0 | 0 |
| Innate Immune System | R-HSA-168249 | 9.199612e-01 | 0.036 | 0 | 0 |
| Elastic fibre formation | R-HSA-1566948 | 9.210754e-01 | 0.036 | 0 | 0 |
| Transcriptional regulation of pluripotent stem cells | R-HSA-452723 | 9.210754e-01 | 0.036 | 0 | 0 |
| SLC-mediated transport of inorganic anions | R-HSA-9958790 | 9.210754e-01 | 0.036 | 0 | 0 |
| Nucleotide biosynthesis | R-HSA-8956320 | 9.218006e-01 | 0.035 | 0 | 0 |
| SLC transporter disorders | R-HSA-5619102 | 9.229409e-01 | 0.035 | 0 | 0 |
| RNA Polymerase III Transcription Initiation From Type 3 Promoter | R-HSA-76071 | 9.259873e-01 | 0.033 | 0 | 0 |
| Biosynthesis of D-series resolvins | R-HSA-9018676 | 9.259873e-01 | 0.033 | 0 | 0 |
| Pentose phosphate pathway | R-HSA-71336 | 9.268025e-01 | 0.033 | 0 | 0 |
| Stimuli-sensing channels | R-HSA-2672351 | 9.280125e-01 | 0.032 | 0 | 0 |
| Parasitic Infection Pathways | R-HSA-9824443 | 9.282239e-01 | 0.032 | 0 | 0 |
| Leishmania infection | R-HSA-9658195 | 9.282239e-01 | 0.032 | 0 | 0 |
| Antigen processing: Ubiquitination & Proteasome degradation | R-HSA-983168 | 9.305117e-01 | 0.031 | 0 | 0 |
| RNA Polymerase II Transcription Pre-Initiation And Promoter Opening | R-HSA-73779 | 9.321354e-01 | 0.031 | 0 | 0 |
| Mitochondrial tRNA aminoacylation | R-HSA-379726 | 9.321354e-01 | 0.031 | 0 | 0 |
| Regulation of PTEN mRNA translation | R-HSA-8943723 | 9.325646e-01 | 0.030 | 0 | 0 |
| Termination of O-glycan biosynthesis | R-HSA-977068 | 9.325646e-01 | 0.030 | 0 | 0 |
| Response of EIF2AK1 (HRI) to heme deficiency | R-HSA-9648895 | 9.325646e-01 | 0.030 | 0 | 0 |
| Synthesis of UDP-N-acetyl-glucosamine | R-HSA-446210 | 9.325646e-01 | 0.030 | 0 | 0 |
| Mitochondrial mRNA modification | R-HSA-9937008 | 9.325646e-01 | 0.030 | 0 | 0 |
| Biosynthesis of maresins | R-HSA-9018682 | 9.325646e-01 | 0.030 | 0 | 0 |
| TRIF (TICAM1)-mediated TLR4 signaling | R-HSA-937061 | 9.348221e-01 | 0.029 | 0 | 0 |
| MyD88-independent TLR4 cascade | R-HSA-166166 | 9.348221e-01 | 0.029 | 0 | 0 |
| Signaling by FGFR1 | R-HSA-5654736 | 9.359280e-01 | 0.029 | 0 | 0 |
| Translesion synthesis by Y family DNA polymerases bypasses lesions on DNA template | R-HSA-110313 | 9.370991e-01 | 0.028 | 0 | 0 |
| Maturation of spike protein | R-HSA-9694548 | 9.370991e-01 | 0.028 | 0 | 0 |
| FLT3 Signaling | R-HSA-9607240 | 9.370991e-01 | 0.028 | 0 | 0 |
| MyD88 cascade initiated on plasma membrane | R-HSA-975871 | 9.381606e-01 | 0.028 | 0 | 0 |
| Toll Like Receptor 5 (TLR5) Cascade | R-HSA-168176 | 9.381606e-01 | 0.028 | 0 | 0 |
| Toll Like Receptor 10 (TLR10) Cascade | R-HSA-168142 | 9.381606e-01 | 0.028 | 0 | 0 |
| Translocation of ZAP-70 to Immunological synapse | R-HSA-202430 | 9.385578e-01 | 0.028 | 0 | 0 |
| Complex III assembly | R-HSA-9865881 | 9.385578e-01 | 0.028 | 0 | 0 |
| Signaling by FLT3 ITD and TKD mutants | R-HSA-9703648 | 9.385578e-01 | 0.028 | 0 | 0 |
| Gamma carboxylation, hypusinylation, hydroxylation, and arylsulfatase activation | R-HSA-163841 | 9.393916e-01 | 0.027 | 0 | 0 |
| RNA Polymerase II HIV Promoter Escape | R-HSA-167162 | 9.417169e-01 | 0.026 | 0 | 0 |
| HIV Transcription Initiation | R-HSA-167161 | 9.417169e-01 | 0.026 | 0 | 0 |
| RNA Polymerase II Transcription Initiation | R-HSA-75953 | 9.417169e-01 | 0.026 | 0 | 0 |
| Scavenging by Class A Receptors | R-HSA-3000480 | 9.417169e-01 | 0.026 | 0 | 0 |
| SLC-mediated transport of neurotransmitters | R-HSA-442660 | 9.417169e-01 | 0.026 | 0 | 0 |
| Acyl chain remodelling of PS | R-HSA-1482801 | 9.440186e-01 | 0.025 | 0 | 0 |
| Hyaluronan degradation | R-HSA-2160916 | 9.440186e-01 | 0.025 | 0 | 0 |
| Biosynthesis of electrophilic ω-3 PUFA oxo-derivatives | R-HSA-9027604 | 9.440186e-01 | 0.025 | 0 | 0 |
| Laminin interactions | R-HSA-3000157 | 9.440186e-01 | 0.025 | 0 | 0 |
| ROS and RNS production in phagocytes | R-HSA-1222556 | 9.457085e-01 | 0.024 | 0 | 0 |
| Activation of GABAB receptors | R-HSA-991365 | 9.460111e-01 | 0.024 | 0 | 0 |
| GABA B receptor activation | R-HSA-977444 | 9.460111e-01 | 0.024 | 0 | 0 |
| Interleukin-1 signaling | R-HSA-9020702 | 9.473461e-01 | 0.023 | 0 | 0 |
| Peroxisomal protein import | R-HSA-9033241 | 9.476646e-01 | 0.023 | 0 | 0 |
| Diseases of branched-chain amino acid catabolism | R-HSA-9865118 | 9.489944e-01 | 0.023 | 0 | 0 |
| TRP channels | R-HSA-3295583 | 9.489944e-01 | 0.023 | 0 | 0 |
| Urea cycle | R-HSA-70635 | 9.489944e-01 | 0.023 | 0 | 0 |
| Sphingolipid catabolism | R-HSA-9845614 | 9.489944e-01 | 0.023 | 0 | 0 |
| RNA Polymerase II Promoter Escape | R-HSA-73776 | 9.500028e-01 | 0.022 | 0 | 0 |
| Sphingolipid de novo biosynthesis | R-HSA-1660661 | 9.511096e-01 | 0.022 | 0 | 0 |
| Signaling by NOTCH1 PEST Domain Mutants in Cancer | R-HSA-2644602 | 9.511096e-01 | 0.022 | 0 | 0 |
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | R-HSA-2894862 | 9.511096e-01 | 0.022 | 0 | 0 |
| Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer | R-HSA-2894858 | 9.511096e-01 | 0.022 | 0 | 0 |
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | R-HSA-2644606 | 9.511096e-01 | 0.022 | 0 | 0 |
| Metabolism of polyamines | R-HSA-351202 | 9.511096e-01 | 0.022 | 0 | 0 |
| Signaling by NOTCH1 in Cancer | R-HSA-2644603 | 9.511096e-01 | 0.022 | 0 | 0 |
| Toll Like Receptor 9 (TLR9) Cascade | R-HSA-168138 | 9.519651e-01 | 0.021 | 0 | 0 |
| Signaling by NOTCH1 | R-HSA-1980143 | 9.520502e-01 | 0.021 | 0 | 0 |
| Toll-like Receptor Cascades | R-HSA-168898 | 9.524927e-01 | 0.021 | 0 | 0 |
| Biosynthesis of DPAn-3 SPMs | R-HSA-9025094 | 9.535282e-01 | 0.021 | 0 | 0 |
| ER Quality Control Compartment (ERQC) | R-HSA-901032 | 9.535282e-01 | 0.021 | 0 | 0 |
| Maturation of hRSV A proteins | R-HSA-9828806 | 9.535282e-01 | 0.021 | 0 | 0 |
| Regulation of RUNX2 expression and activity | R-HSA-8939902 | 9.543420e-01 | 0.020 | 0 | 0 |
| Formation of paraxial mesoderm | R-HSA-9793380 | 9.543420e-01 | 0.020 | 0 | 0 |
| RNA Polymerase II Transcription Initiation And Promoter Clearance | R-HSA-76042 | 9.571566e-01 | 0.019 | 0 | 0 |
| NCAM signaling for neurite out-growth | R-HSA-375165 | 9.573736e-01 | 0.019 | 0 | 0 |
| Telomere Extension By Telomerase | R-HSA-171319 | 9.576593e-01 | 0.019 | 0 | 0 |
| RUNX2 regulates osteoblast differentiation | R-HSA-8940973 | 9.576593e-01 | 0.019 | 0 | 0 |
| Inflammasomes | R-HSA-622312 | 9.576593e-01 | 0.019 | 0 | 0 |
| Negative regulation of FGFR3 signaling | R-HSA-5654732 | 9.576593e-01 | 0.019 | 0 | 0 |
| ATF4 activates genes in response to endoplasmic reticulum stress | R-HSA-380994 | 9.576593e-01 | 0.019 | 0 | 0 |
| Pyroptosis | R-HSA-5620971 | 9.576593e-01 | 0.019 | 0 | 0 |
| RSV-host interactions | R-HSA-9833110 | 9.576832e-01 | 0.019 | 0 | 0 |
| Plasma lipoprotein assembly, remodeling, and clearance | R-HSA-174824 | 9.595698e-01 | 0.018 | 0 | 0 |
| Late SARS-CoV-2 Infection Events | R-HSA-9772573 | 9.595698e-01 | 0.018 | 0 | 0 |
| Regulation of cholesterol biosynthesis by SREBP (SREBF) | R-HSA-1655829 | 9.602937e-01 | 0.018 | 0 | 0 |
| Diseases of DNA repair | R-HSA-9675135 | 9.603551e-01 | 0.018 | 0 | 0 |
| Thyroxine biosynthesis | R-HSA-209968 | 9.614233e-01 | 0.017 | 0 | 0 |
| Nitric oxide stimulates guanylate cyclase | R-HSA-392154 | 9.614233e-01 | 0.017 | 0 | 0 |
| Biosynthesis of EPA-derived SPMs | R-HSA-9018679 | 9.614233e-01 | 0.017 | 0 | 0 |
| Negative regulation of FGFR4 signaling | R-HSA-5654733 | 9.614233e-01 | 0.017 | 0 | 0 |
| Regulation of gene expression in beta cells | R-HSA-210745 | 9.614233e-01 | 0.017 | 0 | 0 |
| MyD88:MAL(TIRAP) cascade initiated on plasma membrane | R-HSA-166058 | 9.630375e-01 | 0.016 | 0 | 0 |
| Toll Like Receptor TLR6:TLR2 Cascade | R-HSA-168188 | 9.630375e-01 | 0.016 | 0 | 0 |
| Cell surface interactions at the vascular wall | R-HSA-202733 | 9.648262e-01 | 0.016 | 0 | 0 |
| Cellular response to hypoxia | R-HSA-1234174 | 9.653740e-01 | 0.015 | 0 | 0 |
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | R-HSA-975138 | 9.661445e-01 | 0.015 | 0 | 0 |
| Budding and maturation of HIV virion | R-HSA-162588 | 9.679778e-01 | 0.014 | 0 | 0 |
| Biosynthesis of DPA-derived SPMs | R-HSA-9018683 | 9.679778e-01 | 0.014 | 0 | 0 |
| MyD88 dependent cascade initiated on endosome | R-HSA-975155 | 9.680026e-01 | 0.014 | 0 | 0 |
| NOTCH1 Intracellular Domain Regulates Transcription | R-HSA-2122947 | 9.686331e-01 | 0.014 | 0 | 0 |
| TNFR2 non-canonical NF-kB pathway | R-HSA-5668541 | 9.692504e-01 | 0.014 | 0 | 0 |
| Cytoprotection by HMOX1 | R-HSA-9707564 | 9.692504e-01 | 0.014 | 0 | 0 |
| Transcriptional regulation of white adipocyte differentiation | R-HSA-381340 | 9.699880e-01 | 0.013 | 0 | 0 |
| DAG1 glycosylations | R-HSA-8931838 | 9.708251e-01 | 0.013 | 0 | 0 |
| Formation of the cornified envelope | R-HSA-6809371 | 9.717440e-01 | 0.012 | 0 | 0 |
| Collagen biosynthesis and modifying enzymes | R-HSA-1650814 | 9.719429e-01 | 0.012 | 0 | 0 |
| Branched-chain amino acid catabolism | R-HSA-70895 | 9.731977e-01 | 0.012 | 0 | 0 |
| Negative regulation of FGFR1 signaling | R-HSA-5654726 | 9.734193e-01 | 0.012 | 0 | 0 |
| Regulation of necroptotic cell death | R-HSA-5675482 | 9.734193e-01 | 0.012 | 0 | 0 |
| Diseases associated with glycosylation precursor biosynthesis | R-HSA-5609975 | 9.734193e-01 | 0.012 | 0 | 0 |
| Recycling of bile acids and salts | R-HSA-159418 | 9.734193e-01 | 0.012 | 0 | 0 |
| Post-translational protein modification | R-HSA-597592 | 9.738884e-01 | 0.011 | 0 | 0 |
| Toll Like Receptor 7/8 (TLR7/8) Cascade | R-HSA-168181 | 9.745365e-01 | 0.011 | 0 | 0 |
| Acyl chain remodelling of PC | R-HSA-1482788 | 9.757830e-01 | 0.011 | 0 | 0 |
| Vitamin B5 (pantothenate) metabolism | R-HSA-199220 | 9.757830e-01 | 0.011 | 0 | 0 |
| ECM proteoglycans | R-HSA-3000178 | 9.773187e-01 | 0.010 | 0 | 0 |
| Metabolism of cofactors | R-HSA-8978934 | 9.773187e-01 | 0.010 | 0 | 0 |
| Signaling by CSF1 (M-CSF) in myeloid cells | R-HSA-9680350 | 9.779366e-01 | 0.010 | 0 | 0 |
| Hyaluronan metabolism | R-HSA-2142845 | 9.779366e-01 | 0.010 | 0 | 0 |
| Negative regulation of FGFR2 signaling | R-HSA-5654727 | 9.779366e-01 | 0.010 | 0 | 0 |
| Acyl chain remodelling of PE | R-HSA-1482839 | 9.798989e-01 | 0.009 | 0 | 0 |
| G alpha (i) signalling events | R-HSA-418594 | 9.801988e-01 | 0.009 | 1 | 0 |
| Paracetamol ADME | R-HSA-9753281 | 9.804795e-01 | 0.009 | 0 | 0 |
| RUNX2 regulates bone development | R-HSA-8941326 | 9.816867e-01 | 0.008 | 0 | 0 |
| NCAM1 interactions | R-HSA-419037 | 9.833156e-01 | 0.007 | 0 | 0 |
| Phenylalanine and tyrosine metabolism | R-HSA-8963691 | 9.833156e-01 | 0.007 | 0 | 0 |
| Lysine catabolism | R-HSA-71064 | 9.833156e-01 | 0.007 | 0 | 0 |
| Collagen chain trimerization | R-HSA-8948216 | 9.833156e-01 | 0.007 | 0 | 0 |
| Metabolism of folate and pterines | R-HSA-196757 | 9.833156e-01 | 0.007 | 0 | 0 |
| Leishmania parasite growth and survival | R-HSA-9664433 | 9.836802e-01 | 0.007 | 0 | 0 |
| Anti-inflammatory response favouring Leishmania parasite infection | R-HSA-9662851 | 9.836802e-01 | 0.007 | 0 | 0 |
| NR1H3 & NR1H2 regulate gene expression linked to cholesterol transport and efflux | R-HSA-9029569 | 9.846413e-01 | 0.007 | 0 | 0 |
| tRNA processing in the mitochondrion | R-HSA-6785470 | 9.847997e-01 | 0.007 | 0 | 0 |
| RIPK1-mediated regulated necrosis | R-HSA-5213460 | 9.847997e-01 | 0.007 | 0 | 0 |
| Triglyceride metabolism | R-HSA-8979227 | 9.858261e-01 | 0.006 | 0 | 0 |
| Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | R-HSA-983695 | 9.860739e-01 | 0.006 | 0 | 0 |
| RAS processing | R-HSA-9648002 | 9.861519e-01 | 0.006 | 0 | 0 |
| Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) | R-HSA-381771 | 9.861519e-01 | 0.006 | 0 | 0 |
| ABC transporter disorders | R-HSA-5619084 | 9.863062e-01 | 0.006 | 0 | 0 |
| GABA receptor activation | R-HSA-977443 | 9.869218e-01 | 0.006 | 0 | 0 |
| Disorders of transmembrane transporters | R-HSA-5619115 | 9.869630e-01 | 0.006 | 0 | 0 |
| Maturation of TCA enzymes and regulation of TCA cycle | R-HSA-9854311 | 9.873838e-01 | 0.006 | 0 | 0 |
| rRNA processing in the mitochondrion | R-HSA-8868766 | 9.873838e-01 | 0.006 | 0 | 0 |
| Collagen degradation | R-HSA-1442490 | 9.879348e-01 | 0.005 | 0 | 0 |
| Bile acid and bile salt metabolism | R-HSA-194068 | 9.881872e-01 | 0.005 | 0 | 0 |
| G alpha (q) signalling events | R-HSA-416476 | 9.887057e-01 | 0.005 | 0 | 0 |
| Intra-Golgi traffic | R-HSA-6811438 | 9.895289e-01 | 0.005 | 0 | 0 |
| Incretin synthesis, secretion, and inactivation | R-HSA-400508 | 9.904606e-01 | 0.004 | 0 | 0 |
| Synthesis of bile acids and bile salts | R-HSA-192105 | 9.913606e-01 | 0.004 | 0 | 0 |
| G alpha (s) signalling events | R-HSA-418555 | 9.916287e-01 | 0.004 | 0 | 0 |
| tRNA modification in the nucleus and cytosol | R-HSA-6782315 | 9.919566e-01 | 0.004 | 0 | 0 |
| Synthesis of Leukotrienes (LT) and Eoxins (EX) | R-HSA-2142691 | 9.920828e-01 | 0.003 | 0 | 0 |
| FCERI mediated Ca+2 mobilization | R-HSA-2871809 | 9.924868e-01 | 0.003 | 0 | 0 |
| Role of phospholipids in phagocytosis | R-HSA-2029485 | 9.924868e-01 | 0.003 | 0 | 0 |
| Kidney development | R-HSA-9830369 | 9.925865e-01 | 0.003 | 0 | 0 |
| PI Metabolism | R-HSA-1483255 | 9.929808e-01 | 0.003 | 0 | 0 |
| Regulated Necrosis | R-HSA-5218859 | 9.931680e-01 | 0.003 | 0 | 0 |
| Metabolism of amino acids and derivatives | R-HSA-71291 | 9.933476e-01 | 0.003 | 0 | 0 |
| Purinergic signaling in leishmaniasis infection | R-HSA-9660826 | 9.934293e-01 | 0.003 | 0 | 0 |
| Cell recruitment (pro-inflammatory response) | R-HSA-9664424 | 9.934293e-01 | 0.003 | 0 | 0 |
| Regulation of pyruvate metabolism | R-HSA-9861718 | 9.934293e-01 | 0.003 | 0 | 0 |
| Pyruvate metabolism | R-HSA-70268 | 9.934571e-01 | 0.003 | 0 | 0 |
| Degradation of the extracellular matrix | R-HSA-1474228 | 9.936300e-01 | 0.003 | 0 | 0 |
| Transcriptional regulation by RUNX2 | R-HSA-8878166 | 9.942242e-01 | 0.003 | 0 | 0 |
| Plasma lipoprotein remodeling | R-HSA-8963899 | 9.945469e-01 | 0.002 | 0 | 0 |
| Diseases associated with O-glycosylation of proteins | R-HSA-3906995 | 9.946572e-01 | 0.002 | 0 | 0 |
| Neurotransmitter release cycle | R-HSA-112310 | 9.947762e-01 | 0.002 | 0 | 0 |
| Class B/2 (Secretin family receptors) | R-HSA-373080 | 9.947762e-01 | 0.002 | 0 | 0 |
| Interconversion of nucleotide di- and triphosphates | R-HSA-499943 | 9.950790e-01 | 0.002 | 0 | 0 |
| Aspirin ADME | R-HSA-9749641 | 9.954680e-01 | 0.002 | 0 | 0 |
| Synthesis of Prostaglandins (PG) and Thromboxanes (TX) | R-HSA-2162123 | 9.954746e-01 | 0.002 | 0 | 0 |
| Complex IV assembly | R-HSA-9864848 | 9.958774e-01 | 0.002 | 0 | 0 |
| Citric acid cycle (TCA cycle) | R-HSA-71403 | 9.961576e-01 | 0.002 | 0 | 0 |
| Iron uptake and transport | R-HSA-917937 | 9.961576e-01 | 0.002 | 0 | 0 |
| TP53 Regulates Transcription of Cell Death Genes | R-HSA-5633008 | 9.961576e-01 | 0.002 | 0 | 0 |
| FCGR3A-mediated IL10 synthesis | R-HSA-9664323 | 9.966169e-01 | 0.001 | 0 | 0 |
| NR1H2 and NR1H3-mediated signaling | R-HSA-9024446 | 9.967438e-01 | 0.001 | 0 | 0 |
| SLC-mediated transport of organic anions | R-HSA-9955298 | 9.970030e-01 | 0.001 | 0 | 0 |
| Interleukin-10 signaling | R-HSA-6783783 | 9.970030e-01 | 0.001 | 0 | 0 |
| Role of LAT2/NTAL/LAB on calcium mobilization | R-HSA-2730905 | 9.971547e-01 | 0.001 | 0 | 0 |
| Potassium Channels | R-HSA-1296071 | 9.971547e-01 | 0.001 | 0 | 0 |
| FCERI mediated NF-kB activation | R-HSA-2871837 | 9.973967e-01 | 0.001 | 0 | 0 |
| Metabolism of amine-derived hormones | R-HSA-209776 | 9.974138e-01 | 0.001 | 0 | 0 |
| Asparagine N-linked glycosylation | R-HSA-446203 | 9.975708e-01 | 0.001 | 0 | 0 |
| Synthesis of PA | R-HSA-1483166 | 9.976441e-01 | 0.001 | 0 | 0 |
| Dectin-2 family | R-HSA-5621480 | 9.976441e-01 | 0.001 | 0 | 0 |
| Interferon alpha/beta signaling | R-HSA-909733 | 9.977443e-01 | 0.001 | 0 | 0 |
| Regulation of beta-cell development | R-HSA-186712 | 9.980451e-01 | 0.001 | 0 | 0 |
| Amino acid transport across the plasma membrane | R-HSA-352230 | 9.980451e-01 | 0.001 | 0 | 0 |
| RAB geranylgeranylation | R-HSA-8873719 | 9.982192e-01 | 0.001 | 0 | 0 |
| Infection with Mycobacterium tuberculosis | R-HSA-9635486 | 9.985419e-01 | 0.001 | 0 | 0 |
| Digestion and absorption | R-HSA-8963743 | 9.986540e-01 | 0.001 | 0 | 0 |
| PPARA activates gene expression | R-HSA-1989781 | 9.987403e-01 | 0.001 | 0 | 0 |
| CD22 mediated BCR regulation | R-HSA-5690714 | 9.987739e-01 | 0.001 | 0 | 0 |
| Neddylation | R-HSA-8951664 | 9.988900e-01 | 0.000 | 0 | 0 |
| Regulation of lipid metabolism by PPARalpha | R-HSA-400206 | 9.988982e-01 | 0.000 | 0 | 0 |
| GPCR downstream signalling | R-HSA-388396 | 9.989119e-01 | 0.000 | 1 | 0 |
| Metabolism of carbohydrates and carbohydrate derivatives | R-HSA-71387 | 9.989406e-01 | 0.000 | 0 | 0 |
| Nicotinate metabolism | R-HSA-196807 | 9.990733e-01 | 0.000 | 0 | 0 |
| SLC-mediated transport of amino acids | R-HSA-9958863 | 9.990733e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation of mucins | R-HSA-913709 | 9.991559e-01 | 0.000 | 0 | 0 |
| FCERI mediated MAPK activation | R-HSA-2871796 | 9.992406e-01 | 0.000 | 0 | 0 |
| COPII-mediated vesicle transport | R-HSA-204005 | 9.992997e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid catabolism | R-HSA-9840310 | 9.992997e-01 | 0.000 | 0 | 0 |
| Fatty acyl-CoA biosynthesis | R-HSA-75105 | 9.992997e-01 | 0.000 | 0 | 0 |
| Diseases of carbohydrate metabolism | R-HSA-5663084 | 9.994707e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation elongation | R-HSA-5389840 | 9.994870e-01 | 0.000 | 0 | 0 |
| Peptide ligand-binding receptors | R-HSA-375276 | 9.995254e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation initiation | R-HSA-5368286 | 9.995672e-01 | 0.000 | 0 | 0 |
| Nuclear Receptor transcription pathway | R-HSA-383280 | 9.996682e-01 | 0.000 | 0 | 0 |
| Mitochondrial ribosome-associated quality control | R-HSA-9937383 | 9.997175e-01 | 0.000 | 0 | 0 |
| Biosynthesis of DHA-derived SPMs | R-HSA-9018677 | 9.997493e-01 | 0.000 | 0 | 0 |
| Peroxisomal lipid metabolism | R-HSA-390918 | 9.998106e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation termination | R-HSA-5419276 | 9.998450e-01 | 0.000 | 0 | 0 |
| Visual phototransduction | R-HSA-2187338 | 9.998466e-01 | 0.000 | 0 | 0 |
| Keratinization | R-HSA-6805567 | 9.998853e-01 | 0.000 | 0 | 0 |
| FCGR activation | R-HSA-2029481 | 9.999322e-01 | 0.000 | 0 | 0 |
| Mitochondrial Fatty Acid Beta-Oxidation | R-HSA-77289 | 9.999438e-01 | 0.000 | 0 | 0 |
| Drug ADME | R-HSA-9748784 | 9.999501e-01 | 0.000 | 0 | 0 |
| Signaling by GPCR | R-HSA-372790 | 9.999533e-01 | 0.000 | 1 | 0 |
| Glycerophospholipid biosynthesis | R-HSA-1483206 | 9.999591e-01 | 0.000 | 0 | 0 |
| Bacterial Infection Pathways | R-HSA-9824439 | 9.999641e-01 | 0.000 | 0 | 0 |
| Binding and Uptake of Ligands by Scavenger Receptors | R-HSA-2173782 | 9.999783e-01 | 0.000 | 0 | 0 |
| Arachidonate metabolism | R-HSA-2142753 | 9.999816e-01 | 0.000 | 0 | 0 |
| Respiratory electron transport | R-HSA-611105 | 9.999874e-01 | 0.000 | 0 | 0 |
| Sphingolipid metabolism | R-HSA-428157 | 9.999892e-01 | 0.000 | 0 | 0 |
| Phospholipid metabolism | R-HSA-1483257 | 9.999896e-01 | 0.000 | 0 | 0 |
| O-linked glycosylation | R-HSA-5173105 | 9.999912e-01 | 0.000 | 0 | 0 |
| Mitochondrial translation | R-HSA-5368287 | 9.999919e-01 | 0.000 | 0 | 0 |
| Glycosphingolipid metabolism | R-HSA-1660662 | 9.999972e-01 | 0.000 | 0 | 0 |
| Sensory perception of sweet, bitter, and umami (glutamate) taste | R-HSA-9717207 | 9.999972e-01 | 0.000 | 0 | 0 |
| Regulation of Complement cascade | R-HSA-977606 | 9.999977e-01 | 0.000 | 0 | 0 |
| Diseases of glycosylation | R-HSA-3781865 | 9.999988e-01 | 0.000 | 0 | 0 |
| Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | R-HSA-198933 | 9.999989e-01 | 0.000 | 0 | 0 |
| Sensory perception of taste | R-HSA-9717189 | 9.999989e-01 | 0.000 | 0 | 0 |
| Synthesis of substrates in N-glycan biosythesis | R-HSA-446219 | 9.999989e-01 | 0.000 | 0 | 0 |
| Metabolism of nucleotides | R-HSA-15869 | 9.999993e-01 | 0.000 | 0 | 0 |
| Metabolism of steroids | R-HSA-8957322 | 9.999996e-01 | 0.000 | 0 | 0 |
| Transport of small molecules | R-HSA-382551 | 9.999996e-01 | 0.000 | 1 | 0 |
| Biosynthesis of specialized proresolving mediators (SPMs) | R-HSA-9018678 | 9.999997e-01 | 0.000 | 0 | 0 |
| Complement cascade | R-HSA-166658 | 9.999998e-01 | 0.000 | 0 | 0 |
| Biosynthesis of the N-glycan precursor (dolichol lipid-linked oligosaccharide, LLO) and transfer to a nascent protein | R-HSA-446193 | 9.999999e-01 | 0.000 | 0 | 0 |
| Class A/1 (Rhodopsin-like receptors) | R-HSA-373076 | 1.000000e+00 | 0.000 | 0 | 0 |
| Aerobic respiration and respiratory electron transport | R-HSA-1428517 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of water-soluble vitamins and cofactors | R-HSA-196849 | 1.000000e+00 | 0.000 | 0 | 0 |
| SLC-mediated transmembrane transport | R-HSA-425407 | 1.000000e+00 | 0.000 | 0 | 0 |
| Glycosaminoglycan metabolism | R-HSA-1630316 | 1.000000e+00 | 0.000 | 0 | 0 |
| Infection with Enterobacteria | R-HSA-9640148 | 1.000000e+00 | 0.000 | 0 | 0 |
| Metabolism of vitamins and cofactors | R-HSA-196854 | 1.000000e+00 | 0.000 | 0 | 0 |
| Phase I - Functionalization of compounds | R-HSA-211945 | 1.000000e+00 | 0.000 | 0 | 0 |
| Diseases of metabolism | R-HSA-5668914 | 1.000000e+00 | 0.000 | 0 | 0 |
| Fatty acid metabolism | R-HSA-8978868 | 1.000000e+00 | 0.000 | 0 | 0 |
| GPCR ligand binding | R-HSA-500792 | 1.000000e+00 | 0.000 | 0 | 0 |
| Expression and translocation of olfactory receptors | R-HSA-9752946 | 1.000000e+00 | -0.000 | 0 | 0 |
| Olfactory Signaling Pathway | R-HSA-381753 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism of lipids | R-HSA-556833 | 1.000000e+00 | -0.000 | 0 | 0 |
| Metabolism | R-HSA-1430728 | 1.000000e+00 | -0.000 | 0 | 0 |
| Sensory Perception | R-HSA-9709957 | 1.000000e+00 | -0.000 | 0 | 0 |
| Biological oxidations | R-HSA-211859 | 1.000000e+00 | -0.000 | 0 | 0 |